



HU000027584T2

(19) **HU****MAGYARORSZÁG**
Szellemi Tulajdon Nemzeti Hivatala(11) Lajstromszám: **E 027 584**(13) **T2****EURÓPAI SZABADALOM**
SZÖVEGÉNEK FORDÍTÁSA(21) Magyar ügyszám: **E 08 745931**(22) A bejelentés napja: **2008. 04. 16.**(51) Int. Cl.: **C07K 16/24** (2006.01)**A61K 39/00** (2006.01)**C07K 16/18** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20080745931

(97) Az európai bejelentés közzétételi adatai:

EP 2146745 A2 **2008. 10. 30.**

(86) A nemzetközi (PCT) bejelentési szám:

PCT/US 08/060424

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2146745 B1 **2015. 06. 17.**

(87) A nemzetközi közzétételi szám:

WO 08130969

(30) Elsőbbségi adatok:

912229 P **2007. 04. 17.** **US****44132** **2008. 04. 11.** **US**

(73) Jogosult(ak):

GlaxoSmithKline LLC, Wilmington, Delaware**19808 (US)**

(72) Feltaláló(k):

CLEGG, Stephanie, Jane, Stevenage, Hertfordshire SG1 2NY (GB)**DOBRYNSKI, Eric, King Of Prussia, PA 19406 (US)****ELLIS, Jonathan, H., Stevenage, Hertfordshire SG1 2NY (GB)****GERMASCHEWSKI, Volker, Stevenage, Hertfordshire SG1 2NY (GB)****GODILLOT, Alexis, Paul, King Of Prussia, PA 19406 (US)****JONAK, Zdenka, Ludmila, King Of Prussia, PA 19406 (US)****LEWIS, Alan, P., Stevenage, Hertfordshire SG1 2NY (GB)****WHITE, John, R., King Of Prussia, PA 19406 (US)**

(74) Képviselő:

Derzsi Katalin, SBGK Szabadalmi Ügyvivői Iroda, Budapest

(54)

Penta-specifikus antitest

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19)



(11)

EP 2 146 745 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
17.06.2015 Bulletin 2015/25

(51) Int Cl.:
C07K 16/24 ^(2006.01) **C07K 16/18** ^(2006.01)
A61K 39/00 ^(2006.01)

(21) Application number: **08745931.9**

(86) International application number:
PCT/US2008/060424

(22) Date of filing: **16.04.2008**

(87) International publication number:
WO 2008/130969 (30.10.2008 Gazette 2008/44)

(54) **penta-specific antibody**

penta-spezifischer Antikörper

anticorps penta-spécifique

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

(30) Priority: **17.04.2007 US 912229 P**
11.04.2008 US 44132

(43) Date of publication of application:
27.01.2010 Bulletin 2010/04

(73) Proprietor: **GlaxoSmithKline LLC**
Wilmington, Delaware 19808 (US)

(72) Inventors:

- **CLEGG, Stephanie, Jane**
Stevenage, Hertfordshire SG1 2NY (GB)
- **DOBZYNSKI, Eric**
King Of Prussia, PA 19406 (US)
- **ELLIS, Jonathan, H.**
Stevenage, Hertfordshire SG1 2NY (GB)
- **GERMASCHEWSKI, Volker**
Stevenage, Hertfordshire SG1 2NY (GB)
- **GODILLOT, Alexis, Paul**
King Of Prussia, PA 19406 (US)
- **JONAK, Zdenka, Ludmila**
King Of Prussia, PA 19406 (US)
- **LEWIS, Alan, P.**
Stevenage, Hertfordshire SG1 2NY (GB)
- **WHITE, John, R.**
King Of Prussia, PA 19406 (US)

(74) Representative: **Sayce, Alastair George et al**
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:

WO-A1-92/04372 WO-A2-02/088185
US-A1- 2004 208 873 US-A1- 2007 161 089
US-A1- 2007 161 089

- **A. KRUPA: "Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 286, no. 6, 1 June 2004 (2004-06-01), pages 1105-1113, XP55010197, ISSN: 1040-0605, DOI: 10.1152/ajplung.00277.2003**
- **RICHARD B. GOODMAN: "Quantitative comparison of C-X-C chemokines produced by endotoxin-stimulated human alveolar macrophages", AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 275, 1 January 1998 (1998-01-01), pages L87-L95, XP55010198, ISSN: 1040-0605**
- **GONG J-H ET AL: "RANTES AND MCP-3 ANTAGONISTS BIND MULTIPLE CHEMOKINE RECEPTORS", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC, US, vol. 271, no. 18, 3 May 1996 (1996-05-03), pages 10521-10527, XP002043933, ISSN: 0021-9258, DOI: 10.1074/JBC.271.32.19037**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 146 745 B1

- ROVIN B H: "Chemokine blockade as a therapy for renal disease", CURRENT OPINION IN NEPHROLOGY & HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, LTD, GB, vol. 9, no. 3, 1 January 2000 (2000-01-01) , pages 225-232, XP008144458, ISSN: 1062-4821
- FRANCIS M J ET AL: "Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 73, no. 3, 1 July 1991 (1991-07-01), pages 249-254, XP009136280, ISSN: 0019-2805
- KATHERINE E. KILPATRICK ET AL: "Rapid Development of Affinity Matured Monoclonal Antibodies Using RIMMS", HYBRIDOMA, vol. 16, no. 4, 1 August 1997 (1997-08-01) , pages 381-389, XP55010201, ISSN: 0272-457X, DOI: 10.1089/hyb.1997.16.381
- FAGETE SEVERINE ET AL: "Specificity tuning of antibody fragments to neutralize two human chemokines with a single agent", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 3, 7 April 2009 (2009-04-07), pages 288-296, XP002598001, ISSN: 1942-0862, DOI: 10.4161/MABS.1.3.8527
- FISCHER N: "New magic bullets can hit more than one target", EXPERT OPINION ON DRUG DISCOVERY, INFORMA HEALTHCARE, LONDON, GB, vol. 3, no. 8, 1 January 2008 (2008-01-01) , pages 833-839, XP008144459, ISSN: 1746-0441
- AHUJA ET AL.: 'the CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor' J. BIOL. CHEM. vol. 271, no. 34, 23 August 1996, pages 20545 - 20550, XP008122069
- SMIT ET AL.: 'The missing link: chemokine receptors and tissue matrix breakdown in COPD' TRENDS IN PHARMACOLOGICAL SCIENCES vol. 27, no. 11, November 2006, pages 555 - 557, XP005710742

Description**Field of the invention**

[0001] The present invention relates to an antibody which has multiple specificities. In particular the antibody of the present invention binds to and neutralises each of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. The antibody may be useful in methods of treating diseases or disorders characterised by elevated or unbalanced level of one or more of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, particularly COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, and/or endometriosis with said antibody.

Background of the invention

[0002] Published data and reports indicate that the members of the ELRCXC subfamily of CXCL chemokines are elevated in a number of diseases. There are a total of 16 CXCL family members. The chemokines are reported to be up-regulated in a number of inflammatory diseases, including COPD, in which CXCL1-3, 5, and 8, also known as Gro- α , - β , - γ (Haskill, S., et al. Proc. Natl. Acad. Sci., 1990: 87, 7732-7736), ENA-78 (Wang, D. and Richmond, A., Cytokine Reference. Oppenheim, J.J. and Feldman, M. ed., Academic Press, London, 1023-1027, Powerm C.A. et al. Gene., 1994: 151, 333-334), and IL-8 (Iizasa, H. and Matsushima, K., Cytokine Reference. Oppenheim, J.J. and Feldman, M. ed., Academic Press, London, 1061-1067, Matsushima, K. et al., J. Exp. Med. 1988: 167, 1883-1893) respectively (Am. J. Respir. Crit Care Med., 163: 349-355, 2001, Am. J. Respir. Crit Care Med., 168: 968-975, 2003, Thorax, 57: 590-595, 2002). It has been postulated that prolonged and elevated expression of these chemokines could be involved in the development of diseases such as COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, or endometriosis. These CXC chemokines are known to stimulate neutrophil chemotaxis by engaging and activating the CXCR1 and/or CXCR2 receptors. Thus the inhibition of these chemokines could prevent inflammatory cells from infiltrating the lung tissue and thus prevent tissue damage. The present invention is directed to inhibiting the activation of CXCR1 and CXCR2 receptors by using an antibody having the ability to bind to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, i.e. a penta-specific antibody.

Summary of the invention

[0003] The present invention relates to an antibody (immunoglobulin) which has multiple specificities contained within one immunoglobulin. In particular the antibody of the present invention binds to and neutralises each of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. The antibody of the present invention may be useful to treat diseases or disorders characterised by elevated or unbalanced level of one or more of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, particularly COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, and/or endometriosis with said antibody.

[0004] The present invention relates to an isolated antibody which has specificity for and neutralises each of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78; thus we define the antibody of the present invention as penta-specific (or pan-ELR) antibody. The definition of antibody includes an antigen binding portion (or fragment) of the antibody such that the antigen binding portion (or fragment) binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. The penta-specific antibody of the invention is preferably murine monoclonal, chimeric, human or humanized. For avoidance of doubt, the penta-specific antibody of the present invention need not bind solely to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 antigens, but it may also bind to other related proteins (such as human GCP-2, or may even bind to non-human orthologues of IL-8, Gro-alpha, Gro-beta, Gro-gamma, ENA-78, and GCP-2); in other words, the penta-specific antibody of the present invention minimally binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.

[0005] Preferably, a penta-specific antibody of the present invention binds to each of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 with equilibrium constant, K_D , values of less than 10^{-7} M, more preferably less than 10^{-8} M, and even more preferably less than 10^{-9} M as determined by surface plasmon resonance. Typically surface plasmon resonance measurement is conducted as described below.

[0006] In one embodiment, a penta-specific antibody binds within epitope of KELRCQCIKTYSKP (SEQ ID NO: 54) in human IL-8.

[0007] In one embodiment, the penta-specific antibody of the present invention is generated by a method comprising the steps of using RIMMs (Kilpatrick, K.E., et al. Hybridoma. 1997: 16, 381.) type protocol using a mixture (cocktail) of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 together with a set of five multiple antigenic peptides (MAPs) each MAP unit having one separate sequence from polypeptides of ID NOs: 49-53.

LATELRSQSLQTLQG	SEQ ID NO: 49
SAKELRSQSIKTYSK	SEQ ID NO: 50
LRELRSVSLQTTQG	SEQ ID NO: 51
SPGPHSAQTEVIAT	SEQ ID NO: 52
ESGPHSANTEIIVK	SEQ ID NO: 53

[0008] Without being bound by theory, MAPs serve two functions within the immunization protocol. First, MAPs allow for a selective multiple presentation of a known target amino acid sequence to the host immune system. Secondly, the increase in mass, due to multiple copies of the sequence linked via a core, such as, but not limited to lysine, increases the immunogenicity of the sequence over that of individual peptides (Francis, J.P., et al., Immunology, 1991: 73; 249, Schott, M.E., et al., Cell. Immuno. 1996: 174: 199-209, Tam, J.P. Proc. Natl. Acad. Sci. 1988: 85; 5409-5413).

[0009] The MAPs used to generate this invention are comprised of multiple copies of the conserved target sequences (e.g. SEQ ID NOs: 49-53) found with and around the ELRCXC and GPHCA regions of target chemokines. Exemplary MAP set is depicted in Figure 1.

[0010] In one embodiment, a penta-specific antibody of the present invention is generated by a method comprising the steps of:

- a. injecting into a mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 in complete Freund's adjuvant (cFA);
- b. injecting into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 in incomplete Freund's adjuvant (iFA); and
- c. injecting into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and a set of five multiple antigenic peptides (MAPs), each MAP unit having one separate sequence from polypeptides of ID NOs: 49-53 in incomplete Freund's adjuvant;
- d. isolating B cells from the mouse;
- e. fusing the B cells with myeloma cells to form immortal hybridoma cells that secrete the desired penta-specific antibody; and
- f. isolating the penta-specific antibody from the culture supernatant of the hybridoma.

If desired, one can optionally inject into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and a set of MAPs comprising amino acid sequences of SEQ ID NOs: 49-53 in PBS between steps c and d.

[0011] In another embodiment, a penta-specific antibody of the present invention is generated by a method comprising the steps of:

- a. injecting into a mouse a set of five multiple antigenic peptides (MAPs) each MAP unit having one separate sequence from polypeptides of ID NOs: 49-53 (hereinafter also referred to as the MAP set) in complete Freund's adjuvant;
- b. injecting into the mouse the MAP set in incomplete Freund adjuvant;
- c. injecting into the mouse a mixture of all human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and the MAP set in incomplete Freund's adjuvant;
- d. isolating B cells from the mouse; and

e. fusing the B cells with myeloma cells to form immortal hybridoma cells that secrete the desired penta-specific antibody; and

f. isolating the penta-specific antibody from the culture supernatant of the hybridoma.

If desired, one can optionally inject into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and a set of MAPs having SEQ ID NOs: 49-53 in PBS between steps c and d.

[0012] In one embodiment, a penta-specific antibody has heavy and light chain variable regions encoded by nucleotide sequences comprising sequences of SEQ ID NO: 1 and SEQ ID NO:3, respectively, or conservative sequence modifications thereof.

[0013] In one embodiment, a penta-specific antibody has heavy and light chain variable regions encoded by nucleotide sequences comprising sequences of SEQ ID NO:5 and SEQ ID NO:7, respectively, or conservative sequence modifications thereof.

[0014] In one embodiment, a penta-specific antibody has heavy chain variable region encoded by a nucleotide sequence comprising sequence of SEQ ID NO:9, or conservative sequence modifications thereof.

[0015] In one embodiment, a penta-specific antibody has heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NO :2 and SEQ ID NO:4, respectively, or conservative sequence modifications thereof.

[0016] In one embodiment, a penta-specific antibody has heavy and light chain variable regions comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:4, respectively.

[0017] In one embodiment, a penta-specific antibody has heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NO:6 and SEQ ID NO:8, respectively, or conservative sequence modifications thereof.

[0018] In one embodiment, a penta-specific antibody has heavy and light chain variable regions comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:6 and SEQ ID NO:8, respectively.

[0019] In one embodiment, a penta-specific antibody has heavy and light variable regions comprising the amino acid sequences of SEQ ID NOs:10 and 12, respectively, or conservative sequence modifications thereof.

[0020] In one embodiment, a penta-specific antibody has heavy and light chain variable regions comprising polypeptide sequences which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NOs:10 and 12, respectively.

[0021] In one embodiment, a penta-specific antibody comprises at least one variable region selected from (i) the amino acid SEQ ID NO: 2,4, 6, 8, 10, or 12; or (ii) an amino acid sequence which is at least 90%, 95%, 98% or 99% identical to any one of the amino acid sequences of (i) above.

[0022] In one embodiment, a penta-specific antibody comprises CDR sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18; or one or more of the CDR sequences can be conservative sequence modifications of the sequences SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

In one embodiment, the present invention relates to hybridoma or transfectoma which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

In one embodiment, the present invention relates to a recombinant eukaryotic or prokaryotic cell which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

[0023] In one embodiment, a penta-specific antibody comprises at least one CDR sequence selected from (i) SEQ ID NO: 13, 14, 15, 16, 17, or 18; or (ii) a conservative sequence modification of the sequences listed in (i).

[0024] In one embodiment, a penta-specific antibody comprises a polypeptide of SEQ ID NO:15.

[0025] In one embodiment, a penta-specific antibody comprises at least four CDR sequences selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17, and 18; or one or more of the CDR sequences can be conservative sequence modifications of the sequences listed in SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

In one embodiment, a penta-specific antibody comprises heavy and light chain variable regions which comprise the CDR amino acid sequences of SEQ ID NOs: 13, 14, and 15, and SEQ ID NOs: 16, 17, and 18, respectively.

[0026] In one embodiment, a penta-specific antibody comprises CDR sequences of SEQ ID NOs: 19, 20, 21, 22, 23, and 24; or one or more the CDR sequences can be conservative sequence modifications of the sequences listed in SEQ ID NOs: 19, 20,21, 22, 23, and 24.

In one embodiment, the present invention relates to an hybridoma or transfectoma which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 19, 20, 21, 22, 23, and 24.

[0027] In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic cell which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 19, 20, 21, 22, 23, and 24.

[0028] In one embodiment, a penta-specific antibody comprises at least one CDR sequence selected from (i) SEQ ID NO: 19, 20, 21, 22, 23, or 24; or (ii) a conservative sequence modification of the sequences listed in (i).

[0029] In one embodiment, a penta-specific antibody comprises a polypeptide of SEQ ID NO:21.

[0030] In one embodiment, a penta-specific antibody comprises at least four CDR sequences selected from the group consisting of: SEQ ID NOs: 19, 20, 21, 22, 23, and 24; or one or more of the CDR sequences can be conservative sequence modifications of the sequences listed in SEQ ID NOs: 19, 20, 21, 22, 23, and 24.

In one embodiment, a penta-specific antibody comprises heavy and light chain variable regions which comprise the CDR amino acid sequences of SEQ ID NOs: 19, 20, and 21, and SEQ ID NOs: 22, 23, and 24, respectively.

[0031] In one embodiment, a penta-specific antibody comprises CDR sequences of SEQ ID NOs: 25, 26, 27, 28, 29, and 30; or one or more the CDR sequences can be conservative sequence modifications of the sequences listed in SEQ ID NOs: 25, 26, 27, 28, 29, and 30.

In one embodiment, the present invention relates to an hybridoma or transfectoma which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 25, 26, 27, 28, 29, and 30.

[0032] In one embodiment, the present invention relates to a recombinant eukaryotic or prokaryotic cell which produces a penta-specific antibody which comprises CDR sequences of SEQ ID NOs: 25, 26, 27, 28, 29 and 30.

[0033] In one embodiment, a penta-specific antibody comprises at least one CDR sequence selected from (i) SEQ ID NO: 25, 26, 27, 28, 29, or 30; or (ii) a conservative sequence modification of the sequences listed in (i).

[0034] In one embodiment, a penta-specific antibody comprises a polypeptide of SEQ ID NO:27.

[0035] In one embodiment, a penta-specific antibody comprises at least four CDR sequences selected from the group consisting of: SEQ ID NOs : 25, 26, 27, 28, 29, and 30; or one or more of the CDR sequences can be conservative modifications of the sequences listed in SEQ ID NOs: 25, 26, 27, 28, 29, and 30.

[0036] In one embodiment, a penta-specific antibody comprises heavy and light variable chain regions which comprise the CDR amino acid sequences of SEQ ID NOs: 25, 26, and 27, and SEQ ID NOs: 28, 29 and 30, respectively.

[0037] In one embodiment, the present invention concerns a hybridoma which produces a monoclonal antibody having heavy or light chain variable region encoded by nucleotide sequences comprising nucleotide sequences of SEQ ID NO: 1, 5, or 9, or SEQ ID NO:3 or 7, respectively.

[0038] In one embodiment, the present invention concerns a hybridoma which produces a monoclonal antibody having heavy or light chain variable region comprising the amino acid sequences of SEQ ID NO:2, 6, or 10, or SEQ ID NO: 4, 8, or 12, respectively, and conservative sequence modifications thereof.

[0039] In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic host cell which produces a penta-specific antibody having heavy or light variable region which comprise the amino acid sequences of SEQ ID NO:2, 6, or 10, or SEQ ID NO:4, 8, or 12, respectively, and conservative sequence modifications thereof.

[0040] In one embodiment, the present invention relates to an expression vector comprising nucleotide sequences encoding a variable heavy or light chain of a penta-specific antibody comprising the CDR sequences of SEQ ID NOs: 13, 14, and 15; or SEQ ID NOs: 16, 17, and 18, respectively.

[0041] In one embodiment, the present invention relates to an expression vector comprising a nucleotide sequence encoding a CDR sequence of a penta-specific antibody selected from SEQ ID NO: 13, 14, 15, 16, 17, or 18.

[0042] In one embodiment, the present invention relates to an expression vector comprising nucleotide sequences encoding at least four CDR sequences of a penta-specific antibody selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17, and 18.

[0043] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences of SEQ ID NOs: 31, 32, or 33.

[0044] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences of SEQ ID NOs: 34, 35, and 36.

[0045] In one embodiment the present invention relates to an expression vector comprising at least four polynucleotide sequences selected from the group of SEQ ID NOs: 31, 32, 33, 34, 35, and 36.

[0046] In one embodiment, the present invention relates to an expression vector comprising nucleotide sequences encoding a variable heavy or light chain of a penta-specific antibody comprising the CDR sequences of SEQ ID NOs: 19, 20, and 21; or 22, 23, and 24, respectively.

[0047] In one embodiment, the present invention relates to an expression vector comprising a nucleotide sequence encoding a CDR sequence of a penta-specific antibody selected from SEQ ID NO: 19, 20, 21, 22, 23, or 24.

[0048] In one embodiment, the present invention relates to an expression vector comprising nucleotide sequences encoding at least four CDR sequences of a penta-specific antibody selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23, and 24.

[0049] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences of SEQ ID NOs: 37, 38, and 39.

[0050] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences of SEQ ID NOs: 40, 41, and 42.

[0051] In one embodiment the present invention relates to an expression vector comprising at least four polynucleotide sequences selected from the group of SEQ ID NOs: 37, 38, 39, 40, 41, and 42.

[0052] In one embodiment, the present invention relates to an expression vector comprising nucleotide sequences

encoding a variable heavy chain of a penta-specific antibody comprising the CDR sequences of SEQ ID NOs: 25,26, and 27.

[0053] In one embodiment, the present invention relates to an expression vector comprising a nucleotide sequence encoding a CDR sequence of a penta-specific antibody selected from SEQ ID NO: 25, 26, or 27.

[0054] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences of SEQ ID NOs: 43, 44, and 45.

[0055] In one embodiment, a penta-specific antibody has heavy and light chains encoded by nucleotide sequences comprising sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively.

[0056] In one embodiment, a penta-specific antibody has heavy and light chains encoded by nucleotide sequences comprising sequences which are at least 90%, 95%, 98% or 99% identical to sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively.

[0057] In one embodiment, a penta-specific antibody has heavy and light chains comprising the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively.

[0058] In one embodiment, a penta-specific antibody has heavy and light chains comprising the amino acid sequences of SEQ ID NO:46 and SEQ ID NO:48, respectively.

[0059] In one embodiment, a penta-specific antibody has heavy and light chains comprising the amino acid sequences of SEQ ID NO:46 and SEQ ID NO:60, respectively.

[0060] In one embodiment, a penta-specific antibody has heavy and light chains comprising the amino acid sequences of SEQ ID NO:46 and SEQ ID NO: 62, respectively.

[0061] In one embodiment, a penta-specific antibody has heavy and light chains comprising the amino acid sequences of SEQ ID NO:46 and SEQ ID NO:64, respectively.

[0062] In one embodiment, a penta-specific antibody has heavy and light chains comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively. In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic host cell which produces a penta-specific antibody having heavy or light chain comprising the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO:48, 60, 62, or 64, respectively.

[0063] In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic host cell which produces a penta-specific antibody having heavy and light chains comprising the amino acid sequences of SEQ ID NO: 46, and SEQ ID NO:48, 60, 62, or 64, respectively.

[0064] In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic host cell which produces a penta-specific antibody having heavy or light chain comprising the amino acid sequence which is at least 90%, 95%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO:48, 60, 62, or 64, respectively.

[0065] In one embodiment, the present invention relates to a recombinant eukaryotic or a prokaryotic host cell which produces a penta-specific antibody having heavy and light chains comprising the amino acid sequences which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO: 46, and SEQ ID NO:48, 60, 62, or 64, respectively.

[0066] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences comprising sequences of SEQ ID NO: 11, and SEQ ID NO:47, 59, 61, or 63, respectively.

[0067] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences comprising sequences which are at least 90%, 95%, 98% or 99% identical to sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively.

[0068] In one embodiment, the present invention relates to an expression vector comprising a polynucleotide sequence comprising a sequence of SEQ ID NO:11, 47, 59, 61, or 63.

[0069] In one embodiment, the present invention relates to an expression vector comprising a polynucleotide sequence comprising a sequence which is at least 90%, 95%, 98% or 99% identical to a sequence of SEQ ID NO:11, 47, 59, 61, or 63, respectively.

[0070] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences which encode a penta-specific antibody comprising heavy and light chains comprising the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively.

[0071] In one embodiment, the present invention relates to an expression vector comprising polynucleotide sequences which encode a penta-specific antibody comprising heavy and light chains comprising the amino acid sequences which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively.

[0072] In one embodiment, the present invention relates to an expression vector comprising a polynucleotide sequence which encode a polypeptide comprising the amino acid sequence of SEQ ID NO:46, 48, 60, 62, or 64.

[0073] In one embodiment, the present invention relates to an expression vector comprising a polynucleotide sequence which encode a polypeptide comprising an amino acid sequence which is at least 90%, 95%, 98% or 99% identical to

the amino acid sequences of SEQ ID NO:46, 48, 60, 62, or 64.

[0074] In one embodiment the present invention relates to a process for producing a penta-specific antibody (immunoglobulin) in a single host cell, comprising the steps of:

- (i) transforming said single host cell with a first DNA sequence encoding a heavy chain comprising polypeptide of SEQ ID NO: 46; and a second DNA sequence encoding a light chain comprising a polypeptide of SEQ ID NO: 48, 60, 62, or 64; and
- (ii) expressing said first DNA sequence and said second DNA sequence so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed single host cell;

furthermore, this process can be carried out such that said first and second DNA sequences are present in different vectors or said first and second DNA sequences are present in a single vector.

[0075] In one embodiment the present invention relates to a process for producing a penta-specific antibody (immunoglobulin) in a single host cell, comprising the steps of:

- (i) transforming said single host cell with a first DNA sequence encoding at least the variable domain of the immunoglobulin heavy chain comprising CDR domains of SEQ ID NOs: 13, 14, and 15; and a second DNA sequence encoding at least the variable domain of the immunoglobulin light chain comprising CDR domains of SEQ ID NOs: 16, 17, and 18; and
- (ii) expressing said first DNA sequence and said second DNA sequence so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed single host cell;

furthermore, this process can be carried out such that said first and second DNA sequences are present in different vectors or said first and second DNA sequences are present in a single vector.

[0076] In one embodiment the present invention relates to a process for producing a penta-specific antibody (immunoglobulin) in a single host cell, comprising the steps of:

- (i) transforming said single host cell with a first DNA sequence encoding at least the variable domain of the immunoglobulin heavy chain comprising CDR domains of SEQ ID NOs: 19, 20, and 21; and a second DNA sequence encoding at least the variable domain of the immunoglobulin light chain comprising CDR domains of SEQ ID NOs: 22, 23, and 24; and
- (ii) expressing said first DNA sequence and said second DNA sequence so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed single host cell;

this process can be carried out such that said first and second DNA sequences are present in different vectors or said first and second DNA sequences are present in a single vector.

[0077] In one embodiment, the present invention relates to a composition comprising an aforementioned penta-specific antibody and a pharmaceutically acceptable carrier.

[0078] In one aspect, the present invention relates to an aforementioned penta-specific antibody for use in preventing and/or treating COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, and/or endometriosis in a mammal.

[0079] In one embodiment, above mammal is human.

Description of Figures

[0080]

Figure 1 depicts an exemplary set of MAPs to generate a penta-specific antibody. For avoidance of doubt, five MAP peptide units are depicted. Each unit contains one identical amino acid sequence selected from linear peptides of SEQ ID NO: 49-53.

Figure 2 shows flow cytometric data comparing neutrophils present in BAL samples. Sessions 1, 2 and 3 are presented. The black solid bars show the baselines 5 day pre-LPS challenge. The grey solid bars depict the BAL data 6-hours post LPS challenge. The Chimera Antibody (HcLc) treatment significantly and dose dependently inhibited neutrophil infiltration. The grey hatched bars represent 24-hour data. (n=6, *p≤0.05, †p≤0.01, error bars represent standard deviation).

Figure 3 shows hematological analysis of total circulating neutrophils (cell count). IV injection of 1 (open squares,

□) and 10 mg/kg (closed circles, •) of the Chimera Antibody (HcLc) prevented inhaled LPS stimulation of circulating neutrophils. Both 1 and 10 mg/kg treatments are significantly reduced compared to the vehicle NHP (†) and 10 mg/kg treatment was also significantly reduced compared to the 1 mg/kg dose (*). Data are represented as total count per ul of blood (n=6, * $p \leq 0.05$ vs. 1 mg/kg, † $p < 0.01$ vs. vehicle, error bars represent standard deviation).

Figure 4 shows inhibition human IL-8 stimulated neutrophil activation (increased CD11b surface expression). Various concentrations of the humanized penta-specific antibodies were pre-incubated with 10 nM hIL-8 prior to addition to purified human neutrophils. Data are expressed as mean values of 4 different donors (n=4). Bars represent standard error. All samples are compared to purified neutrophils stimulated with hIL-8 only (no mAb prior to addition to purified neutrophils). Humanized construct H0L10 and HOMO are more effective at inhibiting hIL-8 stimulated CD11b surface expression.

Figure 5A shows mouse 656.35 mAb binding to target human chemokines.

Figure 5B shows the Chimera Antibody (HcLc) mAb binding to human target chemokines.

Figure 5C shows humanized mAbs binding to human target chemokines.

Detailed Description of the Invention

[0081] An "isolated penta-specific antibody" or simply "penta-specific antibody", as used herein, is intended to refer to an antibody that binds to and therefore cross reacts with human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and is substantially free of other antibodies having different antigenic specificities, and furthermore, is a single composition of matter. For avoidance of doubt, the penta-specific antibody of the present invention need not bind solely to human IL-8, Gro-alpha, Gro-beta, Gro-gamma" and ENA-78 antigens, but it may also happen to bind to other related proteins, such as human GCP-2, or may even bind to non-human orthologues of IL-8, Gro-alpha, Gro-beta, Gro-gamma, ENA-78, and GCP-2; in other words the penta-specific antibody of the present invention minimally binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. Moreover, an isolated penta-specific antibody is substantially free of other cellular material and/or chemicals. A penta-specific antibody, as used in this context, also includes antigen binding fragments and/or derivatives having the binding characteristics of their "parent" penta-specific antibody. The penta-specific antibody of the present invention may comprise two identical heavy chains and two identical light chains, forming the typical, bilaterally symmetric immunoglobulin molecule comprised of two heterodimers which are each comprised of a heavy chain and a light chain. Accordingly, the penta-specific antibody of the present invention may comprise two copies of the same antigen binding domain formed by the association of one heavy chain with one light chain. The penta-specific antibody of the present invention, though having only one kind of binding domain is still able to bind to and therefore cross react with human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.

[0082] As used herein, "antibody" is also referred to as "immunoglobulin".

[0083] As used herein, "an antibody that cross reacts with" means the antibody binds not only to one antigen but binds to other antigens as well.

[0084] "Neutralizing," as used herein is intended to refer to a partial or full inhibition of at least one biological activities of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, or ENA-78. For example, one of the the biological activities of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, or ENA-78 is its ability to induce neutrophil chemotaxis.

[0085] One way of measuring the binding kinetics of an antibody is by surface plasmon resonance. The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, N.J.). For further descriptions, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U., et al. (1991) Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131; and Johnsson, B., et al. (1991) Anal. Biochem. 198:268-277. The term "epitope" means a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.

[0086] A "monoclonal antibody" or mAb (as opposed to polyclonal antibody) as used herein is intended to refer to a preparation of antibody molecules of single molecular composition. For example, a murine derived monoclonal antibody (mouse monoclonal antibody) can be prepared by hybridoma technology, such as the standard Kohler and Milstein hybridoma methodology.

[0087] Antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975, Nature 256:495-497) (see also, Brown et al. (1981) J. Immunol 127:539-46; Brown et al. (1980) J Biol Chem 255:4980-83; Yeh et al. (1976) PNAS 76:2927-31; and Yeh et al. (1982) Int. J. Cancer 29:269-75). The technology for producing monoclonal antibody hybridomas is well known (see generally R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, N.Y. (1980); E. A. Lerner (1981) Yale J. Biol. Med., 54:387-402; M. L. Gefter et al. (1977) Somatic Cell Genet., 3:231-36).

[0088] The term "transfectoma", as used herein, includes recombinant eukaryotic host cell expressing the antibody, such as CHO cells, NS/O cells, HEK293 cells, plant cells, or fungi, including yeast cells.

[0089] As used herein, "specific" binding refers to antibody binding to a predetermined antigen. Typically, the antibody binds with an equilibrium constant, KD , corresponding to about 1×10^{-7} M or less, and binds to the predetermined antigen with an affinity corresponding to a KD that is at least two orders of magnitude lower than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen. The phrases "an antibody recognizing an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody which binds specifically to an antigen".

[0090] As used herein, the term " kd " (sec^{-1}), as used herein, is intended to refer to the dissociation rate constant of a particular antibody-antigen interaction.

[0091] The term " ka " ($M \times \text{sec}^{-1}$), as used herein, is intended to refer to the association rate constant of a particular antibody-antigen interaction.

[0092] The term " KD " (M), as used herein, is intended to refer to the equilibrium constant of a particular antibody-antigen interaction and is obtained by dividing the kd by the ka .

[0093] "Conservative sequence modifications" for nucleotide and amino acid sequence modifications means changes which do not significantly affect or alter the binding characteristics of the antibody encoded by the nucleotide sequence or containing the amino acid sequence. Such conservative sequence modifications include nucleotide and amino acid substitutions, additions and deletions. Modifications can be introduced into the sequences by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an antibody for which sequence is specifically disclosed is preferably replaced with another amino acid residue from the same side chain family. Thus in one aspect, the penta-specific antibody of the present invention includes all the conservative sequence modifications of the specifically disclosed amino acid sequences.

[0094] The present invention also encompasses "derivatives" of the amino acid sequences as specifically disclosed, wherein one or more of the amino acid residues have been derivatized, e.g., by acylation or glycosylation, without significantly affecting or altering the binding characteristics of the antibody containing the amino acid sequences.

[0095] For nucleic acids, the term "substantial identity" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared, are identical, with appropriate nucleotide insertions or deletions, in at least about 80% of the nucleotides, usually at least about 90% to 95%, and more preferably at least about 98% to 99.5% of the nucleotides. Alternatively, substantial identity when the segments will hybridize under selective hybridization conditions, to the complement of the strand.

[0096] For nucleotide and amino acid sequences, the term "identity" indicates the degree of identity between two nucleic acid or amino acid sequences when optimally aligned and compared with appropriate insertions or deletions. Alternatively, substantial identity exists when the DNA segments will hybridize under selective hybridization conditions, to the complement of the strand.

The percent identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., $\% \text{ identity} = \# \text{ of identical positions} / \text{total} \# \text{ of positions} \times 100$), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.

[0097] The percent identity between two nucleotide or polypeptide sequences can be determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0098] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. With respect to transcription of regulatory sequences, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.

For switch sequences, operably linked indicates that the sequences are capable of effecting switch recombination.

[0099] The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0100] The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Recombinant host cells include, for example, transfectomas, such as CHO cells, NS/O cells, and lymphocytic cells.

[0101] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.

1. Antibody Structures

Intact Antibodies

[0102] Intact antibodies are usually heteromultimeric glycoproteins comprising at least two heavy and two light chains. Aside from IgM, intact antibodies are heterotetrameric glycoproteins of approximately 150Kda, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each light chain is linked to a heavy chain by one covalent disulfide bond while the number of disulfide linkages between the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V_H) followed by a number of constant regions. Each light chain has a variable domain (V_L) and a constant region at its other end; the constant region of the light chain is aligned with the first constant region of the heavy chain and the light chain variable domain is aligned with the variable domain of the heavy chain. The light chains of antibodies from most vertebrate species can be assigned to one of two types called Kappa and Lambda based on the amino acid sequence of the constant region. Depending on the amino acid sequence of the constant region of their heavy chains, human antibodies can be assigned to five different classes, IgA, IgD, IgE, IgG and IgM. IgG and IgA can be further subdivided into subclasses, IgG1, IgG2, IgG3 and IgG4; and IgA1 and IgA2. Species variants exist with mouse and rat having at least IgG2a, IgG2b. The variable domain of the antibody confers binding specificity upon the antibody with certain regions displaying particular variability called complementarity determining regions (CDRs). The more conserved portions of the variable region are called framework regions (FR). The variable domains of intact heavy and light chains each comprise four FR connected by three CDRs. The CDRs in each chain are held together in close proximity by the FR regions and with the CDRs from the other chain contribute to the formation of the antigen binding site of antibodies. The constant regions are not directly involved in the binding of the antibody to the antigen but exhibit various effector functions such as participation in antibody dependent cell-mediated cytotoxicity (ADCC), phagocytosis via binding to Fc γ receptor, half-life/clearance rate via neonatal Fc receptor (FcRn) and complement dependent cytotoxicity via the C1q component of the complement cascade. The human IgG2 constant region lacks the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. The IgG4 constant region lacks the ability to activate complement by the classical pathway and mediates antibody-dependent cellular cytotoxicity only weakly. Antibodies essentially lacking these effector functions may be termed 'non-lytic' antibodies.

Human antibodies

[0103] Human antibodies may be produced by a number of methods known to those of skill in the art. Human antibodies can be made by the hybridoma method using human myeloma or mouse-human heteromyeloma cells lines see Kozbor J.Immunol 133, 3001, (1984) and Brodeur, Monoclonal Antibody Production Techniques and Applications, pp51-63

(Marcel Dekker Inc, 1987). Alternative methods include the use of phage libraries or transgenic mice both of which utilize human V region repertoires (see Winter G, (1994), Annu.Rev.Immunol 12,433-455, Green LL (1999), J.Immunol.methods 231, 11-23).

[0104] Several strains of transgenic mice are now available wherein their mouse immunoglobulin loci has been replaced with human immunoglobulin gene segments (see Tomizuka K, (2000) PNAS 97,722-727; Fishwild D.M (1996) Nature Biotechnol. 14,845-851, Mendez MJ, 1997, Nature Genetics, 15,146-156). Upon antigen challenge such mice are capable of producing a repertoire of human antibodies from which antibodies of interest can be selected.

[0105] Of particular note is the TrimerTM system (see Eren R et al, (1998) Immunology 93:154-161) where human lymphocytes are transplanted into irradiated mice, the Selected Lymphocyte Antibody System (SLAM, see Babcook et al, PNAS (1996) 93:7843-7848) where human (or other species) lymphocytes are effectively put through a massive pooled in vitro antibody generation procedure followed by deconvulated, limiting dilution and selection procedure and the Xenomouse IITM (Abgenix Inc). An alternative approach is available from Morphotek Inc using the MorphodomaTM technology.

[0106] Phage display technology can be used to produce human antibodies (and fragments thereof), see McCafferty; Nature, 348, 552-553 (1990) and Griffiths AD et al (1994) EMBO 13:3245-3260. According to this technique antibody V domain genes are cloned in frame into either a major or minor coat of protein gene of a filamentous bacteriophage such as M13 or fd and displayed (usually with the aid of a helper phage) as functional antibody fragments on the surface of the phage particle. Selections based on the functional properties of the antibody result in selection of the gene encoding the antibody exhibiting those properties. The phage display technique can be used to select antigen specific antibodies from libraries made from human B cells taken from individuals afflicted with a disease or disorder described above or alternatively from unimmunized human donors (see Marks; J.Mol.Bio. 222,581-597,1991). Where an intact human antibody is desired comprising a Fc domain it is necessary to reclone the phage displayed derived fragment into a mammalian expression vectors comprising the desired constant regions and establishing stable expressing cell lines.

[0107] The technique of affinity maturation (Marks; Bio/technol 10,779-783 (1992)) may be used to improve binding affinity wherein the affinity of the primary human antibody is improved by sequentially replacing the H and L chain V regions with naturally occurring variants and selecting on the basis of improved binding affinities. Variants of this technique such as "epitope imprinting" are now also available see WO 93/06213. See also Waterhouse; Nucl.Acids Res 21, 2265-2266 (1993).

Chimaeric and Humanised Antibodies

[0108] The use of intact non-human antibodies in the treatment of human diseases or disorders carries with it the now well established problems of potential immunogenicity especially upon repeated administration of the antibody that is the immune system of the patient may recognise the non-human intact antibody as non-self and mount a neutralising response. In addition to developing fully human antibodies (see above) various techniques have been developed over the years to overcome these problems and generally involve reducing the composition of non-human amino acid sequences in the intact therapeutic antibody whilst retaining the relative ease in obtaining non-human antibodies from an immunised animal e.g. mouse, rat or rabbit. Broadly two approaches have been used to achieve this. The first are chimaeric antibodies, which generally comprise a non-human (e.g. rodent such as mouse) variable domain fused to a human constant region. Because the antigen-binding site of an antibody is localised within the variable regions the chimaeric antibody retains its binding affinity for the antigen but acquires the effector functions of the human constant region and are therefore able to perform effector functions such as described *supra*. Chimaeric antibodies are typically produced using recombinant DNA methods. DNA encoding the antibodies (e.g. cDNA) is isolated and sequenced using conventional procedures (e.g. by using oligonucleotide probes that are capable of binding specifically to genes encoding the H and L chain variable regions of the antibody of the invention. Hybridoma cells serve as a typical source of such DNA. Once isolated, the DNA is placed into expression vectors which are then transfected into host cells such as *E.Coli*, COS cells, CHO cells or myeloma cells that do not otherwise produce immunoglobulin protein to obtain synthesis of the antibody. The DNA may be modified by substituting the coding sequence for human L and H chains for the corresponding non-human (e.g. murine) H and L constant regions see e.g. Morrison; PNAS 81, 6851 (1984). Thus another embodiment of the invention there is provided a chimaeric antibody comprising a V_H domain having the sequence: SEQ ID No:2, 6, or 10 and a V_L domain having the sequence: SEQ ID No: 4, 8, or 12 fused to a human constant region (which maybe of a IgG isotype e.g. IgG1).

[0109] The second approach involves the generation of humanised antibodies wherein the non-human content of the antibody is reduced by humanizing the variable regions. Two techniques for humanisation have gained popularity. The first is humanisation by CDR grafting. CDRs build loops close to the antibody's N-terminus where they form a surface mounted in a scaffold provided by the framework regions. Antigen-binding specificity of the antibody is mainly defined by the topography and by the chemical characteristics of its CDR surface. These features are in turn determined by the conformation of the individual CDRs, by the relative disposition of the CDRs, and by the nature and disposition of the

side chains of the residues comprising the CDRs. A large decrease in immunogenicity can be achieved by grafting only the CDRs of a non-human (e.g. murine) antibodies ("donor" antibodies) onto a suitable human framework ("acceptor framework") and constant regions (see Jones et al (1986) Nature 321,522-525 and Verhoeyen M et al (1988) Science 239, 1534-1536). However, CDR grafting *per se* may not result in the complete retention of antigen-binding properties and it is frequently found that some framework residues of the donor antibody need to be preserved (sometimes referred to as "backmutations") in the humanised molecule if significant antigen-binding affinity is to be recovered (see Queen C et al (1989) PNAS 86, 10,029-10,033, Co, M et al (1991) Nature 351, 501-502). In this case, human V regions showing the greatest sequence homology (typically 60% or greater) to the non-human donor antibody maybe chosen from a database in order to provide the human framework (FR). The selection of human FRs can be made either from human consensus or individual human antibodies. Where necessary key residues from the donor antibody are substituted into the human acceptor framework to preserve CDR conformations. Computer modelling of the antibody maybe used to help identify such structurally important residues, see WO99/48523.

[0110] Alternatively, humanisation maybe achieved by a process of "veneering". A statistical analysis of unique human and murine immunoglobulin heavy and light chain variable regions revealed that the precise patterns of exposed residues are different in human and murine antibodies, and most individual surface positions have a strong preference for a small number of different residues (see Padlan E.A. et al; (1991) Mol.Immunol.28, 489-498 and Pedersen J.T. et al (1994) J.Mol.Biol. 235; 959-973). Therefore it is possible to reduce the immunogenicity of a non-human Fv by replacing exposed residues in its framework regions that differ from those usually found in human antibodies. Because protein antigenicity can be correlated with surface accessibility, replacement of the surface residues may be sufficient to render the mouse variable region "invisible" to the human immune system (see also Mark G.E. et al (1994) in Handbook of Experimental Pharmacology vol.113: The pharmacology of monoclonal Antibodies, Springer-Verlag, pp105-134). This procedure of humanisation is referred to as "veneering" because only the surface of the antibody is altered, the supporting residues remain undisturbed. A further alternative approach is set out in WO04/006955. Further alternative approaches include that set out in WO04/006955 and the procedure of Humaneering™ (Kalobios) which makes use of bacterial expression systems and produces antibodies that are close to human germline in sequence (Alfenito-M Advancing Protein Therapeutics January 2007, San Diego, California). Another, approach to humanisation involves selecting human acceptor frameworks on the basis of structural similarity of the human CDR regions to those of the donor mouse antibody CDR regions rather than on homology between other regions of the antibody such as framework regions. This process is also known as Superhumanisation™ (Evogenix Inc.; Hwang et al (2005) Methods 36:35-42).

[0111] It will be apparent to those skilled in the art that the term "derived" is intended to define not only the source in the sense of it being the *physical* origin for the material but also to define material which is structurally identical to the material but which does not originate from the reference source. Thus "residues found in the donor antibody" need not necessarily have been purified from the donor antibody.

Antibody Fragments

[0112] In certain embodiments of the invention there is provided therapeutic antibody which is an antigen binding fragment. Such fragments may be functional antigen binding fragments of intact and/or humanised and/or chimaeric antibodies such as Fab, Fd, Fab', F(ab')₂, Fv, ScFv fragments of the antibodies described *supra*. Fragments lacking the constant region lack the ability to activate complement by the classical pathway or to mediate antibody-dependent cellular cytotoxicity. Traditionally such fragments are produced by the proteolytic digestion of intact antibodies by e.g. papain digestion (see for example, WO 94/29348) but may be produced directly from recombinantly transformed host cells. For the production of ScFv, see Bird et al ;(1988) Science, 242,423-426. In addition, antibody fragments may be produced using a variety of engineering techniques as described below.

[0113] Fv fragments appear to have lower interaction energy of their two chains than Fab fragments. To stabilise the association of the V_H and V_L domains, they have been linked with peptides (Bird et al, (1988) Science 242, 423-426, Huston et al, PNAS, 85, 5879-5883), disulphide bridges (Glockshuber et al, (1990) Biochemistry, 29,1362-1367) and "knob in hole" mutations (Zhu et al (1997), Protein Sci., 6, 781-788). ScFv fragments can be produced by methods well known to those skilled in the art see Whitlow et al (1991) Methods companion Methods Enzymol, 2, 97-105 and Huston et al (1993) Int.Rev.Immunol 10, 195-217. ScFv may be produced in bacterial cells such as *E.Coli* but are more typically produced in eukaryotic cells. One disadvantage of ScFv is the monovalency of the product, which precludes an increased avidity due to polyvalent binding, and their short half-life. Attempts to overcome these problems include bivalent (ScFv)₂ produced from ScFV containing an additional C terminal cysteine by chemical coupling (Adams et al (1993) Can.Res 53,4026-4034 and McCartney et al (1995) Protein Eng. 8, 301-314) or by spontaneous site-specific dimerization of ScFv containing an unpaired C terminal cysteine residue (see Kipriyanov et al (1995) Cell. Biophys 26, 187-204). Alternatively, ScFv can be forced to form multimers by shortening the peptide linker to between 3 to 12 residues to form "diabodies", see Holliger et al PNAS (1993), 90, 6444-6448. Reducing the linker still further can result in ScFV trimers ("triabodies", see Kortt et al (1997) Protein Eng, 10, 423-433) and tetramers ("tetrabodies", see Le Gall et al (1999) FEBS Lett, 453,

164-168). Construction of bivalent ScFv molecules can also be achieved by genetic fusion with protein dimerizing motifs to form "miniantibodies" (see Pack et al (1992) Biochemistry 31, 1579-1584) and "minibodies" (see Hu et al (1996), Cancer Res. 56, 3055-3061). ScFv-Sc-Fv tandems ((ScFv)₂) may also be produced by linking two ScFv units by a third peptide linker, see Kurucz et al (1995) J.Immol. 154,4576-4582. Bispecific diabodies can be produced through the noncovalent association of two single chain fusion products consisting of V_H domain from one antibody connected by a short linker to the V_L domain of another antibody, see Kipriyanov et al (1998), Int.J.Can 77,763-772. The stability of such bispecific diabodies can be enhanced by the introduction of disulphide bridges or "knob in hole" mutations as described *supra* or by the formation of single chain diabodies (ScDb) wherein two hybrid ScFv fragments are connected through a peptide linker see Kontermann et al (1999) J.Immunol.Methods 226 179-188. Tetravalent bispecific molecules are available by e.g. fusing a ScFv fragment to the CH3 domain of an IgG molecule or to a Fab fragment through the hinge region see Coloma et al (1997) Nature Biotechnol. 15, 159-163. Alternatively, tetravalent bispecific molecules have been created by the fusion of bispecific single chain diabodies (see Alt et al, (1999) FEBS Lett 454, 90-94. Smaller tetravalent bispecific molecules can also be formed by the dimerization of either ScFv-ScFv tandems with a linker containing a helix-loop-helix motif (DiBi miniantibodies, see Muller et al (1998) FEBS Lett 432, 45-49) or a single chain molecule comprising four antibody variable domains (V_H and V_L) in an orientation preventing intramolecular pairing (tandem diabody, see Kipriyanov et al, (1999) J.Mol.Biol. 293,41-56). Bispecific F(ab')₂ fragments can be created by chemical coupling of Fab' fragments or by heterodimerization through leucine zippers (see Shalaby et al, (1992) J.Exp.Med. 175, 217-225 and Kostelny et al (1992), J.Immunol. 148,1547-1553). Also available are so-called domain antibodies based on isolated V_H or V_L domains (Domantis Ltd.), see US 6, 248,516; US 6,291,158; US 6,172,197.

Heteroconjugate antibodies

[0114] Heteroconjugate antibodies are derivatives which also form an embodiment of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies formed using any convenient cross-linking methods. See US 4,676,980.

Other Modifications.

[0115] Antibodies of the present invention may also incorporate any other modifications in the constant regions. For example glycosylation of antibodies at conserved positions in their constant regions is known to have a profound effect on antibody function, particularly effector functioning such as those described above, see for example, Boyd et al (1996), Mol.Immunol. 32, 1311-1318. Glycosylation variants of the therapeutic antibodies of the present invention wherein one or more carbohydrate moiety is added, substituted, deleted or modified are contemplated. Introduction of an asparagine-X-serine or asparagine-X-threonine motif creates a potential site for enzymatic attachment of carbohydrate moieties and may therefore be used to manipulate the glycosylation of an antibody. In Raju et al (2001) Biochemistry 40, 8868-8876 the terminal sialylation of a TNFR-IgG immunoadhesin was increased through a process of regalactosylation and/or resialylation using beta-1, 4-galactosyltransferase and/or alpha, 2,3 sialyltransferase. Increasing the terminal sialylation is believed to increase the half-life of the immunoglobulin. Antibodies, in common with most glycoproteins, are typically produced in nature as a mixture of glycoforms. This mixture is particularly apparent when antibodies are produced in eukaryotic, particularly mammalian cells. A variety of methods have been developed to manufacture defined glycoforms, see Zhang et al Science (2004), 303,371, Sears et al, Science, (2001) 291, 2344, Wacker et al (2002) Science, 298 1790, Davis et al (2002) Chem.Rev. 102, 579, Hang et al (2001) Acc.Chem.Res 34, 727. Thus the invention concerns a plurality of therapeutic antibodies (which maybe of the IgG isotype, e.g. IgG1) as described herein comprising a defined number (e.g. 7 or less, for example 5 or less such as two or a single) glycoform(s) of said antibodies.

[0116] Derivatives according to the invention also include therapeutic antibodies of the invention coupled to a non-proteinaceous polymer such as polyethylene glycol (PEG), polypropylene glycol or polyoxyalkylene. Conjugation of proteins to PEG is an established technique for increasing half-life of proteins, as well as reducing antigenicity and immunogenicity of proteins. The use of PEGylation with different molecular weights and styles (linear or branched) has been investigated with intact antibodies as well as Fab' fragments, see Koumenis I.L. et al (2000) Int.J.Pharmaceut. 198:83-95. A particular embodiment comprises an antigen-binding fragment of the invention without the effector functions of a) activation of complement by the classical pathway; and b) mediating antibody-dependent cellular cytotoxicity; (such as a Fab fragment or a scFv) coupled to PEG.

The interaction between the Fc region of an antibody and various Fc receptors (FcγR) is believed to mediate the effector functions of the antibody which include antibody-dependent cellular cytotoxicity (ADCC), fixation of complement, phagocytosis and half-life/clearance of the antibody. Various modifications to the Fc region of antibodies of the invention may be carried out depending on the desired effector property. In particular, human constant regions which essentially lack the functions of a) activation of complement by the classical pathway; and b) mediating antibody-dependent cellular cytotoxicity include the IgG4 constant region, the IgG2 constant region and IgG1 constant regions containing specific

mutations as for example mutations at positions 234, 235, 236, 237, 297, 318, 320 and/or 322 disclosed in EP0307434 (WO8807089), EP 0629 240 (WO9317105) and WO 2004/014953. Mutations at residues 235 or 237 within the CH2 domain of the heavy chain constant region (Kabat numbering; EU Index system) have separately been described to reduce binding to Fc γ RI, Fc γ RII and Fc γ RIII binding and therefore reduce antibody-dependent cellular cytotoxicity (ADCC) (Duncan et al. Nature 1988, 332; 563-564; Lund et al. J. Immunol. 1991, 147; 2657-2662; Chappel et al. PNAS 1991, 88; 9036-9040; Burton and Woof, Adv. Immunol. 1992, 51; 1-84; Morgan et al., Immunology 1995, 86; 319-324; Hezareh et al., J. Virol. 2001, 75 (24); 12161-12168). Further, some reports have also described involvement of some of these residues in recruiting or mediating complement dependent cytotoxicity (CDC) (Morgan et al., 1995; Xu et al., Cell. Immunol. 2000; 200:16-26; Hezareh et al., J. Virol. 2001, 75 (24); 12161-12168). Residues 235 and 237 have therefore both been mutated to alanine residues (Brett et al. Immunology 1997, 91; 346-353; Bartholomew et al. Immunology 1995, 85; 41-48; and WO9958679) to reduce both complement mediated and Fc γ R-mediated effects. Antibodies comprising these constant regions may be termed 'non-lytic' antibodies.

[0117] One may incorporate a salvage receptor binding epitope into the antibody to increase serum half life see US 5,739,277.

[0118] There are five currently recognised human Fc γ receptors, Fc γ R (I), Fc γ RIIa, Fc γ RIIb, Fc γ RIIIa and neonatal FcRn. Shields et al, (2001) J.Biol.Chem 276, 6591-6604 demonstrated that a common set of IgG1 residues is involved in binding all Fc γ Rs, while Fc γ RII and Fc γ RIII utilize distinct sites outside of this common set. One group of IgG1 residues reduced binding to all Fc γ Rs when altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 and Pro-239. All are in the IgG CH2 domain and clustered near the hinge joining CH1 and CH2. While Fc γ RI utilizes only the common set of IgG1 residues for binding, Fc γ RII and Fc γ RIII interact with distinct residues in addition to the common set. Alteration of some residues reduced binding only to Fc γ RII (e.g. Arg-292) or Fc γ RIII (e.g. Glu-293). Some variants showed improved binding to Fc γ RII or Fc γ RIII but did not affect binding to the other receptor (e.g. Ser-267Ala improved binding to Fc γ RII but binding to Fc γ RIII was unaffected). Other variants exhibited improved binding to Fc γ RII or Fc γ RIII with reduction in binding to the other receptor (e.g. Ser-298Ala improved binding to Fc γ RIII and reduced binding to Fc γ RII). For Fc γ RIIIa, the best binding IgG1 variants had combined alanine substitutions at Ser-298, Glu-333 and Lys-334. The neonatal FcRn receptor is believed to be involved in protecting IgG molecules from degradation and thus enhancing serum half life and the transcytosis across tissues (see Junghans R.P (1997) Immunol.Res 16. 29-57 and Ghetie et al (2000) Annu.Rev.Immunol. 18, 739-766). Human IgG1 residues determined to interact directly with human FcRn includes Ile253, Ser254, Lys288, Thr307, Gln311, Asn434 and His435.

[0119] The therapeutic antibody of the invention may incorporate any of the above constant region modifications.

2. Production Methods

[0120] Antibodies of the present invention may be produced in transgenic organisms such as goats (see Pollock et al (1999), J.Immunol.Methods 231:147-157), chickens (see Morrow KJJ (2000) Genet.Eng.News 20:1-55), mice (see Pollock *et al ibid*) or plants (see Doran PM, (2000) Curr.Opinion Biotechnol. 11, 199-204, Ma JK-C (1998), Nat.Med. 4; 601-606, Baez J et al, BioPharm (2000) 13: 50-54, Stoger E et al; (2000) Plant Mol.Biol. 42:583-590). Antibodies may also be produced by chemical synthesis. However, antibodies of the invention are typically produced using recombinant cell culturing technology well known to those skilled in the art. A polynucleotide encoding the antibody is isolated and inserted into a replicable vector such as a plasmid for further cloning (amplification) or expression in a host cell. One useful expression system is a glutamate synthetase system (such as sold by Lonza BiologiCs), particularly where the host cell is CHO or NS0 (see below). Polynucleotide encoding the antibody is readily isolated and sequenced using conventional procedures (e.g. oligonucleotide probes). Vectors that may be used include plasmid, virus, phage, transposons, minichromosomes of which plasmids are a typical embodiment. Generally such vectors further include a signal sequence, origin of replication, one or more marker genes, an enhancer element, a promoter and transcription termination sequences operably linked to the light and/or heavy chain polynucleotide so as to facilitate expression. Polynucleotide encoding the light and heavy chains may be inserted into separate vectors and introduced (e.g. by transformation, transfection, electroporation or transduction) into the same host cell concurrently or sequentially or, if desired both the heavy chain and light chain can be inserted into the same vector prior to such introduction.

[0121] It will be immediately apparent to those skilled in the art that due to the redundancy of the genetic code, alternative polynucleotides to those disclosed herein are also available that will encode the polypeptides of the invention.

Signal sequences

[0122] Antibodies of the present invention maybe produced as a fusion protein with a heterologous signal sequence having a specific cleavage site at the N terminus of the mature protein. The signal sequence should be recognised and processed by the host cell. For prokaryotic host cells, the signal sequence may be an alkaline phosphatase, penicillinase, or heat stable enterotoxin II leaders. For yeast secretion the signal sequences may be a yeast invertase leader, α factor

leader or acid phosphatase leaders see e.g. WO90/13646. In mammalian cell systems, viral secretory leaders such as herpes simplex gD signal and a native immunoglobulin signal sequence (such as human Ig heavy chain) are available. Typically the signal sequence is ligated in reading frame to polynucleotide encoding the antibody of the invention.

Origin of replication

[0123] Origin of replications are well known in the art with pBR322 suitable for most gram-negative bacteria, 2 μ plasmid for most yeast and various viral origins such as SV40, polyoma, adenovirus, VSV or BPV for most mammalian cells. Generally the origin of replication component is not needed for integrated mammalian expression vectors, unless vector propagation is required in E.Coli. However the SV40 ori may be used since it contains the early promoter.

Selection marker

[0124] Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins e.g. ampicillin, neomycin, methotrexate or tetracycline or (b) complement auxotrophic deficiencies or supply nutrients not available in the complex media or (c) combinations of both. The selection scheme may involve arresting growth of the host cells that contain no vector or vectors. Cells, which have been successfully transformed with the genes encoding the therapeutic antibody of the present invention, survive due to e.g. drug resistance conferred by the co-delivered selection marker. One example is the DHFR-selection system wherein transformants are generated in DHFR negative host strains (eg see Page and Sydenham 1991 Biotechnology 9: 64-68). In this system the DHFR gene is co-delivered with antibody polynucleotide sequences of the invention and DHFR positive cells then selected by nucleoside withdrawal. If required, the DHFR inhibitor methotrexate is also employed to select for transformants with DHFR gene amplification. By operably linking DHFR gene to the antibody coding sequences of the invention or functional derivatives thereof, DHFR gene amplification-results in concomitant amplification of the desired antibody sequences of interest. CHO cells are a particularly useful cell line for this DHFR/methotrexate selection and methods of amplifying and selecting host cells using the DHFR system are well established in the art see Kaufman R.J. et al J.Mol.Biol. (1982) 159, 601-621, for review, see Werner RG, Noe W, Kopp K, Schluter M, "Appropriate mammalian expression systems for biopharmaceuticals", Arzneimittel-Forschung. 48(8):870-80, 1998 Aug. A further example is the glutamate synthetase expression system (Lonza Biologies). A suitable selection gene for use in yeast is the trp1 gene; see Stinchcomb et al Nature 282, 38, 1979.

Promoters

[0125] Suitable promoters for expressing antibodies of the invention are operably linked to DNA/polynucleotide encoding the antibody. Promoters for prokaryotic hosts include phoA promoter, Beta-lactamase and lactose promoter systems, alkaline phosphatase, tryptophan and hybrid promoters such as Tac. Promoters suitable for expression in yeast cells include 3-phosphoglycerate kinase or other glycolytic enzymes e.g. enolase, glyceraldehyde 3 phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose 6 phosphate isomerase, 3-phosphoglycerate mutase and glucokinase, among others. Inducible yeast promoters include alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, metallothionein and enzymes responsible for nitrogen metabolism or maltose/galactose utilization, among others.

Promoters for expression in mammalian cell systems include RNA polymerase II promoters including viral promoters such as polyoma, fowlpox and adenoviruses (e.g. adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus (in particular the immediate early gene promoter), retrovirus, hepatitis B virus, actin, rous sarcoma virus (RSV) promoter and the early or late Simian virus 40 and non-viral promoters such as EF-1 α (Mizushima and Nagata Nucleic Acids Res 1990 18(17):5322, among others. The choice of promoter may be based upon suitable compatibility with the host cell used for expression.

Enhancer element

[0126] Where appropriate, e.g. for expression in higher eukaryotics, additional enhancer elements can included instead of or as well as those found located in the promoters described above. Suitable mammalian enhancer sequences include enhancer elements from globin, elastase, albumin, fetoprotein, metallothionein and insulin. Alternatively, one may use an enhancer element from a eukaryotic cell virus such as SV40 enhancer, cytomegalovirus early promoter enhancer, polyoma enhancer, baculoviral enhancer or murine IgG2a locus (see WO04/009823). Whilst such enhancers are typically located on the vector at a site upstream to the promoter, they can also be located elsewhere e.g. within the untranslated region or downstream of the polydenylation signal. The choice and positioning of enhancer may be based upon suitable compatibility with the host cell used for expression.

Polyadenylation/Termination

[0127] In eukaryotic systems, polyadenylation signals are operably linked to polynucleotide encoding the antibody of this invention. Such signals are typically placed 3' of the open reading frame. In mammalian systems, non-limiting example signals include those derived from growth hormones, elongation factor-1 alpha and viral (eg SV40) genes or retroviral long terminal repeats. In yeast systems non-limiting examples of polydenylation/termination signals include those derived from the phosphoglycerate kinase (PGK) and the alcohol dehydrogenase 1 (ADH) genes. In prokaryotic system polyadenylation signals are typically not required and it is instead usual to employ shorter and more defined terminator sequences. The choice of polyadenylation/termination sequences may be based upon suitable compatibility with the host cell used for expression.

Other methods/elements for enhanced yields

[0128] In addition to the above, other features that can be employed to enhance yields include chromatin remodelling elements, introns and host-cell specific codon modification. The codon usage of the antibody of this invention thereof can be modified to accommodate codon bias of the host cell such to augment transcript and/or product yield (eg Hoekema A et al Mol Cell Biol 1987 7(8):2914-24). The choice of codons may be based upon suitable compatibility with the host cell used for expression.

Host cells

[0129] Suitable host cells for cloning or expressing vectors encoding antibodies of the invention are, for example, prokaryotic, yeast or higher eukaryotic cells. Suitable prokaryotic cells include eubacteria e.g. enterobacteriaceae such as *Escherichia* e.g. *E. Coli* (for example ATCC 31,446; 31,537; 27,325), *Enterobacter*, *Erwinia*, *Klebsiella* *Proteus*, *Salmonella* e.g. *Salmonella typhimurium*, *Serratia* e.g. *Serratia marcescans* and *Shigella* as well as Bacilli such as *B. subtilis* and *B. licheniformis* (see DD 266 710), *Pseudomonas* such as *P. aeruginosa* and *Streptomyces*. Of the yeast host cells, *Saccharomyces cerevisiae*, *schizosaccharomyces pombe*, *Kluyveromyces* (e.g. ATCC 16,045; 12,424; 24178; 56,500), *yarrowia* (EP402, 226), *Pichia Pastors* (EP183, 070, see also Peng et al J.Biotechnol. 108 (2004) 185-192), *Candida*, *Trichoderma reesia* (EP244, 234), *Penicillin*, *Tolypocladium* and *Aspergillus* hosts such as *A. nidulans* and *A. niger* are also contemplated.

[0130] Although Prokaryotic and yeast host cells are specifically contemplated by the invention, typically however, host cells of the present invention are vertebrate cells. Suitable vertebrate host cells include mammalian cells such as COS-1 (ATCC No.CRL 1650) COS-7 (ATCC CRL 1651), human embryonic kidney line 293,, PerC6 (Crucell), baby hamster kidney cells (BHK) (ATCC CRL.1632), BHK570 (ATCC NO: CRL 10314), 293 (ATCC NO.CRL 1573), Chinese hamster ovary cells CHO (e.g. CHO-K1, ATCC NO: CCL 61, DHFR-CHO cell line such as DG44 (see Urlaub *et al*, (1986) *ibid*), particularly those CHO cell lines adapted for suspension culture, mouse sertoli cells, monkey kidney cells, African green monkey kidney cells (ATCC CRL-1587), HELA cells, canine kidney cells (ATCC CCL 34), human lung cells (ATCC CCL 75), Hep G2 and myeloma or lymphoma cells e.g. NS0 (see US 5,807,715), Sp2/0, Y0.

[0131] Thus in one embodiment of the invention there is provided a stably transformed host cell comprising a vector encoding a heavy chain and/or light chain of the therapeutic antibody as described herein. Typically such host cells comprise a first vector encoding the light chain and a second vector encoding said heavy chain.

[0132] Such host cells may also be further engineered or adapted to modify quality, function and/or yield of the antibody of this invention. Non-limiting examples include expression of specific modifying (eg glycosylation) enzymes and protein folding chaperones.

Cell Culturing Methods.

[0133] Host cells transformed with vectors encoding the therapeutic antibodies of the invention may be cultured by any method known to those skilled in the art. Host cells may be cultured in spinner flasks, shake flasks, roller bottles or hollow fibre systems but it is preferred for large scale production that stirred tank reactors or bag reactors (eg Wave Biotech, Somerset, New Jersey USA) are used particularly for suspension cultures. Typically the stirred tankers are adapted for aeration using e.g. spargers, baffles or low shear impellers. For bubble columns and airlift reactors direct aeration with air or oxygen bubbles maybe used. Where the host cells are cultured in a serum free culture media it is preferred that the media is supplemented with a cell protective agent such as pluronic F-68 to help prevent cell damage as a result of the aeration process. Depending on the host cell characteristics, either microcarriers maybe used as growth substrates for anchorage dependent cell lines or the cells maybe adapted to suspension culture (which is typical). The culturing of host cells, particularly vertebrate host cells may utilise a variety of operational modes such as batch, fed-batch, repeated batch processing (see Drapeau et al (1994) *cytotechnology* 15: 103-109), extended batch process or

perfusion culture. Although recombinantly transformed mammalian host cells may be cultured in serum-containing media such media comprising fetal calf serum (FCS), it is preferred that such host cells are cultured in synthetic serum -free media such as disclosed in Keen et al. (1995) Cytotechnology 17:153-163, or commercially available media such as ProCHO-CDM or UltraCHO™ (Cambrex NJ, USA), supplemented where necessary with an energy source such as glucose and synthetic growth factors such as recombinant insulin. The serum-free culturing of host cells may require that those cells are adapted to grow in serum free conditions. One adaptation approach is to culture such host cells in serum containing media and repeatedly exchange 80% of the culture medium for the serum-free media so that the host cells learn to adapt in serum free conditions (see e.g. Scharfenberg K et al (1995) in Animal Cell technology: Developments towards the 21st century (Beuvery E.C: et al eds), pp619-623, Kluwer Academic publishers).

[0134] Antibodies of the invention secreted into the media may be recovered and purified from the media using a variety of techniques to provide a degree of purification suitable for the intended use. For example the use of therapeutic antibodies of the invention for the treatment of human patients typically mandates at least 95% purity as determined by reducing SDS-PAGE, more typically 98% or 99% purity, when compared to the culture media comprising the therapeutic antibodies. In the first instance, cell debris from the culture media is typically removed using centrifugation followed by a clarification step of the supernatant using e.g. microfiltration, ultrafiltration and/or depth filtration. Alternatively, the antibody can be harvested by microfiltration, ultrafiltration or depth filtration without prior centrifugation. A variety of other techniques such as dialysis and gel electrophoresis and chromatographic techniques such as hydroxyapatite (HA), affinity chromatography (optionally involving an affinity tagging system such as polyhistidine) and/or hydrophobic interaction chromatography (HIC, see US 5, 429,746) are available. In one embodiment, the antibodies of the invention, following various clarification steps, are captured using Protein A or G affinity chromatography followed by further chromatography steps such as ion exchange and/or HA chromatography, anion or cation exchange, size exclusion chromatography and ammonium sulphate precipitation. Typically, various virus removal steps are also employed (e.g. nanofiltration using e.g. a DV-20 filter). Following these various steps, a purified (typically monoclonal) preparation comprising at least 10mg/ml or greater e.g. 100mg/ml or greater of the antibody of the invention is provided and therefore forms an embodiment of the invention. Concentration to 100mg/ml or greater can be generated by ultracentrifugation. Suitably such preparations are substantially free of aggregated forms of antibodies of the invention.

[0135] Bacterial systems are particularly suited for the expression of antibody fragments. Such fragments are localised intracellularly or within the periplasma. Insoluble periplasmic proteins can be extracted and refolded to form active proteins according to methods known to those skilled in the art, see Sanchez et al (1999) J.Biotechnol. 72, 13-20 and Cupit PM et al (1999) Lett Appl Microbiol, 29, 273-277.

3. Pharmaceutical Compositions and Mode of administration

[0136] Purified preparations of antibodies of the invention as described *supra*, may be incorporated into pharmaceutical compositions for use in the treatment of human diseases and disorders such as those outlined above. Typically such compositions further comprise a pharmaceutically acceptable (i.e. inert) carrier as known and called for by acceptable pharmaceutical practice, see e.g. Remingtons Pharmaceutical Sciences, 16th ed, (1980), Mack Publishing Co. Examples of such carriers include sterilised carrier such as saline, Ringers solution or dextrose solution, buffered with suitable buffers to a pH within a range of 5 to 8. Pharmaceutical compositions for injection (e.g. by intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular or intraportal) or continuous infusion are suitably free of visible particulate matter and may comprise from 0.1mg to 10g of therapeutic antibody, typically between 5mg and 25mg of antibody. Methods for the preparation of such pharmaceutical compositions are well known to those skilled in the art. In one embodiment, pharmaceutical compositions comprise from 0.1mg to 10g of therapeutic antibodies of the invention in unit dosage form, optionally together with instructions for use. Pharmaceutical compositions of the invention may be lyophilised (freeze dried) for reconstitution prior to administration according to methods well known or apparent to those skilled in the art. Where embodiments of the invention comprise antibodies of the invention with an IgG1 isotype, a chelator of copper such as citrate (e.g. sodium citrate) or EDTA or histidine may be added to the pharmaceutical composition to reduce the degree of copper-mediated degradation of antibodies of this isotype, see EP0612251.

[0137] Effective doses and treatment regimes for administering the antibody of the invention are generally determined empirically and are dependent on factors such as the age, weight and health status of the patient and disease or disorder to be treated. Such factors are within the purview of the attending physician. Guidance in selecting appropriate doses may be found in e.g. Smith *et al* (1977) Antibodies in human diagnosis and therapy, Raven Press, New York but will in general be between 0.1mg and 1g. In one embodiment, the dosing regime for treating a human patient is 0.1mg to 10g of therapeutic antibody of the invention administered subcutaneously once per week or every two weeks, or by intravenous infusion every 1 or 2 months. Compositions of the present invention may also be used in prophylactically.

4. Clinical uses.

[0138] The present invention relates to an antibody which binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. The antibodies of the present invention may be useful in methods of treating diseases or disorders characterised by elevated or unbalanced level of one or more of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, particularly, COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, and/or endometriosis with said antibody, pharmaceutical compositions comprising said antibody and methods of manufacture.

[0139] The present invention also relates to use of an antibody in the manufacture of a medicament for the treatment of diseases or disorders characterised by elevated or unbalanced level of one or more of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2 and ENA-78, particularly COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, or endometriosis. Although the present invention has been described principally in relation to the treatment of human diseases or disorders, the present invention may also have applications in the treatment of similar diseases or disorders in non-human mammals.

Specific Embodiments

Example 1. Generation of mouse monoclonal antibody 656.35, 197.2, and 81.1

Generation of a penta-specific mAb against the target chemokines (human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78).

[0140] Multiple methods and schemes were used to immunize mice in an attempt to generate pan-specific mAbs. The generation of pan-specific mAbs were generated using various mixtures of multiple antigenic peptides (MAPs) and / or intact target chemokines (IL-8, Gro- α , - β , - γ , and ENA-78) mixed in complete or incomplete Freund's Adjuvant (cFA or iFA), following a modified Repetitive Immunization Multiple Sites (RIMMS) protocol in the SJL/JOrICrl mouse strain.

[0141] MAPs or multiple antigenic peptides serve two functions within the immunization protocol. First, MAPs allow for a selective multiple presentation of a known target amino acid sequence. Secondly, there is an increase in mass, due to multiple copies of the sequence linked, for example, via a lysine core, which also increases the immunogenicity of the sequence over that of individual peptides (Francis, J.P., et al., Immunology, 1991: 73; 249, Schott, M.E., et al., Cell. Immuno. 1996: 174: 199-209, Tam, J.P. Proc. Natl. Acad. Sci. 1988: 85: 5409-5413). Figure I is a schematic drawing of a set of MAPs having amino acid sequences SEQ ID NOs:49-53. A linker in MAPs can be any linker other than lysines.

General immunization time line:

[0142] Two different immunization protocols following the above time line produced pan-specific mAbs:

1. Initial immunization (day 0) consists of multiple subcutaneous injections (hind quarters, back and neck) of all target chemokines mixed in cFA (10 μ g each). The following 4 boosts consisted of a mixture of all the target chemokines mixed in iFA (10 μ g each). The fifth and all subsequent boosts consisted of a cocktail of all the target chemokines and all 5 linear MAPs (10 μ g each) in iFA. The final boost 3 days prior to sacrifice and fusion consisted of all the target chemokines and linear MAPs in PBS and was delivered via an intraperitoneal (IP) injection.

2. Initial immunization (day 0) consists of multiple subcutaneous injections (hind quarters, back and neck) of all five linear MAPs mixed in cFA (10 μ g each). The following 4 boosts consisted of a mixture of all five linear MAPs in iFA (10 μ g each). The fifth and all subsequent boosts consisted of a cocktail of all the all 5 linear MAPs and all target chemokines (10 μ g each) in iFA. The final boost 3 days prior to sacrifice and fusion consisted of all the all 5 linear MAPs and all target chemokines (10 μ g each) in PBS and was delivered via an intraperitoneal (IP) injection.

[0143] Example 2. Pan-binding of the mAb to the target chemokines (human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and ENA-78) has been confirmed via a time-resolved fluorescence immunofluorescent assay (TRFIA).

[0144] Briefly, each antigen (human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and ENA-78, and hIL-18 when used as negative control) is individually coated onto a 96-well immunofluorescent plate. The plates are then washed and blocked with a commercially available blocking solution. Blocking solution is emptied and samples containing the mAb are added into each well and incubated for 40 to 60 minutes (this allows the mAb to bind to the target chemokines).

The plates are then washed again and a detection Ab is added to each well. Detection reagents were as follows for 2X656.35, chimera (HcLc) and humanized MAbs respectively: biotinylated anti-mouse IgG, biotinylated anti-human IgG Fab2 reagent, and europium anti-human IgG. The detection antibody is conjugated to either europium or biotin. Following another round of washing, to remove unbound detection Ab, a solution of streptavidin-europium was added to biotin detected assays. Streptavidin-europium binds to the biotin allowing for detection. After a final wash to remove unbound streptavidin-europium, or in the case of the humanized MAb assay after the europium conjugate secondary is washed, each well is filled with a chelating detergent solution to activate the europium producing fluorescence. The greater the fluorescence recorded is directly proportionate to the amount of detection Ab present in the well which is directly linked and proportionate to the amount of the chemokine binding mAb.

[0145] Figure 5A shows mouse 656.35 mAb binding to target human chemokines. Figure 5B shows the Chimera Antibody (HcLc) mAb binding to human target chemokines. Figure 5C shows humanized mAbs binding to human target chemokines.

Example 3. Functional pan-inhibition by murine mAb was confirmed using a variety of methods: CXCR2 mediated Ca^{2+} mobilization, human neutrophil chemotaxis, and human neutrophil activation (CD11b surface expression).

[0146] A microtiter plate based calcium mobilization assay, FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale CA, [Schroeder, 1996]), was used for the functional characterization of the neutralizing effect of antibodies on ELR+ chemokine induced $[\text{Ca}^{2+}]_i$ -mobilization in CHO-K1 cells transfected with and stably expressing hCXCR2 and $\text{G}\alpha_{16}$.

[0147] On the day prior to assay, cells were plated in 96 well, blackwall, clear bottom plates (Packard View) at a concentration of 40000 cells per well. After 18 to 24 hours, media was aspirated off cells and replaced with 100 μl load media containing Eagles Minimal Essential Medium (EMEM) with Earl's salts and L-Glutamine, 0.1% BSA (Serologicals Corporation), 4 μM Fluo-4-acetoxymethyl ester fluorescent indicator dye (Fluo-4 AM) and 2.5 mM probenecid. Cells were incubated in this dye containing media for 1 hour at 37°C . The dye containing media was then aspirated off the cells and replaced with identical media without Fluo-4 AM and with 0.1% Gelatin (BSA removed) and 2.5 mM probenecid. Cells were incubated for 10 min. at 37°C and then washed 3 times with KRH assay buffer [Krebs Ringer Henseleit (120 mM NaCl, 4.6 mM KCl, 1.03 mM KH_2PO_4 , 25 mM NaHCO_3 , 1.0 mM CaCl_2 , 1.1 mM MgCl_2 , 11 mM Glucose, 20 mM HEPES (pH 7.4)) with 0.1 % gelatin and 2.5 mM probenecid]. After the final buffer wash, 100 μl KRH assay buffer with 0.1 % gelatin and 2.5 mM probenecid was added to cells and warmed to 37°C for 10 min. before being placed in FLIPR where dye loaded cells were exposed to excitation light (488 nm) from a 6 watt Argon Laser. $[\text{Ca}^{2+}]_i$ -mobilization was monitored as a result of an increase in 516 nm emission intensity of Fluo-4 when bound to Ca^{2+} . Change in emission intensity is directly related to cytosolic calcium levels, $[\text{Ca}^{2+}]_i$. After monitoring baseline for 10 sec., 50 μl of 3X ELR+ chemokine, which had been pre-incubated with a concentration range of antibody, was added to the cell plate and data collected every sec. for 1 min., followed by an additional half min. of recording in 3 sec. intervals. Maximal cellular response above basal reading was exported for plotting in GraphPad Prism (v4.03).

[0148] The IC_{50} was defined as the concentration of antibody required, during pre-treatment of 3X EC_{50} chemokine, to neutralize the CXCR2 mediated stimulatory effect of an EC_{80} concentration of the ELR+ chemokine by 50%. A secondary cellular response to 25 μM ATP was monitored to test cell viability [Sarau, 1999].

Table: Inhibition of human ELR+ chemokine induced calcium flux (geometrically mean IC_{50} , $\mu\text{g/ml}$) by three murine mAb. (n=3 to 6) (n.d. = not determined, N/A = not available)

	3nM hIL-8		10nM hGRO α		6nM hGRO β		30nM hENA-78		100nM hGCP-2	
murine mAB	IC_{50} ($\mu\text{g/ml}$)	95% C. I.	IC_{50} ($\mu\text{g/ml}$)	95% C. I.	IC_{50} ($\mu\text{g/ml}$)	95% C. I.	IC_{50} ($\mu\text{g/ml}$)	95% C. I.	IC_{50} ($\mu\text{g/ml}$)	95% C. I.
656.35	0.18	0.14 - 0.25	1.43	0.60 - 3.42	1.06	0.78 - 1.42	2.09	0.71 - 6.14	9.58	1.17 - 78.57
81.1	67.65	18.80 - 243.50	0.94	0.37 - 2.38	n.d.	N/A	1.84	0.69 - 4.93	9.11	1.44 - 57.61
197.2	2.19	0.61 - 7.88	2.24	0.39 - 12.98	n.d.	N/A	13.86	1.71 - 112.49	>157	N/A

Schroeder KS, Neagle BD. FLIPR: a new instrument for accurate, high throughput optical screening. J. Biomol. Screen. 1996;1:75.

Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ et al. Identification, molecular cloning, expression,

and characterization of a cysteinyl leukotrien receptor. Mol Pharmacol. 1999;56:657-663.

[0149] Inhibition of IL-8 stimulated human neutrophil chemotaxis was also demonstrated using a micro-Boyden chamber. The micro-Boyden apparatus consists of two small chambers one above and one below a 3 micron-porous membrane. The lower chamber is loaded with the chemotactic agent (i.e. IL-8) or a mixture of the chemokine with the penta-specific mAb. The upper chamber contains purified non-activated human neutrophils. Once the chamber is assembled a concentration gradient is formed from the bottom well to the upper, stimulating the neutrophils to chemotax across the membrane. The assay is expressed as a CI (chemotactic index) which is a ratio of the number of cells which chemotax in response to a stimulant over non-stimulated chemotactic cell number. Pre-incubating the chemokine (i.e. IL-8) with the penta-specific mAb in the lower chamber, dose dependently inhibited IL-8 stimulated neutrophil chemotaxis. IL-8 at 10 nM achieved a CI of 3.6 ± 0.8 . Pre-incubation of IL-8 with increasing concentrations of the penta-specific mAb (656.35) dose dependently inhibited human neutrophil chemotaxis, significance was reached at CI of 2.2 ± 0.6 at 1 $\mu\text{g/ml}$. Due to the amounts and sensitivity of the assay the other chemokines were unable to be examined (Gro- α , - β , - γ , and ENA-78).

[0150] Inhibition of purified human neutrophil activation via monitoring surface expression of CD11b. CD11b or Mac-1 mediates adhesion to substrates, aggregation and chemotaxis and is known to be up-regulated on the surface activated neutrophils (Molad, Y., J., et al., Clin. Immunol. Immunopathol. 1994: 71; 281-286). Briefly, non-activated human neutrophils are purified and *ex vivo* stimulated with either target chemokines (i.e. IL-8) or with chemokines pre-incubated with a chemokine penta-specific mAb. Data are presented as percent activation set to the maximal CD11b surface expression due to IL-8 stimulation. Pre-incubation of IL-8 with the 656.35 mAb dose dependently inhibited increased levels of surface expression of CD11b and thus indicates inhibition of neutrophil activation ($79.9\% \pm 3.7$, $48.5\% \pm 7.2$, $28.7\% \pm 3.2$, and $31.6\% \pm 3.4$, at 0.01, 0.1, 1, 10 and 50 $\mu\text{g/ml}$ respectively).

Example 4. Penta-specific mAbs association/dissociation values for each target chemokine (human IL-8, Gro-beta, and ENA-78).

Methods for Biacore Analysis.

[0151] For experiment designated KL, rabbit anti mouse IgG-Fc (Biacore BR-1005-14) is immobilized on a CM5 chip by primary amine coupling in accordance with the manufactures instructions.

[0152] For experiment designated BE, purified antibodies directly immobilized to the chip by amine coupling was used.

[0153] Supernatant or purified antibody from parental mouse mAb is captured on the anti-mouse IgG-Fc surface. Defined concentrations of each analyte (IL8, Gro-b and ENA-78) are passed over the immobilized or captured antibody surface, a separate capture event is used for each analyte injection. After each injection of analyte the surface is regenerated by injection of a mild acidic solution, which removes the captured antibody but does not significantly affect the capability anti mouse IgG-Fc surface to perform another capture event nor does it affect the directly immobilized antibodies. An injection of buffer is also injected over the antibody captured surface and this is used for double referencing. The data is analyzed using the analysis software inherent to the machine, using the 1:1 model of binding.

5
10
15
20
25
30
35
40
45
50
55

	mAb	kd	IL-8 ka	KD	kd	Gro-B ka	KD	kd	ENA-78 ka	KD
KL	656.35	1.48E-03	1.53E+06	9.64E-10	2.01E-03	3.82E+06	5.26E-10	1.87E-03	1.07E+06	1.74E-09
BE		6.87E-04	8.19E+06	8.39E-11	1.46E-03	1.32E+07	1.11E-10	7.96E-04	2.94E+06	2.71E-10
KL	81.1	9.32E-03	1.95E+06	4.80E-09	3.12E-04	2.76E+06	1.13E-10	3.76E-04	6.11E+05	6.16E-10
BE		1.08E-01	1.95E+06	5.55E-08	4.89E-04	5.44E+06	8.98E-11	3.94E-06	1.65E+05	2.39E-11
KL	197.2	3.69E-03	6.27E+05	5.89E-09	9.93E-04	1.55E+05	6.39E-10	2.69E-03	2.99E+05	9.00E-09
BE		4.99E-04	7.23E+05	6.90E-10	4.80E-08	1.04E+06	4.62E-14	3.02E-03	3.01E+05	1.01E-08

Example 5**Epitope Mapping**

5 [0154] 656.35 mAb was epitope mapped and found to bind within KELRCQCIKTYSKP (SEQ ID NO: 54) in human IL-8. Thus in another embodiment, the present invention relates to a penta-specific antibody which binds within epitope of SEQ ID NO:54 of human IL-8.

10 **Example 6. Efficacy study of a chimera antibody made from 656.35 having heavy chain sequence of SEQ ID NO: 56, and light chain sequence of SEQ ID NO: 58. (This antibody will be referred to as the Chimera Antibody)**

- *In vivo* Studies:

15 [0155] An inhaled LPS acute lung inflammatory model was used to examine the ability of the a penta-specific antibody to inhibit infiltration of neutrophils into the lungs of non-human primates (NHPs - cynomolgus). Briefly, NHP (non-human primate) were pre-screened for health and responsiveness to exogenously added cynomolgus IL-8 (cynoIL-8). Selected NHP were then subjected to baseline sample collections (blood and bronchoalveolar lavage - BAL) five days prior to the first LPS challenge. LPS challenged consisted of tranquilizing the NHP with a single IM injection of ketamine HCl (~10 mg/kg). Once the NHP is sedated, anesthesia is administered, via an intravenous infusion of propofol (~0.2 mg/kg/min, as necessary). Anesthetized animals are placed on a circulating warm-water heating blanket and/or within a circulating warm-air blanket and an ophthalmic lubricant is administered to each eye. The animals are then intubated and mechanically ventilated for challenge procedure. A volume regulated Positive Pressure ventilator is used during the procedure (Stoelting Cat/Rabbit ventilator www.stoeltingco.com Cat #5019510). Lipopolysaccharide (LPS) challenge is performed via aerosol inhalation using a DeVilbiss Ultraneb-99 ultrasonic nebulizer. Aerosolized LPS is administered for 5 minutes at 100 ug/ml. Heart rate, body temperature, and respiration rate are monitored and recorded during challenge procedures. The initial challenge confirms that the NHP respond to LPS (increased neutrophil infiltration into the lungs and elevated cynoIL-8 levels). Individual NHP responses were confirmed by sample collections at 6 and 24-hours post challenge.

30 [0156] The initial LPS challenged NHP were then randomly divided into two groups. Following a 4-week recovery all participating NHP were subjected to another baseline sample (blood and BAL). Four days post baseline measurements the subject groups received IV injection of either a vehicle or an injection of 1 mg/kg of the Chimera Antibody. The next day the NHP were challenged again with inhaled LPS and samples for analysis were collected 6 and 24-hour post challenge. Following an additional recovery period base line samples were collected from the vehicle NHP, 4 days later these NHP were treated with a single IV bolus injection of the Chimera Antibody at 10 mg/kg. The next day the animals were exposed to an LPS challenge and samples were collected for analysis at 6 and 24 hours.

35 [0157] The LPS inhalation is an acute inflammatory model which stimulates an elevation of chemotactic chemokines such as IL-8, which lead to increased infiltration of neutrophils into the lungs. The primary efficacy parameter for the Chimera Antibody treatment is inhibition of infiltrating neutrophils into the lungs of NHP challenged with LPS. Neutrophil infiltration in this acute inflammatory model occurs during the first 24 hours following LPS challenge at which point other inflammatory processes are becoming more prominent.

40 [0158] Pretreatment of with the Chimera Antibody significantly and dose dependently inhibited neutrophil infiltration into lungs of LPS challenged NHP. Treatment with the the Chimera Antibody also prevented elevation of circulating neutrophils, while not affecting the actual neutrophil function, (i.e. the cells ability to phagocytosis). Treatment also did not greatly affect other cell types such as macrophages/monocytes in the lung or circulation. See Figure 2.

Example 7**Further studies on humanized mAbs**

50 [0159] Multiple humanized penta-specific antibody constructs have been produced, four of which have been shown to bind tightly to, and inhibit all target chemokines. (For each sequence, see **Sequence Information** below). This analysis consisted of affinity measurements (BiaCore), calcium mobilization assays (*in vitro* functional assay, FLIPR), and CD11b human and NHP neutrophil stimulation assay (*ex vivo* functional assay, flow cytometry).

55 - BiaCore

[0160] A Protein A capture method was used to generate kinetics for the humanised and chimeric constructs as follows:

EP 2 146 745 B1

Protein A is immobilised on a CM5 chip by primary amine coupling in accordance with the manufactures instructions. Purified humanised or chimeric antibody is captured on the Protein A surface. After capture defined concentrations of each analyte (IL8, Gro- β and ENA-78) $\square$ are passed over the antibody captured surface, a separate capture event is used for each analyte injection. After each injection of analyte the surface is regenerated by injection of a mild acidic solution, which removes the captured antibody but does not significantly affect the capability of the Protein A to perform another capture event. An injection of buffer is also injected over the antibody captured surface and this is used for double referencing. The data is analysed using the analysis software inherent to the machine, using the 1:1 model of binding.

Measurements with Gro-beta

[0161]

Construct	ka (1/Ms)	kd(1/s)	KD(M)
HcLc	7.39E+06	8.16E-04	1.11E-10
HcLc	2.11E+07	0.0011	5.21E-11
HcLc	1.59E+07	8.88E-04	5.57E-11
HcLc	1.19E+07	6.16E-04	5.17E-11
HcLc	1.43E+07	5.43E-04	3.79E-11
HcLc	1.33E+07	6.76E-04	5.09E-11
HcLc	1.51E+07	6.73E-04	4.45E-11
HcLc	1.49E+07	6.44E-04	4.33E-11
HcLc	2.54E+07	0.001163	4.57E-11
HcLc	1.81E+07	0.001058	5.85E-11
HcLc	2.04E+07	8.54E-04	4.18E-11
HcLc	1.82E+07	5.06E-04	2.78E-11
H0L7	6.99E+06	9.66E-04	1.38E-10
H0L7	1.76E+07	0.001305	7.40E-11
H0L7	1.63E+07	0.001039	6.39E-11
H0L7	1.14E+07	0.005616	4.93E-10
H0L7	1.20E+07	0.004398	3.66E-10
H0L7	1.42E+07	9.57E-04	6.73E-11
H0L7	1.76E+07	0.00118	6.72E-11
H0L7	1.63E+07	0.001389	8.52E-11
H0L7	1.12E+07	0.008212	7.32E-10
H0L7	2.63E+07	0.001546	5.88E-11
H0L7	2.10E+07	9.28E-04	4.41E-11
H0L8	1.28E+07	0.005462	4.27E-10
H0L8	1.99E+07	0.01065	5.36E-10
H0L8	1.19E+07	0.007727	6.52E-10
H0L8	1.18E+07	0.007799	6.60E-10
H0L8	1.61E+07	0.006903	4.29E-10

EP 2 146 745 B1

(continued)

Construct	ka (1/Ms)	kd(1/s)	KD(M)
H0L8	1.85E+07	0.004586	2.48E-10
H0L10	1.23E+07	0.001395	1.13E-10
H0L10	1.45E+07	0.001261	8.68E-11
H0L10	1.44E+07	0.001477	1.03E-10
H0L10	1.28E+07	0.001394	1.09E-10
H0L10	1.98E+07	0.00144	7.28E-11
H0L10	1.94E+07	0.00109	5.62E-11
H0M0	1.20E+07	0.001394	1.17E-10
H0M0	1.13E+07	0.007071	6.24E-10
H0M0	1.58E+07	0.001708	1.08E-10
H0M0	1.43E+07	0.001829	1.28E-10
H0M0	1.03E+07	0.009588	9.34E-10
H0M0	1.85E+07	0.001728	9.35E-11
H0M0	1.81E+07	0.001252	6.91E-11

Measurements with IL8

[0162]

Construct	ka (1/Ms)	kd(1/s)	KD(M)
HcLc	3.77E+06	2.34E-04	6.22E-11
HcLc	1.03E+07	2.87E-04	2.78E-11
HcLc	8.20E+06	2.76E-04	3.37E-11
HcLc	1.04E+07	2.68E-04	2.58E-11
HcLc	9.44E+06	2.53E-04	2.68E-11
HcLc	9.97E+06	2.30E-04	2.31E-11
H0L7	2.74E+06	2.84E-04	1.04E-10
H0L7	8.99E+06	4.00E-04	4.45E-11
H0L7	7.64E+06	2.84E-04	3.71E-11
H0L7	5.98E+06	0.001167	1.95E-10
H0L7	8.74E+06	3.52E-04	4.03E-11
H0L7	7.51E+06	3.63E-04	4.83E-11
H0L7	9.10E+06	3.89E-04	4.28E-11
H0L8	5.90E+06	0.00111	1.88E-10
H0L8	7.89E+06	0.001126	1.43E-10

EP 2 146 745 B1

(continued)

Construct	ka (1/Ms)	kd(1/s)	KD(M)
H0L8	6.80E+06	0.001193	1.75E-10
H0L8	7.30E+06	0.001112	1.52E-10
H0L10	6.86E+06	4.57E-04	6.66E-11
H0L10	7.20E+06	3.67E-04	5.10E-11
H0L10	7.21E+06	3.96E-04	5.48E-11
H0L10	7.43E+06	3.73E-04	5.02E-11
H0M0	7.02E+06	3.98E-04	5.67E-11
H0M0	6.40E+06	0.001467	2.29E-10
H0M0	7.96E+06	4.09E-04	5.14E-11
H0M0	7.97E+06	4.60E-04	5.77E-11
H0M0	7.50E+06	4.18E-04	5.57E-11

Measurements with ENA78

[0163]

Construct	ka (1/Ms)	kd(1/s)	KD(M)
HcLc	3.67E+06	1.70E-04	4.63E-11
HcLc	5.81E+06	1.71E-04	2.94E-11
HcLc	5.11E+06	1.84E-04	3.60E-11
HcLc	5.28E+06	1.54E-04	2.91E-11
HcLc	4.87E+06	1.56E-04	3.20E-11
HcLc	4.78E+06	1.23E-04	2.58E-11
H0L7	2.95E+06	2.04E-04	6.93E-11
H0L7	5.28E+06	2.97E-04	5.63E-11
H0L7	4.59E+06	2.17E-04	4.74E-11
H0L7	3.03E+06	3.33E-04	1.10E-10
H0L7	5.11E+06	2.58E-04	5.04E-11
H0L7	4.76E+06	3.07E-04	6.45E-11
H0L7	4.91E+06	2.77E-04	5.63E-11
H0L8	2.88E+06	2.88E-04	1.00E-10
H0L8	2.82E+06	2.66E-04	9.41E-11
H0L8	2.95E+06	2.69E-04	9.12E-11
H0L8	3.29E+06	2.48E-04	7.55E-11

EP 2 146 745 B1

(continued)

Construct	ka (1/Ms)	kd(1/s)	KD(M)
H0L10	4.07E+06	3.66E-04	8.99E-11
H0L10	4.72E+06	3.40E-04	7.22E-11
H0L10	4.20E+06	3.12E-04	7.42E-11
H0L10	4.38E+06	2.68E-04	6.13E-11
H0M0	3.91E+06	3.09E-04	7.89E-11
H0M0	2.97E+06	3.49E-04	1.17E-10
H0M0	4.39E+06	3.16E-04	7.20E-11
H0M0	4.18E+06	3.34E-04	7.99E-11
H0M0	4.52E+06	2.94E-04	6.51E-11

Affinity (KD) is determined by examining the association rate (ka) and disassociation rate (kd) of proteins.

[0164] HcLc refers to *chimera antibody made from 656.35 having heavy chain sequence of SEQ ID NO: 56, and light chain sequence of SEQ ID NO: 58.*

-Functional Assay: Calcium Mobilization (FLIPR) using CHO-K1 CXCR2 (w/G α 16)

[0165] A microtiter plate based calcium mobilization assay, FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale CA, [Schroeder, 1996]), was used for the functional characterization of the neutralizing effect of antibodies on ELR+ chemokine induced $[Ca^{2+}]_i$ -mobilization in CHO-K1 cells transfected with and stably expressing hCXCR2 and G α 16.

[0166] On the day prior to assay, cells were plated in 96 well, blackwall, clear bottom plates (Packard View) at a concentration of 40000 cells per well. After 18 to 24 hours, media was aspirated off cells and replaced with 100 μ l load media containing Eagles Minimal Essential Medium (EMEM) with Earl's salts and L-Glutamine, 0.1% BSA (Serologicals Corporation), 4 μ M Fluo-4-acetoxymethyl ester fluorescent indicator dye (Fluo-4 AM) and 2.5 mM probenecid. Cells were incubated in this dye containing media for 1 hour at 37°C. The dye containing media was then aspirated off the cells and replaced with identical media without Fluo-4 AM and with 0.1% Gelatin (BSA removed) and 2.5 mM probenecid. Cells were incubated for 10 min. at 37°C and then washed 3 times with KRH assay buffer [Krebs Ringer Henseleit (120 mM NaCl, 4.6 mM KCl, 1.03 mM KH₂PO₄, 25 mM NaHCO₃, 1.0 mM CaCl₂, 1.1 mM MgCl₂, 11 mM Glucose, 20 mM HEPES (pH 7.4)) with 0.1% gelatin and 2.5 mM probenecid]. After the final buffer wash, 100 μ l KRH assay buffer with 0.1% gelatin and 2.5 mM probenecid was added to cells and warmed to 37°C for 10 min. before being placed in FLIPR where dye loaded cells were exposed to excitation light (488 nm) from a 6 watt Argon Laser. $[Ca^{2+}]_i$ -mobilization was monitored as a result of an increase in 516 nm emission intensity of Fluo-4 when bound to Ca²⁺. Change in emission intensity is directly related to cytosolic calcium levels, $[Ca^{2+}]_i$. After monitoring baseline for 10 sec., 50 μ l of 3X ELR+ chemokine, which had been pre-incubated with a concentration range of antibody, was added to the cell plate and data collected every sec. for 1 min., followed by an additional half min. of recording in 3 sec. intervals. Maximal cellular response above basal reading was exported for plotting in GraphPad Prism (v4.03).

[0167] The IC₅₀ was defined as the concentration of antibody required, during pre-treatment of 3X EC₈₀ chemokine, to neutralize the CXCR2 mediated stimulatory effect of an EC₈₀ concentration of the ELR+ chemokine by 50%. A secondary cellular response to 25 μ M ATP was monitored to test cell viability [Sarau, 1999].

Table: Inhibition of human ELR+ chemokine induced calcium flux (geometrically mean IC₅₀, ug/ml) by four humanized mAb constructs. (n=3)

	H0L7		H0L8		H0L10		H0M0	
<i>Pre-treated 3X EC₈₀ ELR+ Chemokine</i>	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.
3nM hIL8	0.30	0.12 - 0.72	0.83	0.70 - 0.98	0.19	0.15 - 0.22	0.19	0.15 - 0.23

(continued)

	H0L7		H0L8		H0L10		HOMO	
<i>Pre-treated 3X EC₈₀ ELR+ Chemokine</i>	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.	IC ₅₀ (ug/ml)	95% C.I.
10nM hGROa	1.48	0.98 - 2.23	3.52	2.74 - 4.53	1.09	0.58 - 2.06	1.11	0.67 - 1.83
6nM hGROb	1.04	0.19 - 5.58	7.93	4.20 - 14.97	0.66	0.24 - 1.86	0.99	0.35 - 2.76
30nM hENA-78	2.48	0.78 - 7.91	2.42	1.27 - 4.63	1.88	0.83 - 4.26	1.75	1.33 - 2.29
100nM hGCP-2	11.43	8.19 - 15.96	40.38	38.45 - 42.41	11.54	6.30 - 21.17	13.03	7.20 - 23.56

Schroeder KS, Neagle, BD. FLIPR: a new instrument for accurate, high throughput optical screening. J. Biomol. Screen. 1996;1:75.

Sarau HM, Ames RS, Chambers J, Ellis C, Elshourbagy N, Foley JJ et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotrien receptor. Mol Pharmacol. 1999;56:657-663.

- Ex vivo CD11b human neutrophil stimulation assay

[0168] Flow cytometry was used to examine the humanized penta-specific antibodies' ability to prevent chemokine induced human purified neutrophil activation, by following physical cellular changes (size and shape - granulation) and by examining surface activation markers (increased CD11b surface expression). The neutrophil control stimulant fMLP was used to confirm the purified human neutrophils ability to activate. See Figure 4.

Sequence Information

[0169] Total RNA was extracted from 656.35, 197.2 and 81.1 hybridoma cells, heavy and light variable domain cDNA sequence was then generated by reverse transcription and polymerase chain reaction (RT-PCR). The forward primer for RT-PCR was a mixture of degenerate primers specific for murine immunoglobulin gene leader-sequences and the reverse primer was specific for the antibody constant regions, in this case isotype IgG2a/κ. Primers were designed according to the strategy described by Jones and Bendig (Bio/Technology 9:88, 1991). RT-PCR was carried out in duplicate for both V-region sequences to enable subsequent verification of the correct V-region sequences. The V-region products generated by the RT-PCR were cloned (Invitrogen TA Cloning Kit) and sequence data obtained. This process was not successful for 81.1 light variable domain. Thus, the amino acid sequence shown below (Seq ID NO: 12) was therefore generated by protein sequencing the light chain isolated on a SDS-polyacrylamide gel run under reducing conditions.

[0170] Complementarity Determining Regions (CDRs) are underlined.

[0171] Polynucleotide sequences for heavy and light variable regions (SEQ ID NO: 1 and 3, respectively) for 656.35

SEQ ID NO: 1

CAGGTCCAGTTGCAGCAGTCTGGAGCTGAACTGGTAAGGCCTGGGACTTC
 AGTGACGATATCCTGTAAGGCTTCTGGCTACACCTTCACTAACTACTGGAT
 5 AGTTTGGGTCAAACAGAGGCCTGGACATGGACTTGAGTGGATTGGAGATC
 TTTACTCTGGAGGTGGTTATACTTTCTACAGTGAAAATTTCAAGGGGAAG
 GCCACACTGACTGCAGACACATCCTCCAGCACTGCCTACATGCACCTCAT
 10 TAGCCTGACATCTGAGGACTCTGCTGTCTATTTCTGTGCAAGATCGGGTTA
 CGACAGAACCTGGTTTGCTCACTGGGGCCAAGGGTCTCTGGTCACTGTCT
 CTGCA

15 SEQ ID NO: 3

GACATCAAGATGACCCAGTCTCCATCCTCCATGTCTGCATCGCTGGGAGA
 20 GAGAGTCACTATCACTTGTCAGGCGAGTCAGGACATTGAAAGCTATTTAA
 GCTGGTATCAGCAGAAACCATGGAAATCTCCTAAGACCCTGATCTATTAC
 GCTACAAGGTTGGCAGATGGGGTCCCATCAAGATTCAGTGGCAGTGGATC
 25 TGGTCAAGATTATTCTCTAACCATCAGCAGCCTGGAGTCTGACGATACAG
 CAACTTATTACTGTCTACAACATGGTGAGAGCCCTCCCACGTTCCGGTGCTG
 GGACCAAGCTGGAGCTGAAACGG

30 [0172] Polypeptide sequences for heavy and light variable regions (SEQ ID NO: 2 and 4, respectively) for 656.35

SEQ ID NO: 2

35 QVQLQQSGAELVRPGTSVTISCKASGYTFTNYWIVWVKQRPGHGLEWIGDL
YSGGGYTFYSENFKGKATLTADTSSSTAYMHLISLTSEDSAVYFCARSGYDR
TWFAHWGQGSLVTVSA

40 SEQ ID NO: 4

45 DIKMTQSPSSMSASLGERVTITCQASQDIESYLSWYQQKPKWKSPKTLIYYATR
LADGVPSRFSGSGSGQDYSLTISLESDDTATYYCLQHGESPPTFGAGTKLEL
 KR

50 [0173] Polypeptide sequences for heavy chain CDRs (SEQ ID NO: 13, 14, 15, respectively) for 656.35

SEQ ID NO: 13
 NYWIV

55 SEQ ID NO: 14
 DLYSGGGYTFYSENFKG

SEQ ID NO: 15
 SGYDRTWFAH

EP 2 146 745 B1

[0174] Polypeptide sequences for light chain CDRs (SEQ ID NO: 16, 17, 18) for 656.35

SEQ ID NO: 16
QASQDIESYLS

SEQ ID NO: 17
YATRLAD

SEQ ID NO: 18
LQHGESPT

[0175] Polynucleotide sequences for heavy chain CDRs (SEQ ID NO: 31, 32, 33) for 656.35

SEQ ID NO: 31
AACTACTGGATAGTT

SEQ ID NO: 32
GATCTTTACTCTGGAGGTGGTTATACTTTCTACAGTGAAAATTTCAAGGGG

SEQ ID NO: 33
TCGGGTTACGACAGAACCTGGTTTGCTCAC

[0176] Polynucleotide sequences for light chain CDRs (SEQ ID NO: 34, 35, 36) for 656.35

SEQ ID NO: 34
CAGGCGAGTCAGGACATTGAAAGCTATTTAAGC

SEQ ID NO: 35
TACGCTACAAGGTTGGCAGAT

SEQ ID NO: 36
CTACAACATGGTGAGAGCCCTCCCACG

[0177] Polynucleotide sequences for heavy and light variable regions (SEQ ID NO: 5 and 7, respectively) for 197.2

SEQ ID NO: 5

GAGTTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGCGCTTC
AGTGAAGATATCCTGCAAGGCTTCTGGTACTCATTCACTGACTACAACAT
GAACTGGGTGAAGCAGAGCAATGGAAAGAGCCTTGAGTGGATTGGAGTA
ATTAATCCTAAGTATGGTACTACTAGTTACAATCAGAAGTTCAAGGGCAA
GGCCACGTTGACTGTAGACCAATCCTCCAACACAGCCTACATGCAGCTCA
GCAGCCTGACATCTGAGGACTCTGCAGTCTATCACTGTGCAAGAGGAATG
GGACTCCTCTTTGGTATGGACTACTGGGGCCAAGGAACCTCTGTCACCGT
CTCCTCA

SEQ ID NO: 7

GACATTGTGATGACACAGTCTCCATCCTCCCTGAGTGTGTCAGCAGGAGA
 GAAGGTCACATATGAGCTGCAAGTCCAGTCAGAGTCTGTAAACAGTGGAA
 5 ATCARAAGAACTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGCCTCCT
 AAAGTGTGATCTACGGGGCATCCACTAGGAAATCTGGGGTCCCTGATCG
 CTTACAGGCAGTGGATCTGGAACCGATTCTACTCTTACCATCAGCAGTGT
 10 GCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGATCATAGTTTTCC
 GTGCACGTTCCGAGGGGGGACCAAGCTGGAAATAAAACGG

[0178] Polypeptide sequences for heavy and light variable regions (SEQ ID NO: 6 and 8, respectively) for 197.2

SEQ ID NO: 6

20 EFQLQQSGPELVKPGASVKISCKASGYSFTDYNMNWVKQSNGKSLEWIGVIN
 PKYGTTSYNQKFKGKATLTVDQSSNTAYMQLSSLTSEDSAVYHCARGMGLL
 FGMDYWGQGTSTVTVSS

SEQ ID NO: 8

30 DIVMTQSPSSLSVSAGEKVTMSCKSSQSLLNSGNQKNYLA WYQQKPGQPPKL
 LIYGASTRKS GVPDRFTGSGSGTDFTLTISVQAEDLAVYYCQNDHSFPCTFG
 GGTKLEIKR

[0179] Polypeptide sequences for heavy chain CDRs (SEQ ID NO: 19, 20, 21, respectively) for 197.2

35 SEQ ID NO: 19
 DYNMN

40 SEQ ID NO: 20
 VINPKYGTTSYNQKFKG

SEQ ID NO: 21
 GMGLLFGMDY

45 [0180] Polypeptide sequences for light chain CDRs (SEQ ID NO: 22, 23, 24) for 197.2

SEQ ID NO: 22
 KSSQSLLNSGNQKNYLA

50 SEQ ID NO: 23
 GASTRKS

SEQ ID NO: 24
 QNDHSFPCT

55 [0181] Polynucleotide sequences for heavy chain CDRs (SEQ ID NO: 37, 38, 39) for 197.2

SEQ ID NO: 37

EP 2 146 745 B1

GACTACAACATGAAC

SEQ ID NO: 38

GTAATTAATCCTAAGTATGGTACTACTAGTTACAATCAGAAGTTCAAGGG C

5

SEQ ID NO: 39

GGAATGGGACTCCTCTTTGGTATGGACTAC

[0182] Polynucleotide sequences for light chain CDRs (SEQ ID NO:40, 41, 42) for 197.2

10

SEQ ID NO: 40

AAGTCCAGTCAGAGTCTGTAAACAGTGGAAATCAAAGAAGTACTTGGC C

SEQ ID NO: 41

15

GGGGCATCCACTAGGAAATCT

SEQ ID NO: 42

CAGAATGATCATAGTTTCCGTGCACG

20

[0183] Polynucleotide sequence for heavy variable region (SEQ ID NO: 9) for 81.1

SEQ ID NO: 9

25

GAGGTCCAGCTGCAGCAGTCTGGACCTGAACTGGAGAAGCCTGGCGCTTC

AGTGAAGATATCCTGCAAGGCTTCTGGTTACTCTTTCAGTGTCTACGGCAT

GAACTGGGTGAGACAGAGCAATGGAAAGAGCCTTGAATGGATTGGAAAT

30

TTTGATCCTTACTTTAGTGTCACTTCCTACAACCAGAAGTTCCAGGACAAG

GCCACATTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAA

GAACCTCACATCTGAAGACTCTGCAGTCTATTTCTGTGCAAGAGGGAGCT

35

GGGAAACCATTTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTG

CA

[0184] Polypeptide sequence for heavy variable region (SEQ ID NO: 10) for 81.1

40

SEQ ID NO: 10

EVQLQQSGPELEKPGASVKISCKASGYSFTVYGMNWVRQSNGKSLEWIGNF

45

DPYFSVTSYNQKFQDKATLTVDKSSSTAYMQLKNLTSEDSAVYFCARGSWE

TIFAYWGQGTLVTVSA

[0185] Polypeptide sequences for heavy chain CDRs (SEQ ID NO: 25, 26, 27, respectively) for 81.1

50

SEQ ID NO: 25

VYGMN

SEQ ID NO: 26

55

NFDPYFSVTSYNQKFQD

SEQ ID NO: 27

GSWETIFAY

EP 2 146 745 B1

[0186] Polynucleotide sequences for heavy chain CDRs (SEQ ID NO: 43, 44, 45) for 81.1

SEQ ID NO: 43
GTCTACGGCATGAAC

5

SEQ ID NO: 44
AATTTTGATCCTTACTTTAGTGTCACCTCCTACAACCAGAAGTTCCAGGAC

10

SEQ ID NO: 45
GGGAGCTGGGAAACCATTTTGCTTAC

[0187] Polypeptide sequence for light variable region (SEQ ID NO: 12) for 81.1

15

QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPDHLFTGLIGGTNN
RAPGVPARFSGSLIGDKAALTITGAQTEDEAIYFCALWYSNHVFGGGTKLTVLQPK

20

[0188] Polypeptide sequences for light chain CDRs (SEQ ID NO: 28, 29, and 30, respectively) for 81.1

SEQ ID NO:28
RSSTGAVTTSNYAN

25

SEQ ID NO:29
GTNNRAP

30

SEQ ID NO:30
ALWYSNHV

[0189] A chimera* polynucleotide sequence (variable heavy region + codon optimised IgG1) SEQ ID NO: 55

35

40

45

50

55

CAGGTCCAGTTGCAGCAGTCTGGAGCTGAACTGGTAAGGCCTGGGACTTC
 AGTGACGATATCCTGTAAGGCTTCTGGCTACACCTTCACTAACTACTGGAT
 5 AGTTTGGGTCAAACAGAGGCCTGGACATGGACTTGAGTGGATTGGAGATC
 TTTACTCTGGAGGTGGTTATACTTTCTACAGTGAAAATTTCAAGGGGAAG
 GCCACACTGACTGCAGACACATCCTCCAGCACTGCCTACATGCACCTCAT
 10 TAGCCTGACATCTGAGGACTCTGCTGTCTATTTCTGTGCAAGATCGGGTTA
 CGACAGAACCTGGTTTGCTCACTGGGGCCAAAGGGTCACTAGTGACCGTGT
 CCAGCGCCAGCACCAAGGGCCCCAGCGTGTTCCCCCTGGCCCCCAGCAGC
 15 AAGAGCACCAGCGGCGGCACAGCCGCCCTGGGCTGCCTGGTGAAGGACT
 ACTTCCCCGAACCGGTGACCGTGTCTGGAACAGCGGAGCCCTGACCAGC
 GGCGTGACACCTTCCCCGCCGTGCTGCAGAGCAGCGGCCTGTACAGCCT
 20 GAGCAGCGTGGTGACCGTGCCCAGCAGCAGCCTGGGCACCCAGACCTAC
 ATCTGTAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGG
 TGGAGCCCAAGAGCTGTGACAAGACCCACACCTGCCCCCCTGCCCTGCC
 25 CCCGAGCTGCTGGGAGGCCCCAGCGTGTTCTGTTCCCCCCAAGCCTAA
 GGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCTGTGTGGTGGTGG
 ATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTACGTGGACGGC
 30 GTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAGTACAACA
 GCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTGGCTG
 AACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCC
 35 TATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAG
 GTGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTC
 40 CCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGT
 GGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGT
 GCTGGACAGCGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACA
 45 AGAGCAGATGGCAGCAGGGCAACGTGTTTCAGCTGCTCCGTGATGCACGA
 GGCCCTGCACAATCACTACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCA
 AG

[0190] chimera* polypeptide sequence (variable heavy region + codon optimised IgG1) SEQ ID NO: 56

QVQLQQSGAELVRPGTSVTISCKASGYTFTNYWIVWVKQRPBGHGLEWIGDL
 YSGGGYTFYSENFKGKATLTADTSSSTAYMHLISLTSEDSAVYFCARSGYDR
 5 TWFAHWGQGS LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
 VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP
 10 SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT
 CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
 QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ
 15 VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKS
 RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0191] A chimera* polynucleotide sequence (variable light region + codon optimised human cK) SEQ ID NO: 57

20 GACATCAAGATGACCCAGTCTCCATCCTCCATGTCTGCATCGCTGGGAGA
 GAGAGTCACTATCACTTGTCAGGCGAGTCAGGACATTGAAAGCTATTTAA
 25 GCTGGTATCAGCAGAAACCATGGAAATCTCCTAAGACCCTGATCTATTAC
 GCTACAAGGTTGGCAGATGGGGTCCCATCAAGATTCAGTGGCAGTGGATC
 TGGTCAAGATTATTCTCTAACCATCAGCAGCCTGGAGTCTGACGATACAG
 30 CAACTTATTACTGTCTACAACATGGTGAGAGCCCTCCCACGTTCCGGTGCTG
 GGACCAAGCTGGAGCTGAAACGTACGGTGGCCGCCCCCAGCGTGTTTCATC
 TTCCCCCCCAGCGATGAGCAGCTGAAGAGCGGCACCGCCAGCGTGGTGTG
 35 TCTGCTGAACAACCTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGG
 ACAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGA
 CAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTGACCCTGAGCAAGG
 40 CCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGG
 CCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC

[0192] Chimera* polypeptide sequence (variable light region + codon optimised human cK) SEQ ID NO: 58

45 DIKMTQSPSSMSASLGERVTITCQASQDIESYLSWYQQKPKWSPKTLIYYATR
 LADGVPSRFSGSGSGQDYSLTISLESDDTATYYCLQHGESPTFGAGTKLEL
 50 KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
 SQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
 55 GEC

[0193] Chimera* refers to chimeric antibody made from murine 656.35 antibody

H0 DNA sequence of mature heavy chain SEQ ID NO: 11

CAGGTGCAGCTCGTGCAGAGCGGCGCCGAAGTGAAGAAGCCCCGGGGCCAGCG
TGAAGGTGAGCTGCAAGGCCAGCGGCTACACCTTCACCAACTACTGGATCGTG
5 TGGGTCAGGCAGGCCCGGCCAGGGACTGGAGTGGATGGGCGACCTGTATA
GCGGCGGCGGCTACACCTTCTACAGCGAGAACTTCAAGGGCAGGGTGACCAT
GACCAGGGACACCAGCACCAGCACCCTGTACATGGAGCTGAGCAGCCTGAGG
10 AGCGAGGACACCGCCGTGTACTACTGCGCCAGGAGCGGCTACGACAGGACTT
GGTTTGCTCACTGGGGCCAGGGCACACTAGTGACCGTGTCCAGCGCCAGCACC
AAGGGCCCCAGCGTGTTCCTTGGCCCCCAGCAGCAAGAGCACCAGCGGCG
15 GCACAGCCGCCCTGGGCTGCCTGGTGAAGGACTACTTCCCCGAACCGGTGACC
GTGTCCTGGAACAGCGGAGCCCTGACCAGCGGCGTGCACACCTTCCCCGCCGT
GCTGCAGAGCAGCGGCCTGTACAGCCTGAGCAGCGTGGTGACCGTGCCCAGC
20 AGCAGCCTGGGCACCCAGACCTACATCTGTAACGTGAACCACAAGCCCAGCA
ACACCAAGGTGGACAAGAAGGTGGAGCCCAAGAGCTGTGACAAGACCCACAC
CTGCCCCCCCCTGCCCTGCCCCCGAGCTGCTGGGAGGCCCCAGCGTGTTCCTGTT
25 CCCCCCAAGCCTAAGGACACCCTGATGATCAGCAGAACCCCCGAGGTGACCT
GTGTGGTGGTGGATGTGAGCCACGAGGACCCTGAGGTGAAGTTCAACTGGTA
CGTGGACGGCGTGGAGGTGCACAATGCCAAGACCAAGCCCAGGGAGGAGCAG
30 TACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGATTG
GCTGAACGGCAAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCC
CCTATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCAGAGAGCCCCAGG
35 TGTACACCCTGCCCCCTAGCAGAGATGAGCTGACCAAGAACCAGGTGTCCCTG
ACCTGCCTGGTGAAGGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGA
40 GCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAG
CGATGGCAGCTTCTTCCTGTACAGCAAGCTGACCGTGGACAAGAGCAGATGGC
AGCAGGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAATCAC
45 TACACCCAGAAGAGCCTGAGCCTGTCCCCTGGCAAG

H0 protein sequence of mature heavy chain SEQ ID NO: 46

QVQLVQSGAEVKKPGASVKVSCKASGYFTFTNYWIVWVRQAPGGGLEWMGDLY
 SGGGYTFYSENFKGRVTMTRDTSTSTVYMESSLRSEDTAVYYCARSGYDRTWF
 AHWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
 SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
 EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE
 VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV
 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE
 WESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHN
 HYTQKSLSLSPGK

L7 DNA sequence of mature light chain SEQ ID NO: 47

GATATCCAGATGACCCAGAGCCCTAGCTCCCTCAGCGCATCAGTCGGCGACAG
 AGTGACAATCACCTGCCAGGCATCCCAGGACATCGAGTCTTACCTGAGCTGGT
 ACCAGCAGAAGCCCGGAAAGGCCCCAAAGCTCCTGATCTACTACGCCACTCG
 GCTGGCAGacGGCGTGCCTAGCAGGTTCTCCGGCTCAGGGTCTGGGACAGACTT
 CACCCTGACCATCAGCTCACTGCAGCCCGAGGATTTCCGCCACCTACTACTGTC
 TGCAGCACGGAGAGAGCCCCCAACCTTTGGCCAGGGAACCAAGCTGGAGAT
 CaagCGTACGGTGGCCGCCCCCAGCGTGTTTCATCTTCCCCCCCAGCGATGAGCA
 GCTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACCTTCTACCCCC
 GGGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAG
 CCAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGC
 AGCACCCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCT
 GTGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCG
 GGGCGAGTGC

L7 protein sequence of mature light chain SEQ ID NO: 48

DIQMTQSPSSLSASVGDRVTITCQASQDIESYLSWYQQKPGKAPKLLIYYATRLAD
 GVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQHGESPPFTFGQGTKLEIKRTVAAP
 SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
 KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

L8 DNA sequence of mature light chain SEQ ID NO: 59

GATATCCAGATGACCCAGAGCCCTAGCTCCCTCAGCGCATCAGTCGGCGACAG
 AGTGACAATCACCTGCCAGGCATCCCAGGACATCGAGTCTTACCTGAGCTGGT
 5 ACCAGCAGAAGCCCGGAAAGGCCCCAAAGCTCCTGATCTACTACGCCACTCG
 GCTGGCAgacGGCGTGCCTAGCAGGTTCTCCGGCTCAGGGTCTGGGACAGACTT
 CACcTtcACCATCAGCTCACTGCAGCCCGAGGATatcGCCACCTACTACTGTCTGC
 10 AGCACGGAGAGAGCCCCCAACCTTTGGCCAGGGAACCAAGCTGGAGATCaag
 CGTACGGTGGCCGCCCGCCAGCGTGTTTCATCTTCCCCCCCAGCGATGAGCAGCT
 GAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACCTTCTACCCCCGGG
 15 AGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCA
 GGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
 ACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTG
 20 AGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGGGG
 CGAGTGC

25 L8 protein sequence of mature light chain SEQ ID NO: 60

DIQMTQSPSSLSASVGDRVTITCQASQDIESYLSWYQQKPGKAPKLLIYYATRLAD
 30 GVPSRFSGSGSGTDFTFTISSLQPEDIAITYYCLQHGESPPFTFGQGTKLEIKRTVAAPS
 VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
 DSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

35 L10 DNA sequence of mature light chain SEQ ID NO: 61

GATATCCAGATGACCCAGAGCCCTAGCTCCCTCAGCGCATCAGTCGGCGACAG
 AGTGACAATCACCTGCCAGGCATCCCAGGACATCGAGTCTTACCTGAGCTGGT
 5 ACCAGCAGAAGCCCCGGAAAGGCCCCAAAGCTCCTGATCTACTACGCCACTCG
 GCTGGCAGacGGCGTGCCTAGCAGGTTCTCCGGCTCAGGGTCTGGGcagGACtacA
 CCCTGACCATCAGCTCACTGCAGCCCGAGGATTTCCGCCACCTACTACTGTCTG
 10 CAGCACGGAGAGAGAGCCCCCAACCTTTGGCCAGGGAACCAAGCTGGAGATCA
 AGCGTACGGTGGCCGCCCCAGCGTGTTTCATCTTCCCCCCCAGCGATGAGCAG
 CTGAAGAGCGGCACCGCCAGCGTGGTGTGTCTGCTGAACAACTTCTACCCCCG
 15 GGAGGCCAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGC
 CAGGAGAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCA
 GCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTG
 20 TGAGGTGACCCACCAGGGCCTGTCCAGCCCCGTGACCAAGAGCTTCAACCGG
 GGCGAGTGC

25 L10 protein sequence of mature light chain SEQ ID NO: 62

DIQMTQSPSSLSASVGDRVTITCQASQDIESYLSWYQQKPGKAPKLLIYYATRLAD
 30 GVPSRFSGSGSGQDYTLTISSLQPEDFATYYCLQHGESPPFTFGQGTKLEIKRTVAAP
 SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
 KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

35 M0 DNA sequence of mature light chain SEQ ID NO:63

GAGATCGTGCTGACCCAGTCTCCCGCCACCCTGTCACTGTCTCCCGGCGAAAG
 40 GGCAACCCTGAGCTGCCAGGCCAGCCAGGACATCGAGAGCTACCTGAGCTGG
 TACCAGCAGAAGCCCCGGCCAGGCCCCAGGCTGCTGATCTACTACGCCACCAG
 GCTGGCCGACGGCATTCCCGCCAGGTTTCAGCGGAAGCGGCAGCGGCACCGAC
 45 TTTACTCTGACCATCAGCAGCCTGGAGCCCGAGGACTTCGCCGTGTACTACTG
 CCTGCAGCACGGCGAGAGCCCTCCACCTTCGGCCAGGGCACCAAGCTCGAG
 ATCAAGCGTACGGTGGCCGCCCCAGCGTGTTTCATCTTCCCCCCCAGCGATGA
 50 GCAGCTGAAGAGCGGCACCGCCAGCGTGGTGT
 GTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGA
 CAATGCCCTGCAGAGCGGCAACAGCCAGGAGAGCGTGACCGAGCAGGACAGC

AAGGACTCCACCTACAGCCTGAGCAGCACCTGACCCTGAGCAAGGCCGACT
ACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAGGGCCTGTCCAG
5 CCCC GTGACCAAGAGCTTCAACCGGGGCGAGTGC

M0 protein sequence of mature light chain SEQ ID NO: 64

10 EIVLTQSPATLSLSPGERATLSCQASQDIESYLSWYQQKPGQAPRLLIYYATRLAD
GIPARFSGSGSGTDFTLTISSELPEDFAVYYCLQHGESPTFGQGTKLEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
15 DSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQUENCE LISTING

[0194]

<110> CLEGG, Stephanie J.
DOBRZYNSKI, Er i c
ELLIS, Jonathan H.
GERMASCHEWSKI, Vol ker
25 GODI LLOT, A. Paul
JONAK, Zdenka L.
LEW S, Al an P.
WHITE, John R.

30 <120> NOVEL COMPOUNDS

<130> PU62421

<150> 60/ 912, 229 <151> 2007-04-17

35 <150> 61/ 044, 132 <151> 2008-04-11

<160> 64

40 <170> Fast SEQ f or Windows Ver si on 4. 0

<210> 1

<211> 357

<212> DNA

45 <213> Murine

<400> 1

50 caggt ccagt t gcagcagt c t ggagct gaa ct ggt aaggc ct gggact t c agt gacgat a 60
t cct gt aagg ct t ct ggct a cacct t cact aact act gga t agt t t gggc caaacagagg 120
cct ggacat g gact t gagt g gat t ggagat ct t t act ct g gaggt ggt t a t act t t ct ac 180
agt gaaaat t t caaggggaa ggccacact g act gcagaca cat cct ccag cact gcct ac 240
at gcacct ca t t agcct gac at ct gaggac t ct gct gt ct at t t ct gt gc aagat cgggt 300
t acgacagaa cct ggt t t gc t cact ggggc caagggt ct c t ggt cact gt ct ct gca 357

55 <210> 2

<211> 119

<212> PRT

EP 2 146 745 B1

<213> Murine

<400> 2

[illegible]

20

<210>	3
<211>	324
<212>	DNA
<213>	Murine

25 <400> 3

30

gacat caaga	t gacccagt c	t ccat cct cc	at gt ct gcat	cgct gggaga	gagagt cact	60
at cact t gt c	agggcaggt ca	ggacat t gaa	agct at t t aa	gct ggt at ca	gcagaaacca	120
t ggaaat ct c	ct aagaccct	gat ct at t ac	gct acaaggt	t ggcagat gg	ggg cccat ca	180
agat t cagt g	gcagt ggt c	t ggt caagat	t at t ct ct aa	ccat cagcag	cct ggagt ct	240
gacgat acag	caact t at t a	ct gt ct acaa	cat ggt gaga	gccct cccac	gt t cggg gct	300
gggaccaagc	t ggaqct gaa	acgg				324

35 <210> 4
 <211> 108
 <212> PRT
 <213> Murine

<400> 4

45	Asp 1	Ile	Lys	Met	Thr 5	Gln	Ser	Pro	Ser	Ser 10	Met	Ser	Ala	Ser	Leu 15	Gly
	Glu	Arg	Val	Thr 20	Ile	Thr	Cys	Gln	Ala 25	Ser	Gln	Asp	Ile	Glu 30	Ser	Tyr
	Leu	Ser	Trp 35	Tyr	Gln	Gln	Lys	Pro 40	Trp	Lys	Ser	Pro	Lys 45	Thr	Leu	Ile
	Tyr	Tyr 50	Ala	Thr	Arg	Leu	Ala 55	Asp	Gly	Val	Pro	Ser 60	Arg	Phe	Ser	Gly
	Ser 65	Gly	Ser	Gly	Gln	Asp 70	Tyr	Ser	Leu	Thr	Ile 75	Ser	Ser	Leu	Glu 80	Ser
50	Asp	Asp	Thr	Ala	Thr 85	Tyr	Tyr	Cys	Leu	Gln 90	His	Gly	Glu	Ser	Pro 95	Pro
	Thr	Phe	Gly	Ala 100	Gly	Thr	Lys	Leu	Glu 105	Leu	Lys	Arg				

55 <210> 5
 <211> 357
 <212> DNA
 <213> Murine

EP 2 146 745 B1

<400> 5

5

gagt t ccagc	t gcagcagct c	t ggacct gag	ct ggt gaagc	ct ggcgct t c	agt gaagat a	60
t cct gcaagg	ct t ct ggt t a	ct cat t.cact	gact acaaca	t gaact ggg	gaagcagagc	120
aat ggaaaga	gcct t gagt g	gat t ggagt a	at t aat cct a	agt at ggt ac	t act agt t ac	180
aat cagaagt	t caagggcaa	ggccacgt t g	act gt agacc	aat cct ccaa	cacagcct ac	240
at gcagct ca	gcagcct gac	at ct gaggac	t ct gcagt ct	at cact gt gc	aagaggaat g	300
ggact cct ct	t t ggt at gga	ct act ggggc	caaggaaacct	ct gt caccgt	ct cct ca	357

10 <210> 6
<211> 119
<212> PRT
<213> Murine

15 <400> 6

		G u 1	Phe	G n	Leu 5	G n	Ser	G y	Pro	G u 10	Leu	Val	Lys	Pro	G y 15	Al a
20		Ser	Val	Lys	I l e 20	Ser	Oys	Lys	Al a	Ser 25	G y	Tyr	Ser	Phe	Thr 30	Tyr
		Asn	Met	Asn 35	Trp	Val	Lys	G n	Ser 40	Asn	G y	Lys	Ser	Leu 45	G u	Trp
		G y	Val 50	I l e	Asn	Pro	Lys	Tyr 55	G y	Thr	Thr	Ser	Tyr 60	Asn	G n	Lys
25		Lys 65	G y	Lys	Al a	Thr	Leu 70	Thr	Val	Asp	G n	Ser 75	Ser	Asn	Thr	Al a
		Met	G n	Leu	Ser	Ser 85	Leu	Thr	Ser	G u	Asp 90	Ser	Al a	Val	Tyr	Hi s
		Al a	Arg	G y	Met 100	G y	Leu	Leu	Phe	G y 105	Met	Asp	Tyr	Trp	G y 110	G n
30		Thr	Ser	Val 115	Thr	Val	Ser	Ser								

35

<210>	7
<211>	342
<212>	DNA
<213>	Murine

<400> 7

40

gacat t gt ga	t gacacagt c	t ccat cct cc	ct gagt gt gt	cagcaggaga	gaaggt cact	60
at gagct gca	agt ccagt ca	gagt ct gt t a	aacagt ggaa	at car aagaa	ct act t ggcc	120
t ggt accagc	agaaaccagg	gcagcct cct	aaact gt t ga	t ct acggggc	at ccaact agg	180
aaat ct gggg	t cctt gat cg	ct t cacaggc	agt ggaat ct g	gaaccgat t t	cact ct t acc	240
at cagcagt g	t gcaggct ga	agacct ggca	gt t t at t act	gt cagaat ga	t cat agt t t t	300
ccgt qcacgt	t cggaggggg	gaccaagct g	gaaat aaaac	gg		342

<210> 8
<211> 114
<212> PRT
<213> Murine

<400> 8

55

EP 2 146 745 B1

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ser Val Ser Ala Gly
 1 5 10 15
 Gu Lys Val Thr Met Ser Oys Lys Ser Ser Gln Ser Leu Leu Asn Ser
 20 25 30
 5 Gly Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45
 Pro Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Lys Ser Gly Val
 50 55 60
 Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80
 10 Ile Ser Ser Val Gln Ala Gu Asp Leu Ala Val Tyr Tyr Oys Gln Asn
 85 90 95
 Asp His Ser Phe Pro Oys Thr Phe Gly Gly Gly Thr Lys Leu Gu Ile
 100 105 110
 Lys Arg

<210> 9
 <211> 354
 <212> DNA
 <213> Murine

<400> 9

gaggt ccagc tgcagcagt c tggacct gaa ctggagaagc ctggcgcttc agtgaagat a 60
 25 tccctgcaagg cttctgggtta ctctttcact gtctacggca tgaactgggt gagacagagc 120
 aatggaaaga gccttgaatg gattggaaat ttgatcctt actttagtgt cacttcctac 180
 aaccagaagt tccaggacaa ggccacattg actgtagaca aatcctccag cacagcctac 240
 atgcagctca agaacctcac atctgaagac tctgcagctct atttctgtgc aagagggagc 300
 tgggaaacca tttttgctta ctggggccaa gggactctgg tcaactgtctc t gca 354

<210> 10
 <211> 118
 <212> PRT
 <213> Murine

<400> 10

Gu Val Gln Leu Gln Gln Ser Gly Pro Gu Leu Gu Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Ile Ser Oys Lys Ala Ser Gly Tyr Ser Phe Thr Val Tyr
 20 25 30
 Gly Met Asn Trp Val Arg Gln Ser Asn Gly Lys Ser Leu Gu Trp Ile
 35 40 45
 Gly Asn Phe Asp Pro Tyr Phe Ser Val Thr Ser Tyr Asn Gln Lys Phe
 50 55 60
 Gln Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Gln Leu Lys Asn Leu Thr Ser Gu Asp Ser Ala Val Tyr Phe Oys
 85 90 95
 Ala Arg Gly Ser Trp Gu Thr Ile Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala
 115

<210> 11
 <211> 1347
 <212> DNA
 <213> Murine

EP 2 146 745 B1

<400> 11

5 caggt gcagc t cgt gcagag cggcgccgaa gt gaagaagc ccggggccag cgt gaaggt g 60
agct gcaagg ccagcggct a cacct t cacc aact act gga t cgt gt ggt caggcaggcc 120
cccggccagg gact ggagt g gat gggcgac ct gt at agcg gcggcggct a cacct t ct ac 180
agcgagaact t caagggcag ggt gaccat g accagggaca ccagcaccag caccgt gt ac 240
at ggagct ga gcagcct gag gagcgaggac accgccgt gt act act gcgc caggagcggc 300
t acgacagga ct t ggt t t gc t cact ggggc cagggcacac t agt gaccgt gt ccagcgcc 360
agcaccaagg gccccagcgt gt t cccct g gccccagca gcaagagcac cagcggcggc 420
acagccgccc t gggct gcct ggt gaaggac t act t ccccg aaccggt gac cgt gt cct gg 480
10 aacagcggag cctt gaccag cggcgt gcac acct t ccccg ccgt gct gca gagcagcggc 540
ct gt acagcc t gagcagcgt ggt gaccgt g cccagcagca gcct gggcac ccagacct ac 600
at ct gt aacg t gaaccacaa gcccagcaac accaaggi gg acaagaaggi ggagcccaag 660
agct gt gaca agaccacac ct gccccccc t gccc gccc ccgagct gct gggaggcccc 720
agcgt gt t cc t gt t ccccc caagcct aag gacacct ga t gat cagcag aacccccgag 780
15 gt gacct gt g t ggt ggt gga t gt gagccac gaggacct g aggt gaagt t caact ggt ac 840
gt ggacggcg t ggaggt gca caat gccaa accaagcca gggaggagca gt acaacagc 900
acct accggg t ggt gt ccgt gct gaccgt g ct gcaccagg at t ggct gaa cggcaaggag 960
t acaagt gt a aggt gt ccaa caaggccct g cct gcccc a t cgagaaaac cat cagcaag 1020
gccaagggcc agcccagaga gccccaggt t acacct gc cccct agcag agat gagct g 1080
accaagaacc aggt gt cctt gacct gcct g gt gaagggct t ct accccag cgacat cgcc 1140
20 gt ggagt ggg agagcaacgg ccagcccag aacaact aca agaccacccc cct gt gct g 1200
gacagcgat g gcagct t ct t cct gt acagc aagct gaccg t ggacaagag cagat ggcag 1260
cagggaacg t gt t cagct g ct ccgt gat g cagcaggccc t gcacaat ca ct acaccag 1320
aagagcct ga gcct gt cccc t ggcaag 1347

<210> 12

25 <211> 111

<212> PRT

<213> Murine

<400> 12

30

G n A l a V a l V a l T h r G n G u S e r A l a L e u T h r T h r S e r P r o G l y G u
1 5 10 15
T h r V a l T h r L e u T h r O y s A r g S e r S e r T h r G l y A l a V a l T h r T h r S e r
20 25 30
35 A s n T y r A l a A s n T r p V a l G n G u L y s P r o A s p H i s L e u P h e T h r G l y
35 40 45
L e u I l e G l y G l y T h r A s n A s n A r g A l a P r o G l y V a l P r o A l a A r g P h e
50 55 60
S e r G l y S e r L e u I l e G l y A s p L y s A l a A l a L e u T h r I l e T h r G l y A l a
65 70 75
40 G n T h r G u A s p G u A l a I l e T y r P h e O y s A l a L e u T r p T y r S e r A s n
85 90 95
H i s V a l P h e G l y G l y G l y T h r L y s L e u T h r V a l L e u G n P r o L y s
100 105 110

<210> 13

45 <211> 5

<212> PRT

<213> Murine

<400> 13

50

A s n T y r T r p I l e V a l
1 5

<210> 14

55 <211> 17

<212> PRT

<213> Murine

EP 2 146 745 B1

<400> 14

5 Asp Leu Tyr Ser Gly Gly Gly Tyr Thr Phe Tyr Ser Glu Asn Phe Lys
1 5 10 15
Gly

<210> 15

<211> 10

<212> PRT

10 <213> Murine

<400> 15

15 Ser Gly Tyr Asp Arg Thr Trp Phe Ala His
1 5 10

<210> 16

<211> 11

<212> PRT

20 <213> Murine

<400> 16

25 Gln Ala Ser Gln Asp Ile Glu Ser Tyr Leu Ser
1 5 10

<210> 17

<211> 7

<212> PRT

30 <213> Murine

<400> 17

35 Tyr Ala Thr Arg Leu Ala Asp
1 5

<210> 18

<211> 9

<212> PRT

40 <213> Protein

<400> 18

45 Leu Gln His Gly Glu Ser Pro Pro Thr
1 5

<210> 19

<211> 5

<212> PRT

50 <213> Murine

<400> 19

55 Asp Tyr Asn Met Asn
1 5

<210> 20

<211> 17

EP 2 146 745 B1

<212> PRT
<213> Murine

<400> 20

5

Val Ile Asn Pro Lys Tyr Gly Thr Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly

10

<210> 21
<211> 10
<212> PRT
<213> Murine

15

<400> 21

Gly Met Gly Leu Leu Phe Gly Met Asp Tyr
1 5 10

20

<210> 22
<211> 17
<212> PRT
<213> Murine

25

<400> 22

Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu
1 5 10 15
Ala

30

<210> 23
<211> 7
<212> PRT
<213> Murine

35

<400> 23

Gly Ala Ser Thr Arg Lys Ser
1 5

40

<210> 24
<211> 9
<212> PRT
<213> Murine

45

<400> 24

Gln Asn Asp His Ser Phe Pro Cys Thr
1 5

50

<210> 25
<211> 5
<212> PRT
<213> Murine

55

<400> 25

EP 2 146 745 B1

Val Tyr Gly Met Asn
1 5

5 <210> 26
<211> 17
<212> PRT
<213> Murine

10 <400> 26
Asn Phe Asp Pro Tyr Phe Ser Val Thr Ser Tyr Asn Gln Lys Phe Gln
1 5 10 15
Asp

15 <210> 27
<211> 9
<212> PRT
<213> Murine

20 <400> 27
Gly Ser Trp Glu Thr Ile Phe Ala Tyr
1 5

25 <210> 28
<211> 14
<212> PRT
<213> Murine

30 <400> 28
Arg Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn
1 5 10

35 <210> 29
<211> 7
<212> PRT
<213> Murine

40 <400> 29
Gly Thr Asn Asn Arg Ala Pro
1 5

45 <210> 30
<211> 8
<212> PRT
<213> Murine

50 <400> 30
Ala Leu Trp Tyr Ser Asn His Val
1 5

55 <210> 31
<211> 15
<212> DNA
<213> Murine

EP 2 146 745 B1

<400> 31
 aact act gga t agt t 15

 5 <210> 32
 <211> 51
 <212> DNA
 <213> Murine

 10 <400> 32
 gat ct ttact ct ggaggt gg t t at act t t c t acagt gaaa at t t caaggg g 51

 <210> 33
 <211> 30
 <212> DNA
 15 <213> Murine

 <400> 33
 t cgggt t acg acagaacct g gt t t gct cac 30

 20 <210> 34
 <211> 33
 <212> DNA
 <213> Murine

 25 <400> 34
 caggcgagt c aggacat t ga aagct at t t a agc 33

 <210> 35
 <211> 21
 30 <212> DNA
 <213> Murine

 <400> 35
 35 tacgctacaa ggttggcaga t 21

 <210> 36
 <211> 27
 <212> DNA
 <213> Murine
 40
 <400> 36
 ctacaacatg gt gagagccc t cccacg 27

 <210> 37
 45 <211> 15
 <212> DNA
 <213> Murine

 <400> 37
 50 gact acaaca t gaac 15

 <210> 38
 <211> 51
 <212> DNA
 55 <213> Murine

 <400> 38
 gt aat t aat c ct aagt at gg t act act agt t acaat caga agt t caaggg c 51

EP 2 146 745 B1

<210> 39
 <211> 30
 <212> DNA
 <213> Murine
 5
 <400> 39
 ggaat gggac t cct ct t t gg tatggactac 30
 <210> 40
 10 <211> 51
 <212> DNA
 <213> Murine
 <400> 40.
 15 aagt ccagt c agagt ct gt t aaacagtgga aat caaaaga act act t ggc c 51
 <210> 41
 <211> 21
 <212> DNA
 20 <213> Murine
 <400> 41
 ggggcatcca ctaggaaat c t 21
 25 <210> 42
 <211> 27
 <212> DNA
 <213> Murine
 30 <400> 42
 cagaat gat c at agt t t t cc gt gcacg 27
 <210> 43
 <211> 15
 35 <212> DNA
 <213> Murine
 <400> 43
 40 gt ct acggca t gaac 15
 <210> 44
 <211> 51
 <212> DNA
 <213> Murine
 45 <400> 44
 aat t t t gat c ct t act t t ag t gt cact t cc tacaaccaga agt t ccagga c 51
 <210> 45
 50 <211> 27
 <212> DNA
 <213> Murine
 <400> 45
 55 gggagct ggg aaaccatttt t gct t ac 27
 <210> 46
 <211> 449

EP 2 146 745 B1

<212> PRT
<213> Murine

<400> 46

5		G n	Val	G n	Leu	Val	G n	Ser	G y	Al a	G u	Val	Lys	Lys	Pro	G y	Al a
		1				5					10					15	
		Ser	Val	Lys	Val	Ser	Oys	Lys	Al a	Ser	G y	Tyr	Thr	Phe	Thr	Asn	Tyr
					20					25					30		
10		Trp	I l e	Val	Trp	Val	Arg	G n	Al a	Pro	G y	G n	G y	Leu	G u	Trp	Met
				35					40					45			
		G y	Asp	Leu	Tyr	Ser	G y	G y	G y	Tyr	Thr	Phe	Tyr	Ser	G u	Asn	Phe
			50					55					60				
		Lys	G y	Arg	Val	Thr	Met	Thr	Arg	Asp	Thr	Ser	Thr	Ser	Thr	Val	Tyr
		65					70					75					80
15		Met	G u	Leu	Ser	Ser	Leu	Arg	Ser	G u	Asp	Thr	Al a	Val	Tyr	Tyr	Cys
					85					90						95	
		Al a	Arg	Ser	G y	Tyr	Asp	Arg	Thr	Trp	Phe	Al a	Hi s	Trp	G y	G n	G y
					100					105					110		
		Thr	Leu	Val	Thr	Val	Ser	Ser	Al a	Ser	Thr	Lys	G y	Pro	Ser	Val	Phe
				115					120					125			
20		Pro	Leu	Al a	Pro	Ser	Ser	Lys	Ser	Thr	Ser	G y	G y	Thr	Al a	Al a	Leu
			130					135					140				
		G y	Oys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	G u	Pro	Val	Thr	Val	Ser	Trp
		145					150					155					160
		Asn	Ser	G y	Al a	Leu	Thr	Ser	G y	Val	Hi s	Thr	Phe	Pro	Al a	Val	Leu
					165					170						175	
25		G n	Ser	Ser	G y	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser
					180					185					190		
		Ser	Ser	Leu	G y	Thr	G n	Thr	Tyr	I l e	Oys	Asn	Val	Asn	Hi s	Lys	Pro
				195					200					205			
		Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	G u	Pro	Lys	Ser	Oys	Asp	Lys
			210					215					220				
30		Thr	Hi s	Thr	Oys	Pro	Pro	Oys	Pro	Al a	Pro	G u	Leu	Leu	G y	G y	Pro
		225				230						235					240
		Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	I l e	Ser
					245						250				255		
		Arg	Thr	Pro	G u	Val	Thr	Oys	Val	Val	Val	Asp	Val	Ser	Hi s	G u	Asp
					260					265					270		
35		Pro	G u	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	G y	Val	G u	Val	Hi s	Asn
				275				280						285			
		Al a	Lys	Thr	Lys	Pro	Arg	G u	G u	G n	Tyr	Asn	Ser	Thr	Tyr	Arg	Val
			290					295				300					
		Val	Ser	Val	Leu	Thr	Val	Leu	Hi s	G n	Asp	Trp	Leu	Asn	G y	Lys	G u
		305				310					315						320
40		Tyr	Lys	Oys	Lys	Val	Ser	Asn	Lys	Al a	Leu	Pro	Al a	Pro	I l e	G u	Lys
					325						330				335		
		Thr	I l e	Ser	Lys	Al a	Lys	G y	G n	Pro	Arg	G u	Pro	G n	Val	Tyr	Thr
					340					345					350		
45		Leu	Pro	Pro	Ser	Arg	Asp	G u	Leu	Thr	Lys	Asn	G n	Val	Ser	Leu	Thr
				355					360					365			
		Oys	Leu	Val	Lys	G y	Phe	Tyr	Pro	Ser	Asp	I l e	Al a	Val	G u	Trp	G u
			370					375					380				
		Ser	Asn	G y	G n	Pro	G u	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu
		385					390					395					400
50		Asp	Ser	Asp	G y	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
					405						410				415		
		Ser	Arg	Trp	G n	G n	G y	Asn	Val	Phe	Ser	Oys	Ser	Val	Met	Hi s	G u
					420					425				430			
		Al a	Leu	Hi s	Asn	Hi s	Tyr	Thr	G n	Lys	Ser	Leu	Ser	Leu	Ser	Pro	G y
				435					440					445			
55		Lys															

<210> 47
<211> 642

EP 2 146 745 B1

<212> DNA
<213> Murine

<400> 47

5

10

15

```

gat at ccaga t gacccagag ccct agct cc ct cagcgcat cagt cggcga cagagt gaca 60
at cacct gcc aggcatt ccca ggacat cgag t ct t acct ga gct ggt acca gcagaagccc 120
ggaaaggcccc caaagct cct gat ct act ac gccact cggc t ggcagacgg cgt gcct agc 180
aggt t ct ccg gct cagggt c t gggacagac t t caccct ga ccat cagct c act gcagccc 240
gaggat t t cg ccacct act a ct gt ct gcag cacggagaga gccccccaac ct t t ggccag 300
ggaaccaagc t ggagat caa gcgt acggt g gccgccccca gcgt gt t cat ct t ccccccc 360
agcgat gagg agct gaagag cggcaccgcc agcgt ggt gt gt ct gct gaa caact t ct ac 420
ccccgggagg ccaaggt gca gt ggaaggt g gacaaat gccc t gcagagcgg caacagccag 480
gagagcgt ga ccgagcagga cagcaaggac t ccacct aca gcct gagcag caccct gacc 540
ct gagcaagg ccgact acga gaagcacaag gt gt acgcct gt gaggt gac ccaccagggc 600
ct gt ccagcc ccgt gaccaa gagct t caac cggggcgagt gc 642

```

<210> 48
<211> 214
<212> PRT
<213> Murine

20

<400> 48

25

30

35

40

45

```

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Oys Gln Ala Ser Gln Asp Ile Glu Ser Tyr
20 25 30
Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Oys Leu Gln His Gly Glu Ser Pro Pro
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Oys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Oys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Oys
210

```

<210> 49
<211> 15
<212> PRT
<213> Murine

<400> 49

55

```

Leu Ala Thr Glu Leu Arg Ser Gln Ser Leu Gln Thr Leu Gln Gly
1 5 10 15

```

EP 2 146 745 B1

<210> 50
 <211> 15
 <212> PRT
 <213> Murine
 5
 <400> 50

 Ser Ala Lys Glu Leu Arg Ser Gln Ser Ile Lys Thr Tyr Ser Lys
 1 5 10 15
 10
 <210> 51
 <211> 14
 <212> PRT
 <213> Murine
 15
 <400> 51

 Leu Arg Glu Leu Arg Ser Val Ser Leu Gln Thr Thr Gln Gly
 1 5 10
 20
 <210> 52
 <211> 14
 <212> PRT
 <213> Murine
 25
 <400> 52

 Ser Pro Gly Pro His Ser Ala Gln Thr Glu Val Ile Ala Thr
 1 5 10
 30
 <210> 53
 <211> 14
 <212> PRT
 <213> Murine
 35
 <400> 53

 Glu Ser Gly Pro His Ser Ala Asn Thr Glu Ile Ile Val Lys
 1 5 10
 40
 <210> 54
 <211> 14
 <212> PRT
 <213> Murine
 45
 <400> 54

 Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
 1 5 10
 50
 <210> 55
 <211> 1347
 <212> DNA
 <213> Murine
 55
 <400> 55

EP 2 146 745 B1

cagggtccagt tgcagcagtc tggagctgaa ctggt aaggc ctgggacttc agtgacgat a 60
tccctgt aagg cttctggcta caccttcact aactactgga tagtttgggt caaacagagg 120

5 cctggacatg gacttgagt g gat tggagat ct t t act ct g gaggt ggt t a t act t t ct ac 180
agt gaaaat t t caaggggaa ggccacact g act gcagaca cat cct ccag cact gcct ac 240
atgcacct ca t t agcct gac at ct gaggac t ct gct gt ct at t t ct gt gc aagat cgggt 300
t acgacagaa cct ggt t t gc t cact ggggc caaggggt cac t agt gaccgt gt ccagcgcc 360
agcaccaagg gccccagcgt gt t cccct g gccccagca gcaagagcac cagcggcggc 420
10 acagccgccc tgggct gcct ggt gaaggac t act t ccccg aaccggt gac cgt gt cct gg 480
aacagcggag cctt gaccag cggcgt gcac acct t ccccg ccgt gct gca gaggcggc 540
ctgt acagcc t gaggcagcgt ggt gaccgt g cccagcagca gcct gggcac ccagacct ac 600
at ct gt aacg t gaaccacaa gcccagcaac accaaggt gg acaagaaggt ggagcccaag 660
agct gt gaca agaccacac ct gccccccc t gccc t gccc ccgagct gct gggaggcccc 720
agcgt gt t cc t gt t cccccc caagcct aag gacacct ga t gat cagcag aacccccgag 780
15 gt gacct gt g t ggt ggt gga t gt gagccac gaggacct g aggt gaagt t caact ggt ac 840
gt ggacggcg t ggaggt gca caat gccaag accaagcca gggaggagca gt acaacagc 900
acct accggg t ggt gt ccgt gct gaccgt g ct gcaccagg at t ggct gaa cggcaaggag 960
t acaagt gt a aggt gt ccaa caaggccct g cct gcccct a t cgagaaaac cat cagcaag 1020
gccaagggcc agcccagaga gccccaggt g t acacct gc cccct agcag agat gagct g 1080
20 accaagaacc aggt gt cctt gacct gcct g gt gaagggct t ct accccag cgacat cgcc 1140
gt ggagt ggg agagcaacgg ccagcccagag aacaact aca agaccacccc cct gt gct g 1200
gacagcgat g gcagct t ct t cct gt acagc aagct gaccg t ggacaagag cagat ggcag 1260
cagggcaacg t gt t cagct g ct ccgt gat g cacgaggccc t gcacaat ca ct acaccag 1320
aagagcct ga gcct gt cccc t ggcaag 1347

25 <210> 56
<211> 449
<212> PRT
<213> Murine

30 <400> 56

35

40

45

50

55

EP 2 146 745 B1

	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Thr
	1				5					10					15	
	Ser	Val	Thr	Ile	Ser	Oys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asn	Tyr
5				20					25					30		
	Trp	Ile	Val	Trp	Val	Lys	Gln	Arg	Pro	Gly	His	Gly	Leu	Glu	Trp	Ile
			35					40					45			
	Gly	Asp	Leu	Tyr	Ser	Gly	Gly	Gly	Tyr	Thr	Phe	Tyr	Ser	Glu	Asn	Phe
		50					55					60				
	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Thr	Ser	Ser	Ser	Thr	Ala	Tyr
10	65					70					75				80	
	Met	His	Leu	Ile	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Oys
					85					90					95	
	Ala	Arg	Ser	Gly	Tyr	Asp	Arg	Thr	Trp	Phe	Ala	His	Trp	Gly	Gln	Gly
				100					105					110		
	Ser	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe
			115					120					125			
15	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu
		130					135						140			
	Gly	Oys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp
	145					150					155				160	
	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu
					165					170					175	
20	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser
				180					185					190		
	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Oys	Asn	Val	Asn	His	Lys	Pro
			195					200					205			
	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Oys	Asp	Lys
		210					215					220				
25	Thr	His	Thr	Oys	Pro	Pro	Oys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro
	225					230					235				240	
	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser
					245					250				255		
	Arg	Thr	Pro	Glu	Val	Thr	Oys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp
				260					265					270		
30	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn
			275					280					285			
	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val
		290					295					300				
	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu
	305					310					315				320	
35	Tyr	Lys	Oys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys
					325					330					335	
	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr
				340					345					350		
40	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr
			355					360					365			
	Oys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu
		370					375					380				
	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu
	385					390					395				400	
45	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys
					405					410				415		
	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Oys	Ser	Val	Met	His	Glu
				420					425					430		
	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly
			435					440					445			
50	Lys															

<210> 57

<211> 642

<212> DNA

55 <213> Murine

<400> 57

EP 2 146 745 B1

5 gacat caaga t gacccagt c t ccat cct cc at gt ct gcat cgct gggaga gagagt cact 60
 at cact t gt c aggcgagt ca ggacat t gaa agct at t t aa gct ggt at ca gcagaaacca 120
 t ggaaat ct c ct aagaccct gat ct at t ac gct acaagg t ggcagat gg ggt cccat ca 180
 agat t cagt g gcagt ggat c t ggt caagat t at t ct ct aa ccat cagcag cct ggagt ct 240
 gacgat acag caact t at t a ct gt ct acaa cat ggt gaga gccct cccac gt t cggg gct 300
 gggaccaagc t ggagct gaa acgt acggg g gccgccccca gcgt gt t cat ct t ccccccc 360
 agcgat gagg agct gaagag cggcaccgcc agcgt ggt gt gt ct gct gaa caact t ct ac 420
 ccccgagg ccaagg gca gt ggaagg g gacaaat gcc t gcagagcgg caacagccag 480
 gagagcgt ga ccgagcagga cagcaaggac t ccacct aca gcct gagcag caccct gacc 540
 10 ct gagcaagg ccgact acga gaagcacaag gt gt acgcct gt gaggt gac ccaccagggc 600
 ct gt ccagcc ccgt gaccaa gagct t caac cggggcgagt gc 642

<210> 58

<211> 214

<212> PRT

15 <213> Murine

<400> 58

20 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Ser Ala Ser Leu Gly
 1 5 10 15
 Glu Arg Val Thr Ile Thr Oys Gln Ala Ser Gln Asp Ile Glu Ser Tyr
 20 25 30
 Leu Ser Trp Tyr Gln Gln Lys Pro Trp Lys Ser Pro Lys Thr Leu Ile
 35 40 45
 Tyr Tyr Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 25 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser
 65 70 75 80
 Asp Asp Thr Ala Thr Tyr Tyr Oys Leu Gln His Gly Glu Ser Pro Pro
 85 90 95
 30 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Oys Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 35 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 40 Ala Oys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205

Phe Asn Arg Gly Glu Oys
210

45 <210> 59

<211> 642

<212> DNA

<213> Murine

50 <400> 59

55

EP 2 146 745 B1

gat at ccaga t gacccagag ccct agct cc ct cagcgcat cagt cggcga cagagt gaca 60
 at cacct gcc aggcatt ccca ggacat cgag t ct t acct ga gct ggt acca gcagaagccc 120
 ggaaaggccc caaagct cct gat ct act ac gccact cggc t ggcagacgg cgt gcct agc 180
 aggt t ct ccg gct cagggt c t gggacagac t t cacct t ca ccat cagct c act gcagccc 240
 5 gaggat at cg ccacct act a ct gt ct gcag cacggagaga gccccccaac ct t t ggccag 300
 ggaaccaagc t ggagat caa gcgt acggt g gccgccccca gcgt gt t cat ct t cccccc 360
 agcgat gagg agct gaagag cggcaccgcc agcgt ggt gt gt ct gct gaa caact t ct ac 420
 ccccgaggagg ccaaggt gca gt ggaaggt g gacaat gcc t gcagagcgg caacagccag 480
 gagagcgt ga ccgagcagga cagcaaggac t ccacct aca gcct gagcag caccct gacc 540
 ct gagcaagg ccgact acga gaagcacaag gt gt acgcct gt gaggt gac ccaccagggc 600
 10 ct gt ccagcc ccgt gaccaa gagct t caac cggggcgagt gc 642

<210> 60

<211> 214

<212> PRT

15 <213> Murine

<400> 60

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Oys Gln Ala Ser Gln Asp Ile Glu Ser Tyr
 20 25 30
 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Tyr Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Oys Leu Gln His Gly Glu Ser Pro Pro
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Oys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140
 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Oys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Oys
 210

<210> 61

45 <211> 642

<212> DNA

<213> Murine

<400> 61

gat at ccaga t gacccagag ccct agct cc ct cagcgcat cagt cggcga cagagt gaca 60
 at cacct gcc aggcatt ccca ggacat cgag t ct t acct ga gct ggt acca gcagaagccc 120
 ggaaaggccc caaagct cct gat ct act ac gccact cggc t ggcagacgg cgt gcct agc 180
 aggt t ct ccg gct cagggt c t gggcaggac t acacct ga ccat cagct c act gcagccc 240
 5 gaggat t t cg ccacct act a ct gt ct gcag cacggagaga gccccccaac ct t t ggccag 300

55

EP 2 146 745 B1

5 ggaaccaagc t ggagat caa gcgt acggt g gccgccccca gcgt gt t cat ct t cccccc 360
agcgt gagc agct gaagag cggcaccgcc agcgt ggt gt gt ct gct gaa caact t ct ac 420
ccccgggagg ccaaggt gca gt ggaaggt g gacaaat gcc t gcagagcgg caacagccag 480
gagagcgt ga ccgagcagga cagcaaggac t ccacct aca gcct gagcag caccct gacc 540
ct gagcaagg ccgact acga gaagcacaag gt gt acgcct gt gaggt gac ccaccagggc 600
ct gt ccagcc ccgt gaccaa gagct t caac cggggcgagt gc 642

<210> 62

<211> 214

10 <212> PRT

<213> Murine

<400> 62

15 Asp Ile Gl n Met Thr Gl n Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Gl n Ala Ser Gl n Asp Ile Gl u Ser Tyr
20 20 25 30
Leu Ser Trp Tyr Gl n Gl n Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Ala Thr Arg Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Gl n Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gl n Pro
65 70 75 80
Gl u Asp Phe Ala Thr Tyr Tyr Cys Leu Gl n His Gly Gl u Ser Pro Pro
85 90 95
25 Thr Phe Gly Gl n Gly Thr Lys Leu Gl u Ile Lys Arg Thr Val Ala Ala
100 105
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Gl u Gl n Leu Lys Ser Gly
110 115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Gl u Ala
130 135 140
30 Lys Val Gl n Trp Lys Val Asp Asn Ala Leu Gl n Ser Gly Asn Ser Gl n
145 150 155 160
Gl u Ser Val Thr Gl u Gl n Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Gl u Lys His Lys Val Tyr
180 185 190 195
35 Ala Cys Gl u Val Thr His Gl n Gly Leu Ser Ser Pro Val Lys Ser
195 200 205
Phe Asn Arg Gly Gl u Cys
210

40 <210> 63

<211> 642

<212> DNA

<213> Murine

45 <400> 63

50 gagat cgt gc t gacccagt c t cccgccacc ct gt cact gt ct cccggcga aagggcaacc 60
ct gagct gcc aggccagcca ggacat cgag agct acct ga gct ggt acca gcagaagccc 120
ggccaggccc ccaggct gct gat ct act ac gccaccaggc t ggccgacgg cat t cccgcc 180
aggt t cagcg gaagcggcag cggcaccgac t t cact ct ga ccat cagcag cct ggagccc 240
gaggact t cg ccgt gt act a ct gcct gcag cacggcgaga gccct cccac ct t cggccag 300
ggcaccaagc t cgagat caa gcgt acggt g gccgccccca gcgt gt t cat ct t cccccc 360
agcgt gagc agct gaagag cggcaccgcc agcgt ggt gt gt ct gct gaa caact t ct ac 420
ccccgggagg ccaaggt gca gt ggaaggt g gacaaat gcc t gcagagcgg caacagccag 480
gagagcgt ga ccgagcagga cagcaaggac t ccacct aca gcct gagcag caccct gacc 540
55 ct gagcaagg ccgact acga gaagcacaag gt gt acgcct gt gaggt gac ccaccagggc 600
ct gt ccagcc ccgt gaccaa gagct t caac cggggcgagt gc 642

<210> 64

<211> 214
 <212> PRT
 <213> Murine

5 <400> 64

10
 15
 20
 25
 30
 35
 40
 45
 50
 55

G u I l e V a l L e u T h r G n S e r P r o A l a T h r L e u S e r L e u S e r P r o G y
 1 5 10 15
 G u A r g A l a T h r L e u S e r O y s G n A l a S e r G n A s p I l e G u S e r T y r
 20 25 30
 L e u S e r T r p T y r G n G n L y s P r o G y G n A l a P r o A r g L e u L e u I l e
 35 40 45
 T y r T y r A l a T h r A r g L e u A l a A s p G y I l e P r o A l a A r g P h e S e r G y
 50 55 60
 S e r G y S e r G y T h r A s p P h e T h r L e u T h r I l e S e r S e r L e u G u P r o
 65 70 75 80
 G u A s p P h e A l a V a l T y r T y r O y s L e u G n H i s G y G u S e r P r o P r o
 85 90 95
 T h r P h e G y G n G y T h r L y s L e u G u I l e L y s A r g T h r V a l A l a A l a
 100 105 110
 P r o S e r V a l P h e I l e P h e P r o P r o S e r A s p G u G n L e u L y s S e r G y
 115 120 125
 T h r A l a S e r V a l V a l O y s L e u L e u A s n A s n P h e T y r P r o A r g G u A l a
 130 135 140
 L y s V a l G n T r p L y s V a l A s p A s n A l a L e u G n S e r G y A s n S e r G n
 145 150 155 160
 G u S e r V a l T h r G u G n A s p S e r L y s A s p S e r T h r T y r S e r L e u S e r
 165 170 175
 S e r T h r L e u T h r L e u S e r L y s A l a A s p T y r G u L y s H i s L y s V a l T y r
 180 185 190
 A l a O y s G u V a l T h r H i s G n G y L e u S e r S e r P r o V a l T h r L y s S e r
 195 200 205
 P h e A s n A r g G y G u O y s
 210

Claims

1. A penta-specific antibody which has specificity for and neutralizes each of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78.
2. An antibody according to claim 1, which binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 with an equilibrium constant, KD, values of less than 10^{-7} M, 10^{-8} M, or 10^{-9} M as determined by surface plasmon resonance.
3. A method making a penta-specific antibody comprising the steps of:
 - a. injecting into a mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 in complete Freund's adjuvant (cFA);
 - b. injecting into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78 in incomplete Freund's adjuvant (iFA); and
 - c. injecting into the mouse a mixture of human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and a set of five multiple antigenic peptides (MAPs) each MAP unit having one separate sequence from polypeptides of ID NOs: 49-53 in incomplete Freund's adjuvant;
 - d. isolating B cells from the mouse;
 - e. fusing the B cells with myeloma cells to form immortal hybridoma cells that secrete the desired penta-specific antibody; and
 - f. isolating the penta-specific antibody from the culture supernatant of the hybridoma.

4. A method of making a penta-specific antibody comprising the steps of:

- a. injecting into a mouse a set of five multiple antigenic peptides (MAPs) each MAP unit having one separate sequence from polypeptides of ID NOs: 49-53 (the MAP set) in complete Freund's adjuvant;
- b. injecting into the mouse the MAP set in incomplete Freund adjuvant;
- c. injecting into the mouse a mixture of all human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78, and the MAP set incomplete Freund's adjuvant ;
- d. isolating B cells from the mouse; and
- e. fusing the B cells with myeloma cells to form immortal hybridoma cells that secrete the desired penta-specific antibody; and
- f. isolating the penta-specific antibody from the culture supernatant of the hybridoma.

5. An antibody according to claim 1, the antibody comprising:

- a. heavy and light chain variable regions encoded by nucleotide sequences comprising the sequences of SEQ ID NO:1 and SEQ ID NO:3, respectively;
- b. heavy and light chain variable regions encoded by nucleotide sequences comprising the sequences of SEQ ID NO:5 and SEQ ID NO:7, respectively;
- c. a heavy chain variable region encoded by nucleotide sequences comprising the sequence of SEQ ID NO:9;
- d. heavy and light chains encoded by nucleotide sequences comprising sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively; or
- e. heavy and light chains encoded by nucleotide sequences comprising sequences which are at least 90%, 95%, 98% or 99% identical to sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively.

6. An antibody according to claim 1, the antibody comprising:

- a. heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:4, respectively;
- b. heavy and light chain variable regions comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:4, respectively;
- c. heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NO:6 and SEQ ID NO:8, respectively; or
- d. heavy and light chain variable regions comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:6 and SEQ ID NO:8, respectively;
- e. a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:10, or an amino acid sequence which is at least 90%, 95%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:10;
- f. heavy and light chains comprising the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively; or
- g. heavy and light chains comprising polypeptides which are at least 90%, 95%, 98% or 99% identical to the amino acid sequences of SEQ ID NO:46, and SEQ ID NO:48, 60, 62, or 64, respectively.

7. An antibody according to claim 1, the antibody comprising at least one variable region selected from (i) the amino acid SEQ ID NO: 2, 4, 6, 8, or 10; or (ii) an amino acid sequence which is at least 90%, 95%, 98% or 99% identical to any one of the amino acid sequences of (i) above.

8. An antibody according to claim 1, the antibody comprising:

- a. at least one CDR sequence selected from SEQ ID NOs: 13, 14, 15, 16, 17 and 18;
- b. at least one CDR sequence selected from SEQ ID NOs: 19, 20, 21, 22, 23 and 24; or
- c. at least one CDR sequence selected from SEQ ID NOs: 25, 26 and 27.

9. An antibody according to claim 1, the antibody comprising:

- a. the polypeptide of SEQ ID NO:15;
- b. the polypeptide of SEQ ID NO:21; or
- c. polypeptide of SEQ ID NO:27.

10. An antibody according to claim 1, the antibody comprising:

EP 2 146 745 B1

- a. at least four CDR sequences selected from the group consisting of SEQ ID NOs: 13, 14, 15, 16, 17, and 18; or
- b. at least four CDR sequences selected from the group consisting of: SEQ ID NOs: 19, 20, 21, 22, 23, and 24.

11. An antibody according to claim 1, the antibody comprising:

- a. CDR sequences of SEQ ID NOs: 13, 14, 15, 16, 17 and 18;
- b. heavy and light chain variable regions comprising the CDR sequences of SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 16, 17, and 18, respectively;
- c. CDR sequences of SEQ ID NOs: 19, 20, 21, 22, 23, and 24;
- d. heavy and light chain variable regions which comprises the CDR sequences of SEQ ID NOs: 19, 20, and 21, and SEQ ID NOs: 22, 23, and 24, respectively;
- e. CDR sequences of SEQ ID NOs: 25, 26, and 27; or
- f. a heavy chain variable region which comprises the CDR amino acid sequences of SEQ ID NOs: 25, 26, and 27.

12. An antibody according to claim 1, comprising the CDR sequences of SEQ ID NO: 13, 14, 15, 16, 17 and 18.

13. A hybridoma or transfectoma which produces a penta-specific antibody which comprises CDR sequences of:

- a. SEQ ID NOs: 13, 14, 15, 16, 17, and 18;
- b. SEQ ID NOs: 19, 20, 21, 22, 23, and 24; or
- c. SEQ ID NOs: 25, 26, and 27.

14. A recombinant eukaryotic or a prokaryotic cell which produces an antibody which comprises:

- a. CDR sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18;
- b. CDR sequences of SEQ ID NOs: 19, 20, 21, 22, 23, and 24;
- c. CDR sequences of SEQ ID NOs: 25, 26, and 27;
- d. a heavy and/or light chain comprising the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO: 48, 60, 62, or 64, respectively; or
- e. a heavy and/or light chain comprising an amino acid sequence which is at least 90%, 95%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 46, or SEQ ID NO: 48, 60, 62, or 64, respectively.

15. An antibody according to claim 1, comprising heavy and light chain amino acid sequences of, respectively:

- (a) SEQ ID NO: 46 and SEQ ID NO: 48;
- (b) SEQ ID NO: 46 and SEQ ID NO: 62;
- (c) SEQ ID NO: 46 and SEQ ID NO: 60; or
- (d) SEQ ID NO: 46 and SEQ ID NO: 64.

16. An antibody according to claim 1, wherein said antibody binds within epitope of KELRCQCIKTYSKP (SEQ ID NO: 54) of human IL-8.

17. A pharmaceutical composition comprising a penta-specific antibody according to any of claims 1, 2, 5 to 12, or 14 to 16 and a pharmaceutically acceptable carrier.

18. A penta-specific antibody according to any of claims 1, 2, 5 to 12, 15 and 16 for use in the treatment or prevention of COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, exacerbation of asthma and COPD, cystic fibrosis, diffuse panbronchiolitis, reperfusion injury, and/or endometriosis.

19. A process for producing a penta-specific antibody (immunoglobulin) in a single host cell, comprising the steps of:

(i) transforming said single host cell with

- (a) a first DNA sequence encoding at least the variable domain of the immunoglobulin heavy chain comprising CDR domains of SEQ ID NOs: 13, 14, and 15; and a second DNA sequence encoding at least the variable domain of the immunoglobulin light chain comprising CDR domains of SEQ ID NOs: 16, 17, and 18;

(b) a first DNA sequence encoding at least the variable domain of the immunoglobulin heavy chain comprising CDR domains of SEQ ID NOs: 19, 20, and 21; and a second DNA sequence encoding at least the variable domain of the immunoglobulin light chain comprising CDR domains of SEQ ID NOs: 22, 23, and 24; or
(c) a first DNA sequence encoding a heavy chain comprising polypeptide of SEQ ID NO: 46; and a second DNA sequence encoding a light chain comprising a polypeptide of SEQ ID NO: 48, 60, 62, or 64; and

(ii) expressing said first DNA sequence and said second DNA sequence so that said immunoglobulin heavy and light chains are produced as separate molecules in said transformed single host cell.

Patentansprüche

1. Penta-spezifischer Antikörper, der eine Spezifität aufweist für humanes IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 und jedes davon neutralisiert.
2. Antikörper nach Anspruch 1, der an humanes IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 mit einer mittels Oberflächenplasmonenresonanz gemessenen Gleichgewichtskonstante KD mit Werten von weniger als 10^{-7} M, 10^{-8} M oder 10^{-3} M, bindet.
3. Verfahren zur Herstellung eines penta-spezifischen Antikörpers, das die Schritte umfasst:
 - a. Injizieren einer Mischung aus humanem IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 in kompletten Freund-Adjuvans (KFA) in eine Maus;
 - b. Injizieren einer Mischung aus humanem IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 in inkompletten Freund-Adjuvans (IFA) in die Maus; und
 - c. Injizieren einer Mischung aus humanem IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 und einen Satz aus fünf multiplen antigenen Peptiden (MAPs) in inkompletten Freund-Adjuvans in die Maus, wobei jede MAP-Einheit eine verschiedene Sequenz aus den Polypeptiden der SEQ ID NOs: 49 bis 53 aufweist;
 - d. Isolieren von B-Zellen aus der Maus,
 - e. Fusionieren der B-Zellen mit Myelom-Zellen, um unsterbliche Hybridom-Zellen zu bilden, die den gewünschten penta-spezifischen Antikörper sekretieren; und
 - f. Isolieren des penta-spezifischen Antikörpers aus dem Kulturüberstand des Hybridoms.
4. Verfahren zur Herstellung eines penta-spezifischen Antikörpers, das die Schritte umfasst:
 - a. Injizieren eines Satzes aus fünf multiplen antigenen Peptiden (MAPs) in kompletten Freund-Adjuvans in eine Maus, wobei jede MAP-Einheit eine verschiedene Sequenz aus den Polypeptiden mit SEQ ID NOs: 49 bis 53 hat;
 - b. Injizieren des Satzes aus MAPs in inkompletten Freund-Adjuvans in die Maus;
 - c. Injizieren einer Mischung aus allem, humanem IL-8, Gro-alpha, Gro-beta, Gro-gamma und ENA-78 und dem Satz aus MAPs in inkompletten Freund-Adjuvans in die Maus;
 - d. Isolieren der B-Zellen aus der Maus,
 - e. Fusionieren der B-Zellen mit Myelom-Zellen, um unsterbliche Hybridom-Zellen zu bilden, die den gewünschten penta-spezifischen Antikörper sekretieren; und
 - f. Isolieren des penta-spezifischen Antikörpers aus dem Kulturüberstand der Hybridoma.
5. Antikörper nach Anspruch 1, wobei der Antikörper umfasst:
 - a. variable Regionen der schweren und leichten Kette, die von den Nucleotidsequenzen codiert sind, die die Sequenzen von SEQ ID NO:1 bzw. SEQ ID NO:3 umfassen;
 - b. variable Regionen der schweren und leichten Kette, die von den Nucleotidsequenzen codiert sind, die die Sequenzen von SEQ ID NO:5 bzw. SEQ ID NO:7 umfassen;
 - c. variable Region der schweren Kette, die von den Nucleotidsequenzen codiert ist, die die Sequenz von SEQ ID NO:9 umfasst;
 - d. schwere und leichte Ketten, die von den Nucleotidsequenzen codiert sind, die die Sequenzen von SEQ ID NO:11 bzw. SEQ ID NOs:47, 59, 61 oder 63 umfassen; oder
 - e. schwere und leichte Ketten, die von Nucleotidsequenzen codiert sind, die Sequenzen umfassen, die zu mindestens 90%, 95%, 98% oder 99% identisch sind mit den Sequenzen von SEQ ID NO:11 bzw. SEQ ID NOs:47, 59, 61 oder 63.

6. Antikörper nach Anspruch 1, wobei der Antikörper umfasst:

- a. variable Regionen der schweren und leichten Kette, die die Aminosäuresequenzen von SEQ ID NO:2 bzw. SEQ ID NO:4 umfassen;
- b. variable Regionen der schweren und leichten Kette, die Polypeptide umfassen, die zu mindestens 90%, 95%, 98% oder 99% identisch sind zu den Aminosäuresequenzen von SEQ ID NO:2 bzw. SEQ ID NO:4;
- c. variable Regionen der schweren und leichten Kette, die die Aminosäuresequenzen von SEQ ID NO:6 bzw. SEQ ID NO:8 umfassen; oder
- d. variable Regionen der schweren und leichten Kette, die Polypeptide umfassen, die zu mindestens 90%, 95%, 98% oder 99% identisch sind zu den Aminosäuresequenzen von SEQ ID NO:6 bzw. SEQ ID NO:8;
- e. variable Region der schweren Kette, die die Aminosäuresequenz von SEQ ID NO:10 umfasst, oder eine Aminosäuresequenz, die zu mindestens 90%, 95%, 98% oder 99% identisch ist zu der Aminosäuresequenz von SEQ ID NO:10;
- f. schwere und leichte Ketten, die die Aminosäuresequenzen von SEQ ID NO:46 bzw. SEQ ID NOs:48, 60, 62 oder 64 umfassen; oder
- g. schwere und leichte Ketten, die Polypeptide umfassen, die zu mindestens 90%, 95%, 98% oder 99% identisch sind zu den Aminosäuresequenzen von SEQ ID NO:46 bzw. SEQ ID NOs:48, 60, 62 oder 64.

7. Antikörper nach Anspruch 1, wobei der Antikörper mindestens eine variable Region umfasst, die ausgewählt ist aus (i) den Aminosäuresequenzen von SEQ ID NOs: 2, 4, 6, 8 oder 10; oder (ii) einer Aminosäuresequenz, die zu mindestens 90%, 95%, 98% oder 99% identisch ist zu den vorstehenden Aminosäuresequenzen von (i).

8. Antikörper nach Anspruch 1, wobei der Antikörper umfasst:

- a. mindestens eine CDR-Sequenz, die ausgewählt ist aus SEQ ID NOs:13, 14, 15, 16, 17 und 18;
- b. mindestens eine CDR-Sequenz, die ausgewählt ist aus SEQ ID NOs:19, 20, 21, 22, 23 und 24; oder
- c. mindestens eine CDR-Sequenz, die ausgewählt ist aus SEQ ID NOs:25, 26 und 27.

9. Antikörper nach Anspruch 1, wobei der Antikörper umfasst:

- a. Polypeptid mit SEQ ID NO:15;
- b. Polypeptid mit SEQ ID NO:21; oder
- c. Polypeptid mit SEQ ID NO:27.

10. Antikörper nach Anspruch 1, wobei der Antikörper umfasst:

- a. mindestens vier CDR-Sequenzen, die ausgewählt sind aus der Gruppe bestehend aus SEQ ID NOs:13, 14, 15, 16, 17 und 18; oder
- b. mindestens vier CDR-Sequenzen, die ausgewählt sind aus der Gruppe bestehend aus SEQ ID NOs:19, 20, 21, 22, 23 und 24.

11. Antikörper gemäß Anspruch 1, wobei der Antikörper umfasst:

- a. CDR-Sequenzen von SEQ ID NOs:13, 14, 15, 16, 17 und 18;
- b. variable Regionen der schweren und leichten Kette, die die CDR-Sequenzen von SEQ ID NOs:13, 14 und 15 bzw. SEQ ID NOs:16, 17 und 18 umfassen;
- c. CDR-Sequenzen von SEQ ID NOs:19, 20, 21, 22, 23 und 24;
- d. variable Regionen der schweren und leichten Kette, die die CDR-Sequenzen von SEQ ID NOs:19, 20 und 21 bzw. SEQ ID NOs: 22, 23 und 24 umfassen;
- e. CDR-Sequenzen von SEQ ID NOs:25, 26 und 27; oder
- f. variable Region der schweren Kette, die die CDR-Aminosäuresequenzen von SEQ ID NOs:25, 26 und 27 umfasst.

12. Antikörper nach Anspruch 1, der die CDR-Sequenzen von SEQ ID NOs:13, 14, 15, 16, 17 und 18 umfasst.

13. Hybridoma oder Transfectoma, das einen penta-spezifischen Antikörper herstellt, der die CDR-Sequenzen umfasst:

- a. SEQ ID NOs:13, 14, 15, 16, 17 und 18;

- b. SEQ ID NOs:19, 20, 21, 22, 23 und 24; oder
- c. SEQ ID NOs:25, 26 und 27.

14. Rekombinante eukaryotische oder prokaryotische Zelle, die einen Antikörper herstellt, der umfasst:

- a. CDR-Sequenzen von SEQ ID NOs:13, 14, 15, 16, 17 und 18;
- b. CDR-Sequenzen von SEQ ID NOs:19, 20, 21, 22, 23 und 24; oder
- c. CDR-Sequenzen von SEQ ID NOs:25, 26 und 27;
- d. schwere und/oder leichte Kette, die die Aminosäuresequenz von SEQ ID NO:46 bzw. SEQ-ID NOs:48, 60, 62 oder 64 umfasst; oder
- e. schwere und/oder leichte Kette, die eine Aminosäuresequenz umfasst, die zu mindestens 90%, 95%, 98% oder 99% identisch ist zu den Aminosäuresequenzen von SEQ ID NO:46 bzw. SEQ ID NOs:48, 60, 62 oder 64 ist.

15. Antikörper nach Anspruch 1, der die Aminosäuresequenzen der schweren bzw. leichten Kette umfasst:

- (a) SEQ ID NO:46 und SEQ ID NO:48;
- (b) SEQ ID NO:46 und SEQ ID NO:62;
- (c) SEQ ID NO:46 und SEQ ID NO:60; oder
- (d) SEQ ID NO:46 und SEQ ID NO:64.

16. Antikörper nach Anspruch 1, wobei der Antikörper innerhalb des Epitops KELRCQCIKTYSKP (SEQ ID NO:54) von humanem IL-8 bindet.

17. Arzneimittel, das einen penta-spezifischen Antikörper nach einem der Ansprüche 1, 2, 5 bis 12 oder 14 bis 16 und einen pharmazeutisch verträglichen Träger umfasst.

18. Penta-spezifischer Antikörper nach einem der Ansprüche 1, 2, 5 bis 12, 15 und 16 zur Verwendung bei der Behandlung oder Vorbeugung von COPD, Osteoarthritis, rheumatoider Arthritis, erosiver Arthritis, Asthma, Atherosklerose, entzündlicher Darmerkrankung, Psoriasis, Transplant-Abstoßung, Gicht, Krebs, akuter Lungenverletzung, akuter Lungenerkrankung, Sepsis, ARDS, peripherer Arterienerkrankung, systemischer Sklerose, respiratorisches Distresssyndrom bei Neugeborenen, akuter Asthmaanfall und akuter Exazerbation der COPD, cystischer Fibrose, diffuser Panbronchiolitis, Reperfusionsschaden und/oder Endometriose.

19. Verfahren zur Herstellung eines penta-spezifischen Antikörpers (Immunglobulins) in einer einzelnen Wirtszelle, umfassend die Schritte:

(i) die einzelne Wirtszelle zu transformieren mit:

- a) Transformieren einer ersten DNA-Sequenz, die mindestens die variable Domäne der schweren Immunglobulinkette codiert, die die CDR-Domänen der SEQ ID NOs:13, 14 und 15 umfasst; und einer zweiten DNA-Sequenz, die mindestens die variable Domäne der leichten Immunglobulinkette codiert, die die CDR-Domänen der SEQ ID NOs:16, 17 und 18 umfasst;
- b) einer ersten DNA-Sequenz, die mindestens die variable Domäne der schweren Immunglobulinkette codiert, die die CDR-Domänen mit SEQ ID NOs:19, 20 und 21 umfasst; und einer zweiten DNA-Sequenz, die mindestens die variable Domäne der leichten Immunglobulinkette codiert, die die CDR-Domänen mit SEQ ID NOs:22, 23 und 24 umfasst; oder
- c) einer ersten DNA-Sequenz, die eine schwere Kette codiert, die das Polypeptid der SEQ ID NO:46 umfasst; und einer zweiten DNA-Sequenz, die eine leichte Kette codiert, die ein Polypeptid der SEQ ID NOs:48, 60, 62 oder 64 umfasst;

(ii) Exprimieren der ersten DNA-Sequenz und der zweiten DNA-Sequenz, so dass die schweren und leichten Immunglobulinketten als getrennte Moleküle in der transformierten einzelnen Wirtszelle hergestellt werden.

Revendications

1. Anticorps penta-spécifique qui a une spécificité pour et neutralise chacune des IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines.

2. Anticorps suivant la revendication 1, qui se lie aux IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines avec une constante d'équilibre, KD, ayant des valeurs inférieures à 10^{-7} M, 10^{-8} M ou 10^{-9} M, de la manière déterminée par résonance de plasmon de surface.

3. Procédé de préparation d'un anticorps penta-spécifique, comprenant les étapes :

- a. d'injection à une souris d'un mélange de IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines dans de l'adjuvant complet de Freund (cFA) ;
- b. d'injection à la souris d'un mélange de IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines dans de l'adjuvant incomplet de Freund (iFA) ; et
- c. d'injection à la souris d'un mélange de IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines, et d'une série de cinq peptides antigéniques multiples (MAP), chaque motif MAP ayant une séquence distincte provenant des polypeptides ID N° 49-53 dans de l'adjuvant incomplet de Freund ;
- d. d'isolement de lymphocytes B à partir de la souris ;
- e. de fusion des lymphocytes B avec des cellules de myélome pour former des cellules d'hybridome immortelles qui sécrètent l'anticorps penta-spécifique désiré ; et
- f. d'isolement de l'anticorps penta-spécifique du surnageant de culture de l'hybridome.

4. Procédé de préparation d'un anticorps penta-spécifique, comprenant les étapes :

- a. d'injection à une souris d'une série de cinq peptides antigéniques multiples (MAP), chaque motif MAP ayant une séquence distincte provenant des polypeptides ID N° 49-53 (la série de MAP) dans de l'adjuvant complet de Freund ;
- b. d'injection à la souris de la série de MAP dans de l'adjuvant incomplet de Freund ;
- c. d'injection à la souris d'un mélange de l'ensemble des IL-8, Gro-alpha, Gro-bêta, Gro-gamma et ENA-78 humaines, et de la série de MAP dans de l'adjuvant incomplet de Freund ;
- d. d'isolement de lymphocytes B à partir de la souris ;
- e. de fusion des lymphocytes B avec des cellules de myélome pour former des cellules d'hybridome immortelles qui sécrètent l'anticorps penta-spécifique désiré ; et
- f. d'isolement de l'anticorps penta-spécifique du surnageant de culture de l'hybridome.

5. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. les régions variables de chaînes lourdes et légères codées par des séquences de nucléotides comprenant les séquences des SEQ ID N° 1 et SEQ ID N° 3, respectivement ;
- b. les régions variables de chaînes lourdes et légères codées par des séquences de nucléotides comprenant les séquences des SEQ ID N° 5 et SEQ ID N° 7, respectivement ;
- c. une région variable de chaîne lourde codée par des séquences de nucléotides comprenant la séquence de la SEQ ID N° 9 ;
- d. des chaînes lourdes et légères codées par des séquences de nucléotides comprenant les séquences de la SEQ ID N° 11, et de la SEQ ID N° 47, 59, 61 ou 63, respectivement ; ou
- e. des chaînes lourdes et légères codées par des séquences de nucléotides comprenant des séquences qui sont identiques à au moins 90 %, 95 %, 98 % ou 99 % aux séquences de la SEQ ID N° 11, et de la SEQ ID N° 47, 59, 61 ou 63, respectivement.

6. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. des régions variables de chaînes lourdes et légères comprenant les séquences d'acides aminés des SEQ ID N° 2 et SEQ ID N° 4, respectivement ;
- b. des régions variables de chaînes lourdes et légères comprenant des polypeptides qui sont identiques à au moins 90 %, 95 %, 98 % ou 99 % aux séquences d'acides aminés des SEQ ID N° 2 et SEQ ID N° 4, respectivement ;
- c. des régions variables de chaînes lourdes et légères comprenant les séquences d'acides aminés des SEQ ID N° 6 et SEQ ID N° 8, respectivement ; ou
- d. des régions variables de chaînes lourdes et légères comprenant des polypeptides qui sont identiques à au moins 90 %, 95 %, 98 % ou 99 % aux séquences d'acides aminés des SEQ ID N° 6 et SEQ ID N° 8, respectivement ;
- e. une région variable de chaîne lourde comprenant la séquence d'acides aminés de la SEQ ID N° 10, ou une séquence d'acides aminés qui est identique à au moins 90 %, 95 %, 98 % ou 99 % à la séquences d'acides aminés de la SEQ ID N° 10 ;

- f. des chaînes lourdes et légères comprenant les séquences d'acides aminés de la SEQ ID N° 46 et de la SEQ ID N° 48, 60, 62 ou 64, respectivement ; ou
g. des chaînes lourdes et légères comprenant des polypeptides qui sont identiques à au moins 90 %, 95 %, 98 % ou 99 % aux séquences d'acides aminés de la SEQ ID N° 46, et de la SEQ ID N° 48, 60, 62 ou 64, respectivement.

7. Anticorps suivant la revendication 1, l'anticorps comprenant au moins une région variable choisie entre (i) la séquence d'acides aminés SEQ ID N° 2, 4, 8 ou 10 ; ou (ii) une séquence d'acides aminés qui est identique à au moins 90 %, 95 %, 98 % ou 99 % à l'une quelconque des séquences d'acides aminés de (i) ci-dessus.

8. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. au moins une séquence de CDR choisie entre les SEQ ID N° 13, 14, 15, 16, 17 et 18 ;
b. au moins une séquence de CDR choisie entre les SEQ ID N° 19, 20, 21, 22, 23 et 24 ; ou
c. au moins une séquence de CDR choisie entre les SEQ ID N° 25, 26 et 27.

9. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. le polypeptide de la SEQ ID N° 15 ;
b. le polypeptide de la SEQ ID N° 21 ; ou
c. le polypeptide de la SEQ ID N° 27.

10. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. au moins quatre séquences de CDR choisies dans le groupe consistant en les SEQ ID N° 13, 14, 15, 16, 17 et 18 ; ou
b. au moins quatre séquences de CDR choisies dans le groupe consistant en les SEQ ID N° 19, 20, 21, 22, 23 et 24.

11. Anticorps suivant la revendication 1, l'anticorps comprenant :

- a. des séquences de CDR des SEQ ID N°s 13, 14, 15, 16, 17 et 18 ;
b. des régions variables de chaînes lourdes et légères comprenant les séquences de CDR des SEQ ID N°s 13, 14, 15 et des SEQ ID N°s 16, 17 et 18, respectivement ;
c. des séquences de CDR des SEQ ID N°s 19, 20, 21, 22, 23 et 24 ;
d. des régions variables de chaînes lourdes et légères qui comprennent les séquences de CDR des SEQ ID N°s 19, 20 et 21, et des SEQ ID N°s 22, 23 et 24, respectivement ;
e. des séquences de CDR des SEQ ID N°s 25, 26 et 27 ; ou
f. une région variable de chaîne lourde qui comprend les séquences d'acides aminés de CDR des SEQ ID N°s 25, 26 et 27.

12. Anticorps suivant la revendication 1, comprenant les séquences de CDR des SEQ ID N°s 13, 14, 15, 16, 17 et 18.

13. Hybridome ou transfectome qui produit un anticorps penta-spécifique qui comprend les séquences de CDR des :

- a. SEQ ID N°s 13, 14, 15, 16, 17 et 18 ;
b. SEQ ID N°s 19, 20, 21, 22, 23 et 24 ; ou
c. SEQ ID N°s 25, 26 et 27.

14. Cellule eucaryotique ou procaryotique recombinante qui produit un anticorps qui comprend :

- a. les séquences de CDR des SEQ ID N°s 13, 14, 15, 16, 17 et 18 ;
b. les séquences de CDR des SEQ ID N°s 19, 20, 21, 22, 23 et 24 ;
c. les séquences de CDR des SEQ ID N°s 25, 26 et 27 ;
d. une chaîne lourde et/ou légère comprenant la séquence d'acides aminés de la SEQ ID N° 46, ou de la SEQ ID N° 48, 60, 62 ou 64, respectivement ; ou
e. une chaîne lourde et/ou légère comprenant une séquence d'acides aminés qui est identique à au moins 90 %, 95 %, 98 % ou 99 % à la séquence d'acides aminés de la SEQ ID N° 46, ou de la SEQ ID N° 48, 60, 62 ou 64, respectivement.

15. Anticorps suivant la revendication 1, comprenant des séquences d'acides aminés de chaînes lourdes et légères, respectivement de :

- (a) de la SEQ ID N° 46 et de la SEQ ID N° 48 ;
- (b) de la SEQ ID N° 46 et de la SEQ ID N° 62 ;
- (c) de la SEQ ID N° 46 et de la SEQ ID N° 60 ; ou
- (d) de la SEQ ID N° 46 et de la SEQ ID N° 64.

16. Anticorps suivant la revendication 1, ledit anticorps se liant dans l'épitope de KELRXQCIKTYSKP (SEQ ID N° 54) de la IL-8 humaine.

17. Composition pharmaceutique comprenant un anticorps penta-spécifique suivant l'une quelconque des revendications 1, 2, 5 à 12 ou 14 à 16 et un support pharmaceutiquement acceptable.

18. Anticorps penta-spécifique suivant l'une quelconque des revendications 1, 2, 5 à 12, 15 et 16 pour une utilisation dans le traitement ou la prévention de la maladie pulmonaire obstructive chronique (COPD), de l'arthrose, de la polyarthrite rhumatoïde, de l'arthrite érosive, de l'asthme, de l'athérosclérose, d'une maladie intestinale inflammatoire, du psoriasis, du rejet d'un transplant, de la goutte, d'un cancer, d'une lésion pulmonaire aiguë, d'une maladie pulmonaire aiguë, de la septicémie, de la ARDS, d'une maladie des artères périphériques, de la sclérose généralisée, du syndrome de détresse respiratoire du nouveau-né, de l'exacerbation de l'asthme et de la COPD, de la fibrose kystique, de la panbronchiolite diffuse, d'une lésion de reperfusion et/ou de l'endométriose.


19. Procédé pour produire un anticorps penta-spécifique (immunoglobuline) dans une cellule hôte unique, comprenant les étapes :

(i) de transformation de ladite cellule hôte unique avec

- (a) une première séquence d'ADN codant pour au moins le domaine variable de la chaîne lourde d'immunoglobuline comprenant les domaines de CDR des SEQ ID N°s 13, 14 et 15 ; et une seconde séquence d'ADN codant pour au moins le domaine variable de la chaîne légère d'immunoglobuline comprenant les domaines de CDR des SEQ ID N°s 16, 17 et 18 ;
- (b) une première séquence d'ADN codant pour au moins le domaine variable de la chaîne lourde d'immunoglobuline comprenant les domaines de CDR des SEQ ID N°s 19, 20 et 21 ; et une seconde séquence d'ADN codant pour au moins le domaine variable de la chaîne légère d'immunoglobuline comprenant les domaines de CDR des SEQ ID N°s 22, 23 et 24 ; ou
- (c) une première séquence d'ADN codant pour une chaîne lourde comprenant le polypeptide de la SEQ ID N° 46 ; et une seconde séquence d'ADN codant pour une chaîne légère comprenant un polypeptide de la SEQ ID N° 48, 60, 62, ou 64 ; et


(ii) d'expression de ladite première séquence d'ADN et de ladite seconde séquence d'ADN de telle sorte que lesdites chaînes lourdes et légères d'immunoglobuline soient produites sous forme de molécules séparées dans ladite cellule hôte unique transformée.

Figure 1

**Linear Peptides**


LATELRSQSLQTLQG - SEQ ID NO:49
 SAKELRSQSIKTYSK - SEQ ID NO:50
 LRELRSVSLQTTQG - SEQ ID NO:51
 SPGPHSAQTEVIAT - SEQ ID NO:52
 ESGPHSANTEIIVK - SEQ ID NO:53

Figure 2




Flow cytometric data comparing neutrophils present in BAL samples. Sessions 1, 2 and 3 are presented. The black solid bars show the baselines 5 day pre-LPS challenge. The grey solid bars depict the BAL data 6-hours post LPS challenge. The Chimera Antibody treatment significantly and dose dependently inhibited neutrophil infiltration. The grey hatched bars represent 24-hour data. (n=6, * $p \leq 0.05$, † $p \leq 0.01$, error bars represent standard deviation).

Figure 3



Hematological analysis of total circulating neutrophils (cell count). IV injection of 1 (open squares, □) and 10 mg/kg (closed circles, •) of the Chimera Antibody prevented inhaled LPS stimulation of circulating neutrophils. Both 1 and 10 mg/kg treatments are significantly reduced compared to the vehicle: NHP (†) and 10 mg/kg treatment was also significantly reduced compared to the 1 mg/kg dose (*). Data are represented as total count per ul of blood (n=6, * $p \leq 0.05$ vs. 1 mg/kg, † $p \leq 0.01$ vs. vehicle, error bars represent standard deviation).

Figure 4



Inhibition human IL-8 stimulated neutrophil activation (increased CD11b surface expression). Various concentrations of the humanized penta-specific antibodies were pre-incubated with 10 nM hIL-8 prior to addition to purified human neutrophils. Data are expressed as mean values of 4 different donors (n=4). Bars represent standard error. All samples are compared to purified neutrophils stimulated with hIL-8 only (no mAb prior to addition to purified neutrophils). Humanized construct H0L10 and H0M0 are more effective at inhibiting hIL-8 stimulated CD11b surface expression.

Figure 5A

Mouse 2X656.35 mAb binding to target human chemokines.






Figure 5B

The Chimera Antibody (HcLc) mAb binding to human target chemokines.

Chimera v. human Chemokines

hIL-18 run as a negative control

Figure 5C
Humanized mAbs binding to human target chemokines



hIL-18 run as a negative control

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 9306213 A [0107]
- WO 9948523 A [0109]
- WO 04006955 A [0110]
- WO 9429348 A [0112]
- US 6248516 B [0113]
- US 6291158 B [0113]
- US 6172197 B [0113]
- US 4676980 A [0114]
- EP 0307434 A [0116]
- WO 8807089 A [0116]
- EP 0629240 A [0116]
- WO 9317105 A [0116]
- WO 2004014953 A [0116]
- WO 9958679 A [0116]
- US 5739277 A [0117]
- WO 9013646 A [0122]
- WO 04009823 A [0126]
- DD 266710 [0129]
- EP 402226 A [0129]
- EP 183070 A [0129]
- EP 244234 A [0129]
- US 5807715 A [0130]
- US 5429746 A [0134]
- EP 0612251 A [0136]
- US 60912229 B [0194]
- US 61044132 B [0194]

Non-patent literature cited in the description

- HASKILL, S. et al. *Proc. Natl. Acad. Sci.*, 1990, vol. 87, 7732-7736 [0002]
- WANG, D. ; RICHMOND, A. Cytokine Reference. Academic Press, 1023-1027 [0002]
- POWERM C.A. et al. *Gene*, vol. 151, 333-334 [0002]
- IIZASA, H. ; MATSUSHIMA, K. Cytokine Reference. Academic Press, 1061-1067 [0002]
- MATSUSHIMA, K. et al. *J. Exp. Med.*, 1988, vol. 167, 1883-1893 [0002]
- *Am. J. Respir. Crit Care Med.*, 2001, vol. 163, 349-355 [0002]
- *Am. J. Respir. Crit Care Med.*, 2003, vol. 168, 968-975 [0002]
- *Thorax*, 2002, vol. 57, 590-595 [0002]
- KILPATRICK, K.E. et al. *Hybridoma*, 1997, vol. 16, 381 [0007]
- FRANCIS, J.P et al. *Immunology*, 1991, vol. 73, 249 [0008] [0141]
- SCHOTT, M.E. et al. *Cell. Immuno*, 1996, vol. 174, 199-209 [0008]
- TAM, J.P. *Proc. Natl. Acad. Sci.*, 1988, vol. 85, 5409-5413 [0008] [0141]
- JONSSON, U. et al. *Ann. Biol. Clin.*, 1993, vol. 51, 19-26 [0085]
- JONSSON, U et al. *Biotechniques*, 1991, vol. 11, 620-627 [0085]
- JOHNSON, B. et al. *J. Mol. Recognit.*, 1995, vol. 8, 125-131 [0085]
- JOHNSON, B. et al. *Anal. Biochem.*, 1991, vol. 198, 268-277 [0085]
- KOHLER ; MILSTEIN. *Nature*, 1975, vol. 256, 495-497 [0087]
- BROWN et al. *J. Immunol*, 1981, vol. 127, 539-46 [0087]
- BROWN et al. *J Biol Chem*, 1980, vol. 255, 4980-83 [0087]
- YEH et al. *PNAS*, 1976, vol. 76, 2927-31 [0087]
- YEH et al. *Int. J. Cancer*, 1982, vol. 29, 269-75 [0087]
- R. H. KENNETH. *Monoclonal Antibodies: A New Dimension In Biological Analyses*. Plenum Publishing Corp, 1980 [0087]
- E. A. LERNER. *Yale J. Biol. Med.*, 1981, vol. 54, 387-402 [0087]
- M. L. GEFTER et al. *Somatic Cell Genet.*, 1977, vol. 3, 231-36 [0087]
- E. MEYERS ; W. MILLER. *Comput. Appl. Biosci.*, 1988, vol. 4, 11-17 [0097]
- *J. Mol. Biol.*, 1970, vol. 48, 444-453 [0097]
- KOZBOR. *J. Immunol*, 1984, vol. 133, 3001 [0103]
- BRODEUR. *Monoclonal Antibody Production Techniques and Applications*. Marcel Dekker Inc, 1987, 51-63 [0103]
- WINTER G. *Annu. Rev. Immunol*, 1994, vol. 12, 433-455 [0103]
- GREEN LL. *J. Immunol. methods*, 1999, vol. 231, 11-23 [0103]
- TOMIZUKA K. *PNAS*, vol. 97, 722-727 [0104]
- FISHWILD D.M. *Nature Biotechnol.*, 1996, vol. 14, 845-851 [0104]
- MENDEZ MJ. *Nature Genetics*, 1997, vol. 15, 146-156 [0104]
- EREN R et al. *Immunology*, 1998, vol. 93, 154-161 [0105]

- **BABCOOK et al.** *PNAS*, 1996, vol. 93, 7843-7848 [0105]
- **MCCAFFERTY.** *Nature*, 1990, vol. 348, 552-553 [0106]
- **GRIFFITHS AD et al.** *EMBO*, 1994, vol. 13, 3245-3260 [0106]
- **MARKS.** *J.Mol.Bio.*, 1991, vol. 222, 581-597 [0106]
- **MARKS.** *Biolotechnol*, 1992, vol. 10, 779-783 [0107]
- **WATERHOUSE.** *Nucl.Acids Res*, 1993, vol. 21, 2265-2266 [0107]
- **MORRISON.** *PNAS*, 1984, vol. 81, 6851 [0108]
- **JONES et al.** *Nature*, 1986, vol. 321, 522-525 [0109]
- **VERHOEYEN M et al.** *Science*, 1988, vol. 239, 1534-1536 [0109]
- **QUEEN C et al.** *PNAS*, 1989, vol. 86, 10, 029-10, 033 [0109]
- **CO, M et al.** *Nature*, 1991, vol. 351, 501-502 [0109]
- **PADLAN E.A. et al.** *Mol.Immunol.*, 1991, vol. 28, 489-498 [0110]
- **PEDERSEN J.T. et al.** *J.Mol.Biol.*, 1994, vol. 235, 959-973 [0110]
- **MARK G.E. et al.** *Handbook of Experimental Pharmacology vol.113: The pharmacology of monoclonal Antibodies.* Springer-Verlag, 1994, vol. 113, 105-134 [0110]
- **ALFENITO-M.** *Advancing Protein Therapeutics*, January 2007 [0110]
- **HWANG et al.** *Methods*, 2005, vol. 36, 35-42 [0110]
- **BIRD et al.** *Science*, 1988, vol. 242, 423-426 [0112]
- **HUSTON et al.** *PNAS*, vol. 85, 5879-5883 [0113]
- **GLOCKSHUBER et al.** *Biochemistry*, 1990, vol. 29, 1362-1367 [0113]
- **ZHU et al.** *Protein Sci.*, 1997, vol. 6, 781-788 [0113]
- **WHITLOW et al.** *Methods companion Methods Enzymol*, 1991, vol. 2, 97-105 [0113]
- **HUSTON et al.** *Int.Rev.Immunol*, 1993, vol. 10, 195-217 [0113]
- **ADAMS et al.** *Can.Res*, 1993, vol. 53, 4026-4034 [0113]
- **MCCARTNEY et al.** *Protein Eng.*, 1995, vol. 8, 301-314 [0113]
- **KIPRIYANOV et al.** *Cell. Biophys*, 1995, vol. 26, 187-204 [0113]
- **HOLLIGER et al.** *PNAS*, 1993, vol. 90, 6444-6448 [0113]
- **KORTT et al.** *Protein Eng*, 1997, vol. 10, 423-433 [0113]
- **LE GALL et al.** *FEBS Lett*, 1999, vol. 453, 164-168 [0113]
- **PACK et al.** *Biochemistry*, 1992, vol. 31, 1579-1584 [0113]
- **HU et al.** *Cancer Res.*, 1996, vol. 56, 3055-3061 [0113]
- **KURUCZ et al.** *J.Immol.*, 1995, vol. 154, 4576-4582 [0113]
- **KIPRIYANOV et al.** *Int.J.Can*, 1998, vol. 77, 763-772 [0113]
- **KONTERMANN et al.** *J.Immunol.Methods*, 1999, vol. 226, 179-188 [0113]
- **COLOMA et al.** *Nature Biotechnol.*, 1997, vol. 15, 159-163 [0113]
- **ALT et al.** *FEBS Lett*, 1999, vol. 454, 90-94 [0113]
- **MULLER et al.** *FEBS Lett*, 1998, vol. 432, 45-49 [0113]
- **KIPRIYANOV et al.** *J.Mol.Biol.*, 1999, vol. 293, 41-56 [0113]
- **SHALABY et al.** *J.Exp.Med.*, 1992, vol. 175, 217-225 [0113]
- **KOSTELNY et al.** *J.Immunol.*, 1992, vol. 148, 1547-1553 [0113]
- **BOYD et al.** *Mol.Immunol.*, 1996, vol. 32, 1311-1318 [0115]
- **RAJU et al.** *Biochemistry*, 2001, vol. 40, 8868-8876 [0115]
- **ZHANG et al.** *Science*, 2004, vol. 303, 371 [0115]
- **SEARS et al.** *Science*, 2001, vol. 291, 2344 [0115]
- **WACKER et al.** *Science*, 2002, vol. 298, 1790 [0115]
- **DAVIS et al.** *Chem.Rev.*, 2002, vol. 102, 579 [0115]
- **HANG et al.** *Acc.Chem.Res*, 2001, vol. 34, 727 [0115]
- **KOUMENIS I.L et al.** *Int.J.Pharmaceut.*, 2000, vol. 198, 83-95 [0116]
- **DUNCAN et al.** *Nature*, 1988, vol. 332, 563-564 [0116]
- **LUND et al.** *J. Immunol.*, 1991, vol. 147, 2657-2662 [0116]
- **CHAPPEL et al.** *PNAS*, 1991, vol. 88, 9036-9040 [0116]
- **BURTON ; WOOF.** *Adv. Immunol.*, 1992, vol. 51, 1-84 [0116]
- **MORGAN et al.** *Immunology*, 1995, vol. 86, 319-324 [0116]
- **HEZAREH et al.** *J. Virol.*, 2001, vol. 75 (24), 12161-12168 [0116]
- **XU et al.** *Cell. Immunol.*, 2000, vol. 200, 16-26 [0116]
- **BRETT et al.** *Immunology*, 1997, vol. 91, 346-353 [0116]
- **BARTHOLOMEW et al.** *Immunology*, 1995, vol. 85, 41-48 [0116]
- **SHIELDS et al.** *J.Biol.Chem*, 2001, vol. 276, 6591-6604 [0118]
- **JUNGHANS R.P.** *Immunol.Res*, 1997, vol. 16, 29-57 [0118]
- **GHETIE et al.** *Annu.Rev.Immunol.*, 2000, vol. 18, 739-766 [0118]
- **POLLOCK et al.** *J.Immunol.Methods*, 1999, vol. 231, 147-157 [0120]
- **MORROW KJJ.** *Genet.Eng.News*, 2000, vol. 20, 1-55 [0120]
- **DORAN PM.** *Curr.Opinion Biotechnol.*, 2000, vol. 11, 199-204 [0120]
- **MA JK-C.** *Nat.Med.*, 1998, vol. 4, 601-606 [0120]
- **BAEZ J et al.** *BioPharm*, 2000, vol. 13, 50-54 [0120]
- **STOGER E et al.** *Plant Mol.Biol.*, 2000, vol. 42, 583-590 [0120]

- **PAGE ; SYDENHAM.** *Biotechnology*, 1991, vol. 9, 64-68 [0124]
- **KAUFMAN R.J. et al.** *J.Mol.Biol.*, 1982, vol. 159, 601-621 [0124]
- **WERNER RG ; NOE W ; KOPP K ; SCHLUTER M.** Appropriate mammalian expression systems for biopharmaceuticals. *Arzneimittel-Forschung*, August 1998, vol. 48 (8), 870-80 [0124]
- **STINCHCOMB et al.** *Nature*, vol. 282 (38), 1979 [0124]
- **MIZUSHIMA ; NAGATA.** *Nucleic Acids Res*, 1990, vol. 18 (17), 5322 [0125]
- **HOEKEMA A et al.** *Mol Cell Biol*, 1987, vol. 7 (8), 2914-24 [0128]
- **PENG et al.** *J.Biotechnol.*, 2004, vol. 108, 185-192 [0129]
- **DRAPEAU et al.** *cytotechnology*, 1994, vol. 15, 103-109 [0133]
- **KEEN et al.** *Cytotechnology*, 1995, vol. 17, 153-163 [0133]
- **SCHARFENBERG K et al.** *Animal Cell technology: Developments towards the 21st century*. Kluwer Academic publishers, 1995, 619-623 [0133]
- **SANCHEZ et al.** *J.Biotechnol.*, 1999, vol. 72, 13-20 [0135]
- **CUPIT PM et al.** *Lett Appl Microbiol*, 1999, vol. 29, 273-277 [0135]
- **SCHOTT, M.E. et al.** *Cell. Immuno.*, 1996, vol. 174, 199-209 [0141]
- *J. Biomol. Screen.*, 1996, 1-75 [0148]
- **SARAU HM ; AMES RS ; CHAMBERS J ; ELLIS C ; ELSHOURBAGY N ; FOLEY JJ et al.** Identification, molecular cloning, expression, and characterization of a cysteinyl leukotrien receptor. *Mol Pharmacol.*, 1999, vol. 56, 657-663 [0148] [0167]
- **MOLAD, Y., J. et al.** *Clin. Immunol. Immunopathol.*, 1994, vol. 71, 281-286 [0150]
- **SCHROEDER KS ; NEAGLE, BD.** FLIPR: a new instrument for accurate, high throughput optical screening. *J. Biomol. Screen.*, 1996, 1-75 [0167]
- **JONES ; BENDIG.** *BiolTechnology*, 1991, vol. 9, 88 [0169]

Penta-specifikus antitest

SZABADALMI IGÉNYPONTOK

1. Penta-specifikus antitest, mely humán IL-8, Gro-alfa, Gro-béta, Gro-gamma és ENA-78 specifikussággal rendelkezik, és ezek mindegyikét neutralizálja.
2. Az 1. igénypont szerinti antitest, amely humán IL-8-hoz, Gro-alfához, Gro-bétához, Gro-gammához és ENA-78-hoz kevesebb, mint 10^{-7} M, 10^{-8} M vagy 10^{-9} M értékű, felületi plazmon rezonanciával meghatározott KD egyensúlyi állandóval kötődik.
3. Eljárás pentaspecifikus antitest előállítására, mely eljárás a következő lépéseket tartalmazza:
 - a. humán IL-8, Gro-alfa, Gro-béta, Gro-gamma és ENA-78 komplett Freund-féle adjuvánsban (cFA) lévő keverékét egy egérbe injektáljuk;
 - b. humán IL-8, Gro-alfa, Gro-béta, Gro-gamma és ENA-78 inkomplett Freund-féle adjuvánsban (iFA) lévő keverékét az egérbe injektáljuk;
 - c. humán IL-8, Gro-alfa, Gro-béta, Gro-gamma és ENA-78 keverékét és öt többszörös antigén peptid (MAP) sorozatát, ahol mindegyik MAP egység egy külön, 49-53 azonosítású számú polipeptid szekvenciával rendelkezik, inkomplett Freund-féle adjuvánsban az egérbe injektáljuk;
 - d. az egérből izoláljuk a B sejteket;
 - e. a B sejteket mielóma sejtekkel fuzionáljuk, immortális hibridóma sejtek előállítására, melyek a kívánt penta-specifikus antitesteket szekretálják; és
 - f. a penta-specifikus antitesteket a hibridóma kultúra felülúszójából izoláljuk.
4. Eljárás pentaspecifikus antitest előállítására, mely eljárás a következő lépéseket tartalmazza:
 - a. öt többszörös antigén peptid (MAP) sorozatát komplett Freund-féle adjuvánsban, ahol mindegyik MAP egység egy külön, 49-53 azonosítású számú polipeptid szekvenciával (MAP sorozat) rendelkezik, egy egérbe injektáljuk;
 - b. az egérbe injektáljuk a MAP sorozatot inkomplett Freund-féle adjuvánsban;

- c. az egérbe injektáljuk a humán IL-8, Gro-alfa, Gro-béta, Gro-gamma és ENA-78 mindegyikét és a MAP sorozatot tartalmazó keveréket inkomplett Freund-féle adjuvánsban;
- d. az egérből izoláljuk a B sejteket; és
- e. a B sejteket mielóma sejtekkel fuzionáljuk immortális hibridóma sejtek előállítására, melyek a kívánt penta-specifikus antitesteket szekretálják; és
- f. a penta-specifikus antitestet a hibridóma kultúra felülúszójából izoláljuk.

5. Egy 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a. 1. azonosító számú, illetve 3. azonosító számú szekvenciákat tartalmazó nukleotid szekvenciákkal kódolt nehéz- és könnyűlánc variábilis régiókat;
- b. 5. azonosító számú, illetve 7. azonosító számú szekvenciákat tartalmazó nukleotid szekvenciákkal kódolt nehéz- és könnyűlánc variábilis régiókat;
- c. a 9. azonosító számú szekvenciát tartalmazó nukleotid szekvenciákkal kódolt nehézlánc variábilis régiót;
- d. 11. azonosító számú illetve 47., 59., 61. vagy 63. azonosító számú szekvenciákat tartalmazó nukleotid szekvenciákkal kódolt nehéz- és könnyűláncokat; vagy
- e. legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban olyan szekvenciákat tartalmazó, melyek a 11. azonosító számú, illetve 47., 59., 61. vagy 63. azonosító számú szekvenciákkal azonosak, nukleotid szekvenciákkal kódolt nehéz- és könnyűláncokat.

6. Az 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a) a 2. azonosító számú, illetve 4. azonosító számú aminosav szekvenciát tartalmazó nehéz- és könnyűlánc variábilis régiókat;
- b. legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban olyan polipeptideket tartalmazó, amelyek a 2. azonosító számú, illetve a 4. azonosító számú aminosav szekvenciákkal azonosak, nehéz- és könnyűlánc variábilis régiókat;
- c. a 6. azonosító számú illetve 8. azonosító számú aminosav szekvenciákat tartalmazó nehéz- és könnyűlánc variábilis régiókat; vagy

- d. legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban olyan polipeptideket tartalmazó, amelyek a 6. azonosító számú, illetve a 8. azonosító számú aminosav szekvenciákkal azonosak, nehéz- és könnyűlánc variábilis régiókat;
- e. a 10. azonosító számú aminosav szekvenciát, vagy egy olyan aminosav szekvenciát, amely legalább 90%-ban, 95%-ban, 98%-ban vagy 99%-ban azonos a 10. azonosító számú aminosav szekvenciával, tartalmazó nehézlánc variábilis régiót;
- f. a 46. azonosító számú illetve 48., 60., 62. vagy 64. azonosító számú aminosav szekvenciákat tartalmazó nehéz- és könnyűláncokat; vagy
- g. legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban olyan polipeptideket tartalmazó, amelyek a 46. azonosító számú, illetve 48., 60., 62. vagy 64. azonosító számú aminosav szekvenciákkal azonosak, nehéz- és könnyűláncokat.

7. Az 1. igénypont szerinti antitest, mely antitest tartalmaz legalább egy variábilis régiót a következők közül kiválasztva: (i) a 2., 4., 6., 8. vagy 10. azonosító számú aminosav szekvencia; vagy (ii) egy aminosav szekvencia, amely legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban azonos a fenti (i) pont alatti bármelyik aminosav szekvenciával.

8. Az 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a. legalább egy CDR szekvenciát, mely a 13., 14., 15., 16., 17. és 18. azonosító számú szekvenciák közül van kiválasztva;
- b. legalább egy CDR szekvenciát, mely a 19., 20., 21., 22., 23. és 24. azonosító számú szekvenciák közül van kiválasztva; vagy
- c. legalább egy CDR szekvenciát, mely a 25., 26. és 27. azonosító számú szekvenciák közül van kiválasztva.

9. Az 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a. 15. azonosító számú polipeptidet;
- b. 21. azonosító számú polipeptidet; vagy
- c. 27. azonosító számú polipeptidet.

10. Az 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a. legalább négy CDR szekvenciát, a 13., 14., 15., 16., 17. és 18. azonosító számú szekvenciák közül kiválasztva; vagy
- b. legalább négy CDR szekvenciát, a 19., 20., 21., 22., 23. és 24. azonosító számú szekvenciák közül kiválasztva.

11. Az 1. igénypont szerinti antitest, mely antitest tartalmaz:

- a. 13., 14., 15., 16., 17. és 18. azonosító számú CDR szekvenciákat;
- b. 13., 14., és 15., illetve 16., 17. és 18. azonosító számú CDR szekvenciákat tartalmazó nehéz- és könnyűlánc variábilis régiókat;
- c. 19., 20., 21., 22., 23. és 24. azonosító számú CDR szekvenciákat;
- d. 19., 20. és 21., illetve 22., 23. és 24. azonosító számú CDR szekvenciákat tartalmazó nehéz- és könnyűlánc variábilis régiókat;
- e. 25., 26. és 27. azonosító számú CDR szekvenciákat; vagy
- f. 25., 26. és 27. azonosító számú CDR aminosav szekvenciákat tartalmazó nehézlánc variábilis régiót.

12. Az 1. igénypont szerinti antitest, mely antitest tartalmazza a 13., 14., 15., 16., 17. és 18. azonosító számú CDR szekvenciákat.

13. Egy hibridoma vagy transzfektoma, mely egy, az alábbi CDR szekvenciákat tartalmazó penta-specifikus antitestet termel:

- a. 13., 14., 15., 16., 17. és 18. azonosító számú;
- b. 19., 20., 21., 22., 23. és 24. azonosító számú; vagy
- c. 25., 26. és 27. azonosító számú.

14. Egy rekombináns eukarióta vagy prokarióta sejt, mely olyan antitestet állít elő, amely tartalmaz:

- a. 13., 14., 15., 16., 17. és 18. azonosító számú CDR szekvenciát;
- b. 19., 20., 21., 22., 23., és 24. azonosító számú CDR szekvenciát;
- c. 25., 26., és 27. azonosító számú CDR szekvenciát;
- d. 46., illetve 48., 60., 62. vagy 64. azonosító számú aminosav szekvenciát tartalmazó nehéz- és/vagy könnyűláncot; vagy

e. legalább 90%-ban, 95%-ban, 98%-ban, vagy 99%-ban a 46., illetve 48., 60., 62, vagy 64. azonosító számú aminosav szekvenciával azonos aminosav szekvenciát tartalmazó nehéz- és/vagy könnyűláncot.

15. Az 1. igénypont szerinti antitest, mely az alábbi nehéz- illetve könnyűlánc aminosav szekvenciákat tartalmazza:

- a. 46. azonosító számú és 48. azonosító számú;
- b. 46. és 62. azonosító számú;
- c. 46. és 60. azonosító számú;
- d. 46. és 64. azonosító számú.

16. Az 1. igénypont szerinti antitest, ahol az említett antitest humán IL-8 KELRCQCIKTYSKP (54 azonosító szám) epitópban kötődik.

17. Gyógyszerkészítmény, mely az 1., 2., 5-12. vagy 14-16. igénypontok bármelyike szerinti penta-specifikus antitestet és egy gyógyászatilag elfogadható hordozót tartalmaz.

18. Az 1., 2., 5-12., 15 és 16. igénypontok bármelyike szerinti penta-specifikus antitest, COPD, osteoarthritis, rheumatoid arthritis, erosív arthritis, asztma, atherosclerosis, gyulladásos bélbetegség, psoriasis, transzplantációs kilökődés, köszvény, rák, akut tüdővérzés, akut tüdőbetegség, szepszis, ARDS, perifériás artériás betegség, szisztémás sclerosis, csecsemőkori légzőszervi distressz-szindróma, asztma és COPD roham, cisztás fibrózis, diffúz panbronchiolitis, reperfüziós sérülés, és/vagy endometriosis kezelésében vagy megelőzésében való alkalmazásra.

19. Eljárás penta-specifikus antitest (immunoglobulin) előállítására egyes gazda sejten, mely eljárás a következő lépéseket tartalmazza:

- (i) az említett egyes gazda sejtet transzformáljuk
 - (a) egy első DNS szekvencia transzformálásával, mely a 13,14 és 15 azonosító számú CDR doméneket tartalmazó immunoglobulin legalább nehézlánc variábilis doménjeit kódolja; és egy második DNS szekvencia


transzformálásával, mely a 16, 17 és 18 azonosító számú CDR doméneket tartalmazó immunoglobulin legalább könnyűlánc variábilis doménjeit kódolja;

(b) egy első DNS szekvencia transzformálásával, mely a 19, 20 és 21 azonosító számú doméneket tartalmazó immunoglobulin legalább nehézlánc variábilis doménjeit kódolja; és egy második DNS szekvencia transzformálásával, mely a 22, 23 és 24 azonosító számú CDR doméneket tartalmazó immunoglobulin legalább könnyűlánc variábilis doménjeit kódolja; vagy

(c) egy első DNS szekvencia transzformálásával, mely egy, a 46 azonosító számú polipeptidet tartalmazó nehézláncot kódolja; és egy második DNS szekvencia transzformálásával, mely a 48, 60, 62 vagy 64 azonosító számú polipeptidet tartalmazó könnyűláncot kódolja; és

(ii) az említett első DNS szekvenciát és az említett második DNS szekvenciát expresszáljuk, úgy, hogy az említett immunoglobulin nehéz- és könnyűláncok külön molekulákként vannak előállítva az említett transzformált egyes gazdasejtben.

A meghatalmazott


 Dorosi Katalin
 Szakmai Igazgató
 SBC Szakmai Igazgatói Iroda
 1052 Budapest, Andrássy út 113.
 Telefon: 461-1000 Fax: 461-1099
 E-mail: ujszabaskat.hu